Methods of measuring factor D activity and potency of factor D inhibitors

ABSTRACT

Methods of measuring the activity of Factor D, the key driver in the activation of the alternative complement pathway, methods of determining the potency of Factor D inhibitors, and methods of screening for Factor D inhibitors are provided.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of U.S. Provisional Application Nos.62/249,073, filed on Oct. 30, 2015, and 62/250,885, filed Nov. 4, 2015,which are incorporated by reference herein in their entireties.

REFERENCE TO SEQUENCE LISTING SUBMITTED ELECTRONICALLY

This application incorporates by reference a Sequence Listing submittedwith this application as a text file entitled“12279-705-999_SEQLIST.txt” created on Oct. 27, 2016 and having a sizeof 1,647,547 bytes.

1. FIELD

The invention relates to methods of measuring the activity of Factor D,the key driver in the activation of the alternative complement pathway,methods of determining the potency of Factor D inhibitors, and methodsof screening for Factor D inhibitors.

2. BACKGROUND

Factor D is a highly specific chymotrypsin like serine protease that isa rate limiting enzyme in the activation of the complement alternativepathway (Katsche et al., 2012, J Biol Chem 287:12886-12892). Increasedactivation of the alternative complement pathway has been found indrusen, cytotoxic deposits present on the Bruch's membrane, which areassociated with the development of age related macular degeneration(AMD) (Damico et al., 2012, Arq Bras Oftalmol 75:71-75).

Inhibitors of Factor D are being developed as therapeutics to preventactivation of the alternative complement pathway, thereby inhibitinginflammation and cytotoxic activity of the activated complementcomponents (Tanhehco, 1999, Transplant Proc 31:2168-2171).

Activation of the alternative complement pathway is typically measuredby adding human serum to rabbit erythrocytes. Next, intact erythrocytesand cellular debris are pelleted by centrifugation and lysis isdetermined by measuring the absorbance at 412 nm arising from therelease of hemoglobin into the supernatant.

Citation of a reference herein shall not be construed as an admissionthat such is prior art to the present disclosure.

3. SUMMARY OF THE INVENTION

The invention relates to methods of measuring Factor D activity, methodsof determining the potency of Factor D inhibitors, and methods ofscreening for Factor D inhibitors, all of which comprise measuringFactor B cleavage using a proximity-based measurement assay. The methodsare simple, fast, homogeneous and adaptable to high-throughput assays,and are based in part on the inventors' development and characterizationof an assay that measures the ability of lampalizumab (an anti-Factor Dantibody) to inhibit the enzymatic activity of Factor D (see Section 6).The substrate for Factor D is another alternative complement pathwayserine protease, Factor B. Factor C3b binds to Factor B; then, Factor Dcleaves Factor B into Factor Ba and Factor Bb. Factor Bb remains boundto Factor C3b, forming the active C3 convertase, which initiates thealternative complement pathway (Volanakis, et al., 1996, Protein Science5:553-564). Therefore, if Factor B is not cleaved by Factor D, Factor Baand Factor Bb will be in spatial proximity with each other, Factor C3band Factor Ba will also be in spatial proximity with each other. WhenFactor B is cleaved by Factor D, however, Factor Ba and Factor Bb willbe apart from each other, and Factor C3b and Factor Ba will also beapart from each other.

In certain embodiments, the methods described herein rely on thedistance between Factor Ba and Factor Bb, wherein one of the two islabeled with a donor, and the other is labeled with an acceptor. In suchembodiments, the donor and/or the acceptor may be attached to Factor Baor Factor Bb, respectively, by a protein (e.g., an antibody orantigen-binding fragment thereof), peptide, peptide mimetic, aptamer,nucleotide (e.g., DNA, RNA, shRNA, miRNA, siRNA, antisense DNA), or anyother molecule that binds to Factor Ba or Factor Bb, or by directchemical labeling (when the donor is attached to Factor Ba, the acceptoris attached to Factor Bb; when the donor is attached to Factor Bb, theacceptor is attached to Factor Ba).

In certain embodiments, the methods described herein rely on thedistance between Factor C3b and Factor Ba, wherein one of the two islabeled with a donor, and the other is labeled with an acceptor. In suchembodiments, the donor and/or the acceptor may be attached to Factor C3bor Factor Ba, respectively, by a protein (e.g., an antibody orantigen-binding fragment thereof), peptide, peptide mimetic, aptamer,nucleotide (e.g., DNA, RNA, shRNA, miRNA, siRNA, antisense DNA), or anyother molecule that binds to Factor C3b or Factor Ba, or by directchemical labeling (when the donor is attached to Factor C3b, theacceptor is attached to Factor Ba; when the donor is attached to FactorBa, the acceptor is attached to Factor C3b).

To more precisely measure Factor D activity or the potency of Factor Dinhibitors, a quencher can be added to terminate the enzymatic cleavageof Factor B by Factor D before measuring. Luckily, the inventors havediscovered that when both anti-Factor Ba and anti-Factor Bb are used asdetection reagents, they quench the Factor D activity in the assay,therefore obviating the need to add another quencher.

The methods of measuring Factor D activity are useful, for example, indiagnosing or staging a human patient having or suspected of having adisorder associated with increased or decreased Factor D activityrelative to a normal person. The methods of determining the potency ofFactor D inhibitors are useful, for example, in assessing the quality ofanti-Factor D therapeutics for quality control in batch manufacturing,and in testing the potency of selected anti-Factor D therapeutic leads.The methods of screening for Factor D inhibitors are useful, forexample, in high-throughput screening for new Factor D inhibitors.

In one aspect, provided herein are methods of measuring the activity ofFactor D in a sample derived from a subject (e.g., a human), comprisingperforming a proximity-based measurement assay, wherein theproximity-based measurement assay measures the cleavage of Factor B.

In various embodiments, the methods of measuring the activity of FactorD comprise (a) adding to the sample an anti-Factor Ba antibody labeledwith a first moiety and an anti-Factor Bb antibody labeled with a secondmoiety, wherein one of the moieties is a donor, and the other moiety isan acceptor, and wherein a proximity signal generated by the acceptorand/or the donor indicates that Factor Ba and Factor Bb are inproximity; and (b) measuring the value of the proximity signal from thesample; wherein the activity of Factor D in the sample is negativelycorrelated with the value of the proximity signal. In some embodiments,the methods further comprise a step of quenching the activity of FactorD in the sample by providing an excessive amount of a quencher (e.g., aFactor D inhibitor) to the sample before the step of (a).

In certain aspects of such various embodiments, the methods of measuringthe activity of Factor D further comprise: (c) adding to a controlsample the anti-Factor Ba antibody labeled with the first moiety and theanti-Factor Bb antibody labeled with the second moiety; and (d)measuring the value of the proximity signal from the control sample;wherein a greater value of the proximity signal from the sample relativeto the control sample indicates a lower activity of Factor D in thesample relative to the control sample. In some embodiments, the methodsfurther comprise a step of quenching the activity of Factor D in thesample by providing an excessive amount of a quencher (e.g., a Factor Dinhibitor) to the sample before the step of (a), and a step of quenchingthe activity of Factor D in the control sample by providing an excessiveamount of the quencher to the control sample before the step of (c).

In some embodiments of the methods of measuring the activity of Factor Das described, the anti-Factor Ba antibody and the anti-Factor Bbantibody quench the activity of Factor D.

In other various embodiments, the methods of measuring the activity ofFactor D comprise (a) adding to the sample an anti-Factor C3b antibodylabeled with a first moiety and an anti-Factor Ba antibody labeled witha second moiety, wherein one of the moieties is a donor, and the othermoiety is an acceptor, and wherein a proximity signal generated by theacceptor and/or the donor indicates that Factor C3b and Factor Ba are inproximity; and (b) measuring the value of the proximity signal from thesample; wherein the activity of Factor D in the sample is negativelycorrelated with the value of the proximity signal. In some embodiments,the methods further comprise a step of quenching the activity of FactorD in the sample by providing an excessive amount of a quencher (e.g., aFactor D inhibitor) to the sample before the step of (a).

In certain aspects of such other various embodiments, the methods ofmeasuring the activity of Factor D further comprise: (c) adding to acontrol sample the anti-Factor C3b antibody labeled with the firstmoiety and the anti-Factor Ba antibody labeled with the second moiety;and (d) measuring the value of the proximity signal from the controlsample; wherein a greater value of the proximity signal from the samplerelative to the control sample indicates a lower activity of Factor D inthe sample relative to the control sample. In some embodiments, themethods further comprise a step of quenching the activity of Factor D inthe sample by providing an excessive amount of a quencher (e.g., aFactor D inhibitor) to the sample before the step of (a), and a step ofquenching the activity of Factor D in the control sample by providing anexcessive amount of the quencher to the control sample before the stepof (c).

In specific embodiments of the methods of measuring the activity ofFactor D described herein, the Factor B is a recombinantly expressedFactor B. In specific embodiments of the methods of measuring theactivity of Factor D described herein, the Factor B is endogenouslyexpressed Factor B purified from a sample derived from a subject.

In another aspect, provided herein are methods of determining thepotency of a Factor D inhibitor in inhibiting Factor D activity,comprising performing a proximity-based measurement assay, wherein theproximity-based measurement assay measures the cleavage of Factor B.

In various embodiments, the methods of determining the potency of aFactor D inhibitor comprise: (a) mixing the Factor D inhibitor withFactor D, Factor B and Factor C3b in a test reaction mix; (b) incubatingthe test reaction mix; (c) adding to the test reaction mix ananti-Factor Ba antibody labeled with a first moiety and an anti-FactorBb antibody labeled with a second moiety after the step of (b), whereinone of the moieties is a donor, and the other moiety is an acceptor, andwherein a proximity signal generated by the acceptor and/or the donorindicates that Factor Ba and Factor Bb are in proximity; and (d)measuring the value of the proximity signal from the test reaction mix;wherein the potency of the Factor D inhibitor is positively correlatedwith the value of the proximity signal. In some embodiments, the methodsfurther comprise a step of quenching the activity of Factor D in thesample by providing an excessive amount of a quencher (e.g., a Factor Dinhibitor) to the sample before the step of (c).

In certain aspects of such various embodiments, the methods ofdetermining the potency of a Factor D inhibitor further comprise: (e)mixing a control reaction mix; (f) incubating the control reaction mix;(g) adding to the control reaction mix the anti-Factor Ba antibodylabeled with the first moiety and the anti-Factor Bb antibody labeledwith the second moiety after the step of (f); and (h) measuring thevalue of the proximity signal from the control test reaction mix;wherein a greater value of the proximity signal from the test reactionmix relative to the control reaction mix indicates a greater inhibitionof Factor D activity by the Factor D inhibitor in the test reaction mixrelative to the control reaction mix. In some embodiments, the methodsfurther comprise a step of quenching the activity of Factor D in thesample by providing an excessive amount of a quencher (e.g., a Factor Dinhibitor) to the sample before the step of (c), and a step of quenchingthe activity of Factor D in the control sample by providing an excessiveamount of the quencher to the control sample before the step of (g).

In some embodiments of the methods of determining the potency of aFactor D inhibitor, the anti-Factor Ba antibody and the anti-Factor Bbantibody quench the activity of Factor D.

In other various embodiments, the methods of determining the potency ofa Factor D inhibitor comprise: (a) mixing the Factor D inhibitor withFactor D, Factor B and Factor C3b in a test reaction mix; (b) incubatingthe test reaction mix; (c) adding to the test reaction mix ananti-Factor C3b antibody labeled with a first moiety and an anti-FactorBa antibody labeled with a second moiety after the step of (b), whereinone of the moieties is a donor, and the other moiety is an acceptor, andwherein a proximity signal generated by the acceptor and/or the donorindicates that Factor C3b and Factor Ba are in proximity; and (d)measuring the value of the proximity signal from the test reaction mix;wherein the potency of the Factor D inhibitor is positively correlatedwith the value of the proximity signal. In some embodiments, the methodsfurther comprise a step of quenching the activity of Factor D in thesample by providing an excessive amount of a quencher (e.g., a Factor Dinhibitor) to the sample before the step of (c).

In certain aspects of such other various embodiments, the methods ofdetermining the potency of a Factor D inhibitor further comprise: (e)mixing a control reaction mix; (f) incubating the control reaction mix;(g) adding to the control reaction mix the anti-Factor C3b antibodylabeled with the first moiety and the anti-Factor Ba antibody labeledwith the second moiety after the step of (f); and (h) measuring thevalue of the proximity signal from the control test reaction mix;wherein a greater value of the proximity signal from the test reactionmix relative to the control reaction mix indicates a greater inhibitionof Factor D activity by the Factor D inhibitor in the test reaction mixrelative to the control reaction mix. In some embodiments, the methodsfurther comprise a step of quenching the activity of Factor D in thesample by providing an excessive amount of a quencher (e.g., a Factor Dinhibitor) to the sample before the step of (c), and a step of quenchingthe activity of Factor D in the control sample by providing an excessiveamount of the quencher to the control sample before the step of (g).

In specific embodiments of the methods of determining the potency of aFactor D inhibitor, the Factor D inhibitor is an antibody or anantigen-binding fragment thereof (e.g., lampalizumab).

In specific embodiments, the antibody comprises one, two, three, four,five or six of the following HVRs: (i) an HVR-H1 comprising the aminoacid sequence of SEQ ID NO: 1; (ii) an HVR-H2 comprising the amino acidsequence of SEQ ID NO: 2, SEQ ID NO: 3, or SEQ ID NO: 4; (iii) an HVR-H3comprising the amino acid sequence of SEQ ID NO: 5, SEQ ID NO:6, SEQ IDNO: 7, or SEQ ID NO: 8; (iv) an HVR-L1 comprising the amino acidsequence of SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12,SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, or SEQ IDNO: 17; (v) an HVR-L2 comprising the amino acid sequence of SEQ ID NO:18; or (vi) an HVR-L3 comprising the amino acid sequence of SEQ ID NO:19 or SEQ ID NO: 20.

In specific embodiments, the antibody comprises one, two, three, four,five or six of the following HVRs: (i) an HVR-H1 comprising the aminoacid sequence of SEQ ID NO: 85; (ii) an HVR-H2 comprising the amino acidsequence of SEQ ID NO: 86, SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89,SEQ ID NO: 90, SEQ ID NO: 91, SEQ ID NO: 92, SEQ ID NO: 93, or SEQ IDNO: 94; (iii) an HVR-H3 comprising the amino acid sequence of SEQ ID NO:95; (iv) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 96;(v) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 97, SEQID NO: 98, or SEQ ID NO: 99; or (vi) an HVR-L3 comprising the amino acidsequence of SEQ ID NO: 100 or SEQ ID NO: 101.

In specific embodiments of the methods of determining the potency of aFactor D inhibitor described herein, the Factor D is a recombinantlyexpressed Factor D. In specific embodiments of the methods ofdetermining the potency of a Factor D inhibitor described herein, theFactor D is endogenously expressed Factor D purified from a samplederived from a subject.

In specific embodiments of the methods of determining the potency of aFactor D inhibitor described herein, the Factor B is a recombinantlyexpressed Factor B. In specific embodiments of the methods ofdetermining the potency of a Factor D inhibitor described herein, theFactor B is endogenously expressed Factor B purified from a samplederived from a subject.

In another aspect, provided herein are methods of screening for a FactorD inhibitor from a plurality of Factor D inhibitor candidates,comprising performing a proximity-based measurement assay, wherein theproximity-based measurement assay measures the cleavage of Factor B.

In various embodiments, the methods of screening for a Factor Dinhibitor comprise: (a) mixing a Factor D inhibitor candidate withFactor D, Factor B and Factor C3b in a test reaction mix; (b) incubatingthe test reaction mix; (c) adding to the test reaction mix ananti-Factor Ba antibody labeled with a first moiety and an anti-FactorBb antibody labeled with a second moiety after the step of (b), whereinone of the moieties is a donor, and the other is an acceptor, andwherein a proximity signal generated by the acceptor and/or the donorindicates that Factor Ba and Factor Bb are in proximity; and (d)measuring the value of the proximity signal from the test reaction mix;wherein the degree of Factor D activity inhibition by a Factor Dcandidate is positively correlated with the value of the proximitysignal. In some embodiments, the methods further comprise a step ofquenching the activity of Factor D in the sample by providing anexcessive amount of a quencher (e.g., a Factor D inhibitor) to thesample before the step of (c).

In certain aspects of such various embodiments, the methods of screeningfor a Factor D inhibitor further comprise: (e) mixing a control reactionmix; (f) incubating the control reaction mix; (g) adding to the controlreaction mix the anti-Factor Ba antibody labeled with the first moietyand the anti-Factor Bb antibody labeled with the second moiety after thestep of (f); and (h) measuring the value of the proximity signal fromthe control test reaction mix; wherein a greater value of the proximitysignal from the test reaction mix relative to the control reaction mixindicates a greater inhibition of Factor D activity by the Factor Dinhibitor candidate in the test reaction mix relative to the controlreaction mix. In some embodiments, the methods further comprise a stepof quenching the activity of Factor D in the sample by providing anexcessive amount of a quencher to the sample before the step of (c), anda step of quenching the activity of Factor D in the control sample byproviding an excessive amount of the quencher (e.g., a Factor Dinhibitor) to the control sample before the step of (g).

In some embodiments of the methods of screening for a Factor Dinhibitor, the anti-Factor Ba antibody and the anti-Factor Bb antibodyquench the activity of Factor D.

In other various embodiments, the methods of screening for a Factor Dinhibitor comprise: (a) mixing a Factor D inhibitor candidate withFactor D, Factor B and Factor C3b in a test reaction mix; (b) incubatingthe test reaction mix; (c) adding to the test reaction mix ananti-Factor C3b antibody labeled with a first moiety and an anti-FactorBa antibody labeled with a second moiety after the step of (b), whereinone of the moieties is a donor, and the other is an acceptor, andwherein a proximity signal generated by the acceptor and/or the donorindicates that Factor C3b and Factor Ba are in proximity; and (d)measuring the value of the proximity signal from the test reaction mix;wherein the degree of Factor D activity inhibition by a Factor Dcandidate is positively correlated with the value of the proximitysignal. In some embodiments, the methods further comprise a step ofquenching the activity of Factor D in the sample by providing anexcessive amount of a quencher (e.g., a Factor D inhibitor) to thesample before the step of (c).

In certain aspects of such other various embodiments, the methods ofscreening for a Factor D inhibitor further comprise: (e) mixing acontrol reaction mix; (f) incubating the control reaction mix; (g)adding to the control reaction mix the anti-Factor C3b antibody labeledwith the first moiety and the anti-Factor Ba antibody labeled with thesecond moiety after the step of (f); and (h) measuring the value of theproximity signal from the control test reaction mix; wherein a greatervalue of the proximity signal from the test reaction mix relative to thecontrol reaction mix indicates a greater inhibition of Factor D activityby the Factor D inhibitor candidate in the test reaction mix relative tothe control reaction mix. In some embodiments, the methods furthercomprise a step of quenching the activity of Factor D in the sample byproviding an excessive amount of a quencher to the sample before thestep of (c), and a step of quenching the activity of Factor D in thecontrol sample by providing an excessive amount of the quencher (e.g., aFactor D inhibitor) to the control sample before the step of (g).

In specific embodiments of the methods of screening for a Factor Dinhibitor, the steps of (a)-(d) are carried out for each Factor Dinhibitor candidate from the plurality.

In specific embodiments of the methods of screening for a Factor Dinhibitor, the proximity-based measurement assay is carried out in amicroplate.

In specific embodiments of the methods of screening for a Factor Dinhibitor, the proximity-based measurement assay is conducted in ahigh-throughput manner.

In specific embodiments of the methods of screening for a Factor Dinhibitor, the Factor D inhibitor candidate is an antibody or anantigen-binding fragment thereof (e.g., lampalizumab).

When anti-Factor Ba antibody and anti-Factor Bb antibody are used, insome embodiments of the methods described above, the anti-Factor Baantibody is biotinylated, and the first moiety comprises streptavidin,avidin, or neutravidin (preferably streptavidin). In other embodiments,the anti-Factor Ba antibody is directly conjugated to the first moiety.In some embodiments, the anti-Factor Bb antibody is biotinylated, andthe second moiety comprises streptavidin, avidin, or neutravidin(preferably streptavidin). In other embodiments, the anti-Factor Bbantibody is directly conjugated to the second moiety.

When anti-Factor C3b antibody and anti-Factor Ba antibody are used, insome embodiments of the methods described above, the anti-Factor C3bantibody is biotinylated, and the first moiety comprises streptavidin,avidin, or neutravidin (preferably streptavidin). In other embodiments,the anti-Factor C3b antibody is directly conjugated to the first moiety.In some embodiments, the anti-Factor Ba antibody is biotinylated, andthe second moiety comprises streptavidin, avidin, or neutravidin(preferably streptavidin). In other embodiments, the anti-Factor Baantibody is directly conjugated to the second moiety.

In certain embodiments of the methods described above, the donor and/orthe acceptor is in the form of beads (e.g., AlphaScreen® beads).

In certain embodiments of the methods described above, the donorcomprises Europium, the acceptor comprises Alexa Fluor® 647 dye, and thelight source has a wavelength of about 340 nm.

In specific embodiments of the methods of screening for a Factor Dinhibitor described herein, the Factor D is a recombinantly expressedFactor D. In specific embodiments of the methods of screening for aFactor D inhibitor described herein, the Factor D is endogenouslyexpressed Factor D purified from a sample derived from a subject.

In specific embodiments of the methods of screening for a Factor Dinhibitor described herein, the Factor B is a recombinantly expressedFactor B. In specific embodiments of the methods of screening for aFactor D inhibitor described herein, the Factor B is endogenouslyexpressed Factor B purified from a sample derived from a subject.

In another aspect, provided herein are kits for measuring Factor Dactivity, determining Factor D inhibitor potency, and/or screening forFactor D inhibitors.

In various embodiments, the kits comprise an anti-Factor Ba antibody, ananti-Factor Bb antibody, a first moiety and a second moiety, wherein:(a) the anti-Factor Ba antibody is labeled or can be labeled with thefirst moiety, the anti-Factor Bb antibody is labeled or can be labeledwith the second moiety; and (b) one of the moieties is a donor, and theother moiety is an acceptor.

In specific embodiments, the anti-Factor Ba antibody and/or theanti-Factor Bb antibody is immobilized on a solid surface. In specificembodiments, the solid surface is a plate, a microplate, a chip, amembrane, or a bead.

In other various embodiments, the kits comprise an anti-Factor C3bantibody, an anti-Factor Ba antibody, a first moiety and a secondmoiety, wherein: (a) the anti-Factor C3b antibody is labeled or can belabeled with the first moiety, the anti-Factor Ba antibody is labeled orcan be labeled with the second moiety; and (b) one of the moieties is adonor, and the other moiety is an acceptor.

In specific embodiments, the anti-Factor C3b antibody and/or theanti-Factor Ba antibody is immobilized on a solid surface. In specificembodiments, the solid surface is a plate, a microplate, a chip, amembrane, or a bead.

In certain embodiments, the kits described herein further comprise acontrol sample with known Factor D activity.

In certain embodiments, the kits described herein further comprise acontrol Factor D inhibitor with known potency of inhibiting Factor Dactivity.

In certain embodiments, the kits described herein further comprise aquencher. In specific embodiments, the quencher is a Factor D inhibitor.

In specific embodiments, the kits described herein further comprise arecombinantly expressed Factor B. In specific embodiments, the kitsdescribed herein further comprise an endogenously expressed Factor Bpurified from a sample derived from a subject.

In specific embodiments, the kits described herein further comprise arecombinantly expressed Factor D. In specific embodiments, the kitsdescribed herein further comprise an endogenously expressed Factor Dpurified from a sample derived from a subject.

3.1. Definitions

The terms used throughout this application are to be construed withordinary and typical meaning to those of ordinary skill in the art.However, the following definitions are provided in order to facilitatean understanding of the invention.

The phrase “proximity signal” refers to a signal that is generated by anacceptor and/or a donor when the acceptor and the donor (each of whichis part of, binds to, or is attached to one member of a protein pair)are brought to close proximity. The value of the proximity signal issensitive to the distance between the acceptor and the donor. In someembodiments, the proximity signal is a signal generated by the acceptorand the donor which indicates that the acceptor and the donor (and thusthe protein pair) are in proximity. In some embodiments, the proximitysignal is a signal generated by the acceptor which indicates that theacceptor and the donor (and thus the protein pair) are in proximity. Insome embodiments, the proximity signal is a signal generated by thedonor which indicates that the acceptor and the donor (and thus theprotein pair) are in proximity. For example, when the FluorescenceResonance Energy Transfer (FRET) technology is utilized to assay thedistance between the donor and the acceptor, the proximity signal can bethe ratio between the FRET acceptor's fluorescence emission intensityand the FRET donor's fluorescence emission intensity that is higher thana baseline level (e.g., about 2-fold, 5-fold, 10-fold, 20-fold, 50-fold,100-fold higher or more) (a baseline level here is the ratio between theFRET acceptor's fluorescence emission intensity and the FRET donor'sfluorescence emission intensity when the FRET acceptor and the FRETdonor are apart (e.g., more than 10 nm, 20 nm, 50 nm, 100 nm, or 200 nmapart)). In another example, when the AlphaScreen® technology isutilized to assay the distance between the donor and the acceptor, theproximity signal can be the acceptor's emission intensity that is higherthan a baseline level (e.g., about 2-fold, 5-fold, 10-fold, 20-fold,50-fold, 100-fold higher or more) (a baseline level here is theacceptor's emission intensity when the acceptor and the donor are apart(e.g., more than 200 nm, 300 nm, 400 nm, 500 nm, 1000 nm, 2000 nmapart)).

The phrase “Factor D activity” or “activity of Factor D” refers to theenzymatic activity of Factor D to cleave Factor B.

The phrase “Factor D inhibitor” or “inhibitor of Factor D” refers to apharmaceutical agent that reduces or blocks the activity of Factor D.

The phrase “positively correlated” is used to describe the relationshipbetween a pair of items that both change in value in the same direction.For example, if A is “positively correlated” with B, the value of A willincrease when the value of B increases, and will decrease when the valueof B decreases.

The phrase “negatively correlated” is used to describe the relationshipbetween a pair of items that both change in value in the oppositedirection. For example, if A is “negatively correlated” with B, thevalue of A will decrease when the value of B increases, and willincrease when the value of B decreases.

The term “subject” referred to throughout this application, can be, butis not limited to, a human or non-human vertebrate such as a wild,domestic or farm animal. In certain embodiments, the subject is amammal, e.g., a human, a cow, a dog, a cat, a goat, a horse, a sheep, apig, a rat, or a mouse. In a preferred embodiment, the subject is ahuman. In some embodiments, the subject is a human patient having orsuspected of having a disorder associated with increased or decreasedFactor D activity relative to a normal person.

The term “quench” with respect to the activity of Factor D means toterminate the enzymatic cleavage of Factor B by Factor D.

The term “quencher” refers to an agent capable of terminating theenzymatic cleavage of Factor B by Factor D.

The term “antibody” is used in the broadest sense, and specificallycovers full length monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies) and antibody fragmentsso long as they exhibit the desired biological activity such asantigen-binding activity. Antibodies (Abs) and immunoglobulins (Igs) areglycoproteins having the same structural characteristics. Whileantibodies exhibit binding specificity to a specific target,immunoglobulins include both antibodies and other antibody-likemolecules which lack target specificity. Native antibodies andimmunoglobulins are usually heterotetrameric glycoproteins of about150,000 daltons, composed of two identical light (L) chains and twoidentical heavy (H) chains. Each heavy chain has at one end a variabledomain (V_(H)) followed by a number of constant domains. Each lightchain has a variable domain at one end (V_(L)) and a constant domain atits other end. The term “Antibody” as used herein expressly encompassesantibody fragments retaining antigen-binding activity.

An “antibody fragment” refers to a molecule other than an intactantibody that comprises a portion of an intact antibody that binds theantigen to which the intact antibody binds. Examples of antibodyfragments include but are not limited to Fv, Fab, Fab′, Fab-SH, Fab′-SH,Fab-C, Fab′-C, Fab-C-SH, Fab′-C-SH, F(ab′)2; diabodies; linearantibodies; single-chain antibody molecules (e.g., scFv); andmultispecific antibodies formed from antibody fragments.

As used herein, a “Fab” refers to an antibody that comprises a heavychain constant region that comprises the CH1 domain, or a sufficientportion of the CH1 domain to form a disulfide bond with the light chainconstant region, but does not contain a CH2 domain or a CH3 domain. Asused herein, a Fab may comprise one or more amino acids of the hingeregion. Thus, as used herein, the term “Fab” encompasses Fab'antibodies. A Fab may comprise additional non-native amino acids, suchas a C-terminal cysteine, in which case it may be referred to as aFab-C. As discussed below, the term Fab-C also encompasses Fabscomprising native amino acids of the hinge region, including a nativecysteine at the C-terminus. In some embodiments, a Fab comprises anengineered cysteine (i.e., a Fab may be a THIOMAB™).

A “Fab-C” refers to a Fab with a C-terminal cysteine, which may be anative cysteine that occurs at that residue position (such as a cysteinefrom the hinge region), or may be a cysteine added to the C-terminusthat does not correspond to a native cysteine. Nonlimiting exemplaryFab-C heavy chain constant regions include the sequences of SEQ ID NOs:863, 875, and 876.

A “Fab-SH” refers to a Fab with a free thiol group. In some embodiments,the free thiol group is located in the last 10 amino acids of theC-terminus of the Fab. Fab-C antibodies are typically also Fab-SHantibodies. A further nonlimiting exemplary Fab-SH heavy chain constantregion having the amino acid sequence of SEQ ID NO: 865. Typically, aFab comprising an engineered cysteine (i.e., a Fab that is a THIOMAB™)is a Fab-SH.

The term “variable region” or “variable domain” refers to the domain ofan antibody heavy or light chain that is involved in binding theantibody to antigen. The variable domains of the heavy chain and lightchain (VH and VL, respectively) of a native antibody generally havesimilar structures, with each domain comprising four conserved frameworkregions (FRs) and three hypervariable regions (HVRs). (See, e.g., Kindtet al. Kuby Immunology, 6th ed., W.H. Freeman and Co., page 91 (2007).)A single VH or VL domain may be sufficient to confer antigen-bindingspecificity. Furthermore, antibodies that bind a particular antigen maybe isolated using a VH or VL domain from an antibody that binds theantigen to screen a library of complementary VL or VH domains,respectively. See, e.g., Portolano et al., J. Immunol. 150:880-887(1993); Clarkson et al., Nature 352:624-628 (1991).

The term “variable” refers to the fact that certain portions of thevariable domains differ extensively in sequence among antibodies and areused in the binding and specificity of each particular antibody for itsparticular antigen. However, the variability is not evenly distributedthroughout the variable domains of antibodies. It is concentrated inthree segments called hypervariable regions both in the light chain andthe heavy chain variable domains. The more highly conserved portions ofvariable domains are called the framework regions (FRs). The variabledomains of native heavy and light chains each comprise four FRs, largelyadopting a (3-sheet configuration, connected by three hypervariableregions, which form loops connecting, and in some cases forming part of,the (3-sheet structure. The hypervariable regions in each chain are heldtogether in close proximity by the FRs and, with the hypervariableregions from the other chain, contribute to the formation of theantigen-binding site of antibodies (see Kabat et al., Sequences ofProteins of Immunological Interest, 5th Ed. Public Health Service,National Institutes of Health, Bethesda, Md. (1991)). The constantdomains are not involved directly in binding an antibody to an antigen,but exhibit various effector functions, such as participation of theantibody in antibody dependent cellular cytotoxicity (ADCC).

Papain digestion of antibodies produces two identical antigen-bindingfragments, called “Fab” fragments, each with a single antigen-bindingsite, and a residual “Fc” fragment, whose name reflects its ability tocrystallize readily. Pepsin treatment yields an F(ab′)2 fragment thathas two antigen-binding sites and is still capable of cross-linkingantigen.

The Fab fragment also contains the constant domain of the light chainand the first constant domain (CH1) of the heavy chain. Fab′ fragmentsdiffer from Fab fragments by the addition of a few residues at thecarboxy terminus of the heavy chain CH1 domain including one or morecysteines from the antibody hinge region. Fab′-SH is the designationherein for Fab′ in which the cysteine residue(s) of the constant domainsbear at least one free thiol group. F(ab′)2 antibody fragmentsoriginally were produced as pairs of Fab′ fragments which have hingecysteines between them. Other chemical couplings of antibody fragmentsare also known.

“Fv” is the minimum antibody fragment which contains a completeantigen-recognition and antigen-binding site. This region consists of adimer of one heavy chain and one light chain variable domain in tight,non-covalent association. It is in this configuration that the threehypervariable regions of each variable domain interact to define anantigen-binding site on the surface of the VH-VL dimer. Collectively,the six hypervariable regions confer antigen-binding specificity to theantibody. However, even a single variable domain (or half of an Fvcomprising only three hypervariable regions specific for an antigen) hasthe ability to recognize and bind antigen, although at a lower affinitythan the entire binding site.

The term “hypervariable region” or “HVR,” as used herein, refers to eachof the regions of an antibody variable domain which are hypervariable insequence and/or form structurally defined loops (“hypervariable loops”).Generally, native four-chain antibodies comprise six HVRs; three in theVH (H1, H2, H3), and three in the VL (L1, L2, L3). HVRs generallycomprise amino acid residues from the hypervariable loops and/or fromthe “complementarity determining regions” (CDRs), the latter being ofhighest sequence variability and/or involved in antigen recognition.HVR-H3 is believed to play a unique role in conferring fine specificityto antibodies. See, e.g., Xu et al. (2000) Immunity 13:37-45; Johnsonand Wu (2003) in Methods in Molecular Biology 248:1-25 (Lo, ed., HumanPress, Totowa, N.J.). “Framework Region” or “FR” residues are thosevariable domain residues other than the hypervariable region residues asherein defined. An HVR region as used herein comprise any number ofresidues located within positions 24-36 (for L1), 46-56 (for L2), 89-97(for L3), 26-35B (for H1), 47-65 (for H2), and 93-102 (for H3).Therefore, an HVR includes residues in positions described previously:

A) 24-34 (L1), 50-52 (L2), 91-96 (L3), 26-32 (H1), 53-55 (H2), and96-101 (H3) (Chothia and Lesk, J. Mol. Biol. 196:901-917 (1987);

B) 24-34 of L1, 50-56 of L2, 89-97 of L3, 31-35B of H1, 50-65 of H2, and95-102 of H3 (Kabat et al., Sequences of Proteins of ImmunologicalInterest, 5th Ed. Public Health Service, National Institutes of Health,Bethesda, Md. (1991).

C) 30-36 (L1), 46-55 (L2), 89-96 (L3), 30-35 (H1), 47-58 (H2), 93-100a-j(H3) (MacCallum et al. J. Mol. Biol. 262:732-745 (1996).

Hypervariable regions may comprise “extended hypervariable regions” asfollows: 24-36 or 24-34 (L1), 46-56 or 50-56 (L2) and 89-97 (L3) in theVL and 26-35B (H1), 50-65, 47-65 or 49-65 (H2) and 93-102, 94-102 or95-102 (H3) in the VH. The variable domain residues are numberedaccording to Kabat et al., supra for each of these definitions.

4. BRIEF DESCRIPTION OF FIGURES

FIG. 1 depicts the assay schematic for the factor D TR-FRET (TimeResolved-FRET) assay.

FIG. 2 depicts the co-titration of Streptavidin-Alexa Fluor® 647conjugate and anti-Factor Ba-Europium. Varying concentrations of the

Streptavidin-Alexa Fluor® 647 and anti-Factor Ba-Europium were analyzedwith fixed concentrations of the other reagents and then the assay wasperformed as described in Section 6.1, in order to optimize the signalof the TR-FRET assay.

FIG. 3 depicts the TR-FRET ratios with different incubation times of theenzymatic reaction of the lampalizumab/Factor D/Factor B/Factor C3bmixture. Note that the activity of Factor D was greatly diminished whenthe detection reagents were added prior to initiation of the enzymaticreaction (t=0) and increased with increasing time.

FIG. 4 depicts the TR-FRET ratios with different incubation times of thedetection reagents (i.e., the mixture of anti-Factor Bb, anti-FactorBa-Europium and Streptavidin-Alexa Fluor® 647).

FIGS. 5A and 5B show that both the TR-FRET and the AlphaScreen®detection technologies generated good signal and dynamic range.

5. DETAILED DESCRIPTION

The present invention provides methods of measuring Factor D activitycomprising performing a proximity-based measurement assay, methods ofdetermining the potency of Factor D inhibitors comprising performing aproximity-based measurement assay, and methods of screening for Factor Dinhibitors comprising measuring Factor B cleaving using aproximity-based measurement assay. The methods are simple, fast,homogeneous and adaptable to high-throughput assays, and are based inpart on the inventors' development and characterization of an assay thatmeasures the ability of Factor D inhibitors (including lampalizumab (ananti-Factor D antibody)) to inhibit the enzymatic activity of Factor D(see Section 6). To more precisely measure Factor D activity or thepotency of Factor D inhibitors, a quencher can be added to terminate theenzymatic cleavage of Factor B by Factor D before measuring. Luckily,the inventors have discovered that when both anti-Factor Ba andanti-Factor Bb are used as detection reagents, they quench the Factor Dactivity in the assay, therefore obviating the need to add anotherquencher.

5.1. Proximity-Based Measurement Assays

The proximity-based measurement assay performed according to the methodsdescribed herein can utilize any proximity-based technology known in theart for measuring the binding of a protein pair. Such assays utilize aproximity signal that is generated by an acceptor and/or a donor whenthe acceptor and the donor (each of which is part of, binds to, or isattached to one member of the protein pair) are brought to closeproximity. Thus, the value of the proximity signal is sensitive to thedistance between the acceptor and the donor. In some embodiments, theproximity signal is a signal generated by the acceptor and the donorwhich indicates that the acceptor and the donor (and thus the proteinpair) are in proximity. In some embodiments, the proximity signal is asignal generated by the acceptor which indicates that the acceptor andthe donor (and thus the protein pair) are in proximity. In someembodiments, the proximity signal is a signal generated by the donorwhich indicates that the acceptor and the donor (and thus the proteinpair) are in proximity.

The donor/acceptor pair thus can be any pair of molecules that cangenerate a proximity signal whose value is sensitive to their distance.The donor and/or the acceptor may be attached to the molecule(s) ofinterest (i.e., member(s) of the protein pair) by a protein (e.g., anantibody or antigen-binding fragment thereof), peptide, peptide mimetic,aptamer, nucleotide (e.g., DNA, RNA, shRNA, miRNA, siRNA, antisenseDNA), or any other molecule that binds to the member of the proteinpair, or by direct chemical labeling. The degree of proximity betweenthe donor and the acceptor that is required to elicit a proximity signalis dependent on the specific technology employed. Non-limiting exemplaryproximity-based technologies for measuring the binding of a protein pairinclude Fluorescence Resonance Energy Transfer (FRET) and otherFRET-based methods such as Time Resolved-FRET (TR-FRET), AlphaScreen®,AlphaLISA®, and PCR-based proximity ligation assays (see for example,Morrison, 1988, Anal Biochem 174:101-120; Ullman et al., 1994, Proc NatlAcad Sci USA 91: 5426-5430; Ullman et al., 1996, Clin Chem 42:1518-1526;Glickman et al., 2002, Journal of Biomolecular Screening 7:3-10;Bielefeld-Sevigny, 2009, Assay Drug Dev Technol 7:90-92; and Gullberg etal., 2004, Proc Natl Acad Sci USA 101: 8420-8424).

Fluorescence resonance energy transfer (FRET) is the transfer of energybetween a light-sensitive donor and a light-sensitive acceptor. Thedonor, after being excited by a light source, may transfer energy to theacceptor. The transfer of energy leads to a reduction in the donor'sfluorescence emission intensity and an increase in the acceptor'sfluorescence emission intensity. The efficiency of this energy transferis inversely proportional to the sixth power of the distance betweendonor and acceptor, making FRET extremely sensitive to small changes indistance, and making FRET useful in determining if the donor and theacceptor are within a certain distance of each other. When theproximity-based technology is Fluorescence Resonance Energy Transfer(FRET), the proximity signal can be the ratio between the FRETacceptor's fluorescence emission intensity and the FRET donor'sfluorescence emission intensity that is higher than a baseline level(e.g., about 2-fold, 5-fold, 10-fold, 20-fold, 50-fold, 100-fold higheror more). A baseline level here is the ratio between the FRET acceptor'sfluorescence emission intensity and the FRET donor's fluorescenceemission intensity when the FRET acceptor and the FRET donor are apart(e.g., more than 10 nm, 20 nm, 50 nm, 100 nm, or 200 nm apart).

TR-FRET is a FRET technology that has introduced a time delay betweenthe excitation of the donor and the fluorescence measurement to reduceor clear the non-specific interfering short-lived emission signals fromthe background (for example, buffers and cell lysates). The emissionsignals from the donor and the acceptor, however, are long-lived andwill not be affected.

A pair of light-sensitive donor and acceptor molecules that interact insuch a manner that FRET occurs is often referred to as a FRET pair, andis known to those skilled in the art. The mechanism of FRET-pairinteraction requires that the excitation spectrum of the acceptoroverlaps the emission spectrum of the donor (see, Stryer, 1978, Ann RevBiochem 47:819-846; Cantor and Schimmel, 1980, Biophysical ChemistryPart II: Techniques for the Study of Biological Structure And Function,pages 448-455, San Francisco, Calif.: W. H. Freeman and Co.; and Selvin,1995, Methods in Enzymology 246:300-335). The efficiency of FRETinteraction is linearly proportional to this overlap (Haugland et al.,1969, Proc Natl Acad Sci USA 63:24-30). FRET pairs have been chosen onthis basis.

Any of a number of FRET-pair combinations can be selected for use in thepresent invention (see for example, Pesce et al, eds, 1971, FluorescenceSpectroscopy, New York, N.Y.: Marcel Dekker; White et al., 1970,Fluorescence Analysis: A practical Approach, New York, N.Y.: MarcelDekker; and Haugland, 1996, Handbook of Fluorescent Probes and ResearchChemicals, 6th Ed, Eugene, Oreg.: Molecular Probes, Inc.). In general, apreferred donor is selected that has an emission spectrum thatsubstantially overlaps the acceptor's excitation spectrum. In suchapplications the use of intense laser light, high-powered LED, or xenonflash lamp can serve as an effective means to excite the donor. Theacceptor has a substantial overlap of its excitation spectrum with theemission spectrum of the donor. In addition, the wavelength maximum ofthe emission spectrum of the acceptor is preferably at least 10 nmgreater than the wavelength maximum of the excitation spectrum of thedonor. The emission spectrum of the acceptor is typically in the redportion of the visible spectrum, although, it is believed that acceptorshaving emission at longer wavelengths in the infrared region of thespectrum can be used. In some embodiments, the donor comprises Europium,the acceptor comprises Alexa 647, and the light source has a wavelengthof about 340 nm.

In order to obtain FRET between the donor and the acceptor, the two haveto be in spatial proximity with each other. Thus, in certainembodiments, the assay components are labeled such that the donor andthe acceptor can be about 0.1 nm, 0.5 nm, 1 nm, 5 nm, or 10 nm apartfrom each other, or less than about 10 nm to allow FRET to occur.

AlphaScreen® and AlphaLISA® are bead-based technologies, and the assaysare conducted in a microplate format. The donor and the acceptor are inthe form of beads. Donor beads contain a photosensitizer,phthalocyanine, which converts ambient oxygen to an excited and reactiveform of O₂, singlet oxygen, upon illumination at 680 nm. Singlet oxygenhas a limited lifetime prior to falling back to ground state. Within its4 μsec half-life, singlet oxygen can diffuse approximately 200 nm insolution. If an acceptor bead is within that proximity, energy istransferred from the singlet oxygen to thioxene derivatives within theacceptor bead, subsequently culminating in light production at 520 to620 nm (AlphaScreen®) or at 615 nm (AlphaLISA®). In the absence of anacceptor bead, singlet oxygen falls to ground state and no signal isproduced. When the proximity-based technology is AlphaScreen®, theproximity signal can be the acceptor's emission intensity that is higherthan a baseline level (e.g., about 2-fold, 5-fold, 10-fold, 20-fold,50-fold, 100-fold higher or more). A baseline level here is theacceptor's emission intensity when the acceptor and the donor are apart(e.g., more than 200nm, 300 nm, 400 nm, 500 nm, 1000 nm, 2000 nm apart).

In order to obtain proximity signal from the acceptor using theAlphaScreen® or the AlphaLISA® technology, the donor and the acceptorhave to be in spatial proximity with each other. Thus, in certainembodiments, the assay components are labeled such that the donor andthe acceptor can be about 1 nm, 5 nm, 10 nm, 25 nm, 50 nm, 75 nm, 100nm, 125 nm, 150 nm, 175 nm, 200 nm apart from each other, or less thanabout 200 nm apart from each other to allow the proximity-dependentchemical energy transfer to occur.

In PCR-based proximity ligation assays, the donor and the acceptor eachcontains an oligonucleotide that can be ligated. The binding of thedonor and the acceptor brings in close proximity the twooligonucleotides, which are then ligated, amplified, and detected byPCR.

In certain embodiments, the proximity-based measurement assay is carriedout in a microplate. In specific embodiments, the proximity-basedmeasurement assay is conducted in a high-throughput manner. In someembodiments, the donor and/or the acceptor is in the form of beads(e.g., AlphaScreen® beads). In certain embodiments, the donor and/or theacceptor comprises streptavidin, avidin, or neutravidin (preferablystreptavidin) that can bind to biotin conjugated to an assay component.In certain embodiments, the donor and/or the acceptor is directlyconjugated to an assay component.

5.2. The Assay Components

The substrate for Factor D is another alternative complement pathwayserine protease, Factor B. Factor C3b binds to Factor B; then, Factor Dcleaves Factor B into Factor Ba and Factor Bb. Factor Bb remains boundto Factor C3b, forming the active C3 convertase, which initiates thealternative complement pathway (Volanakis, et al., 1996, Protein Science5:553-564). Therefore, if Factor B is not cleaved by Factor D, Factor Baand Factor Bb will be in spatial proximity with each other, Factor C3band Factor Ba will also be in spatial proximity with each other. WhenFactor B is cleaved by Factor D, however, Factor Ba and Factor Bb willbe apart from each other, and Factor C3b and Factor Ba will also beapart from each other.

In certain embodiments, the methods described herein rely on thedistance between Factor Ba and Factor Bb, wherein one of the two islabeled with a donor, and the other is labeled with an acceptor. In suchembodiments, the donor and/or the acceptor may be attached to Factor Baor Factor Bb, respectively, by a protein (e.g., an antibody orantigen-binding fragment thereof), peptide, peptide mimetic, aptamer,nucleotide (e.g., DNA, RNA, shRNA, miRNA, siRNA, antisense DNA), or anyother molecule that binds to Factor Ba or Factor Bb, or by directchemical labeling (when the donor is attached to Factor Ba, the acceptoris attached to Factor Bb; when the donor is attached to Factor Bb, theacceptor is attached to Factor Ba).

In certain embodiments, the methods described herein rely on thedistance between Factor C3b and Factor Ba, wherein one of the two islabeled with a donor, and the other is labeled with an acceptor. In suchembodiments, the donor and/or the acceptor may be attached to Factor C3bor Factor Ba, respectively, by a protein (e.g., an antibody orantigen-binding fragment thereof), peptide, peptide mimetic, aptamer,nucleotide (e.g., DNA, RNA, shRNA, miRNA, siRNA, antisense DNA), or anyother molecule that binds to Factor C3b or Factor Ba, or by directchemical labeling (when the donor is attached to Factor C3b, theacceptor is attached to Factor Ba; when the donor is attached to FactorBa, the acceptor is attached to Factor C3b).

5.3. Methods of Measuring Factor D Activity

In one aspect, provided herein are method of measuring the activity ofFactor D in a sample derived from a subject, comprising performing aproximity-based measurement assay, wherein the proximity-basedmeasurement assay measures the cleavage of Factor B. The proximity-basedmeasurement assay can utilize any proximity-base technology known in theart for measuring the binding of a protein pair, as described in Section5.1. The methods described in this section are useful, for example, indiagnosing or staging a human patient having or suspected of having adisorder associated with increased or decreased Factor D activityrelative to a normal person.

In various embodiments, the methods of measuring the activity of FactorD comprise (a) adding to the sample an anti-Factor Ba antibody labeledwith a first moiety and an anti-Factor Bb antibody labeled with a secondmoiety, wherein one of the moieties is a donor, and the other moiety isan acceptor, and wherein a proximity signal generated by the acceptorand/or the donor indicates that Factor Ba and Factor Bb are inproximity; and (b) measuring the value of the proximity signal from thesample; wherein the activity of Factor D in the sample is negativelycorrelated with the value of the proximity signal.

In certain aspects of such various embodiments, the methods of measuringthe activity of Factor D further comprise: (c) adding to a controlsample the anti-Factor Ba antibody labeled with the first moiety and theanti-Factor Bb antibody labeled with the second moiety; and (d)measuring the value of the proximity signal from the control sample;wherein a greater value of the proximity signal from the sample relativeto the control sample (e.g., about 10%, 15%, 20%, 25%, 30%, 40%, 50%,60%, 70%, 80%, 90% greater or more, or about 1-fold, 1.5-fold, 2-fold,3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold,15-fold, 20-fold, 30-fold, 40-fold, 50-fold greater or more) indicates alower activity of Factor D in the sample relative to the control sample.

When the proximity signal generated by the donor and/or the acceptor isbased on energy transfer between the donor and the acceptor upon lightactivation, in various embodiments, the methods of measuring theactivity of Factor D comprise: (A) adding to the sample an anti-FactorBa antibody labeled with a first moiety and an anti-Factor Bb antibodylabeled with a second moiety, wherein one of the moieties is a donor,and the other moiety is an acceptor; (B) providing a light source toexcite the donor in the sample; and (C) measuring the donor fluorescenceemission intensity from the sample, and/or the acceptor fluorescenceemission intensity from the sample; wherein the activity of Factor D inthe sample is positively correlated with the donor fluorescence emissionintensity from the sample, and/or is negatively correlated with theacceptor fluorescence emission intensity from the sample. In certainembodiments, the step of (C) is performed after a period of time of thestep of (B) that results in a decrease in interfering short-livedbackground signals. In specific embodiments, the methods of measuringthe activity of Factor D further comprise: (D) adding to a controlsample the anti-Factor Ba antibody labeled with the first moiety and theanti-Factor Bb antibody labeled with the second moiety; (E) providingthe same light source to excite the donor in the control sample; and (F)measuring the donor fluorescence emission intensity from the controlsample, and/or the acceptor fluorescence emission intensity from thecontrol sample; wherein a lower donor fluorescence emission intensityfrom the sample relative to the control sample, and/or a higher acceptorfluorescence emission intensity from the sample relative to the controlsample, indicates a lower activity of Factor D in the sample relative tothe control sample. In certain embodiments, the step of (C) is performedafter a period of time of the step of (B) that results in a decrease ininterfering short-lived background signals, and the step of (F) isperformed after the same period of time of the step of (E).

In certain embodiments, the anti-Factor Ba antibody and the anti-FactorBb antibody used in the methods of measuring the activity of Factor Dquench the activity of Factor D. In such embodiments, the need to addanother quencher is obviated. In certain embodiments, the methods ofmeasuring the activity of Factor D further comprise a step of quenchingthe activity of Factor D in the sample by providing an excessive amountof a quencher to the sample before the step of (a). When a controlsample is used, in certain embodiments, the methods of measuring theactivity of Factor D further comprise a step of quenching the activityof Factor D in the sample by providing an excessive amount of a quencherto the sample before the step of (a), and a step of quenching theactivity of Factor D in the control sample by providing an excessiveamount of the quencher to the control sample before the step of (c). Inspecific embodiments, the quencher is a Factor D inhibitor (for example,an anti-Factor D antibody or an excess amount of EDTA).

In certain embodiments, the anti-Factor Ba antibody is biotinylated, andthe first moiety comprises streptavidin, avidin, or neutravidin. In someembodiments, the anti-Factor Ba antibody is biotinylated, and the firstmoiety comprises streptavidin. In certain embodiments, the anti-FactorBb antibody is biotinylated, and the second moiety comprisesstreptavidin, avidin, or neutravidin. In some embodiments, theanti-Factor Bb antibody is biotinylated, and the second moiety comprisesstreptavidin.

In other various embodiments, the methods of measuring the activity ofFactor D comprise (a) adding to the sample an anti-Factor C3b antibodylabeled with a first moiety and an anti-Factor Ba antibody labeled witha second moiety, wherein one of the moieties is a donor, and the othermoiety is an acceptor, and wherein a proximity signal generated by theacceptor and/or the donor indicates that Factor C3b and Factor Ba are inproximity; and (b) measuring the value of the proximity signal from thesample; wherein the activity of Factor D in the sample is negativelycorrelated with the value of the proximity signal.

In certain aspects of such other various embodiments, the methods ofmeasuring the activity of Factor D further comprise: (c) adding to acontrol sample the anti-Factor C3b antibody labeled with the firstmoiety and the anti-Factor Ba antibody labeled with the second moiety;and (d) measuring the value of the proximity signal from the controlsample; wherein a greater value of the proximity signal from the samplerelative to the control sample (e.g., about 10%, 15%, 20%, 25%, 30%,40%, 50%, 60%, 70%, 80%, 90% greater or more, or about 1-fold, 1.5-fold,2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold,15-fold, 20-fold, 30-fold, 40-fold, 50-fold greater or more) indicates alower activity of Factor D in the sample relative to the control sample.

When the proximity signal generated by the donor and/or the acceptor isbased on energy transfer between the donor and the acceptor upon lightactivation, in various embodiments, the methods of measuring theactivity of Factor D comprise: (A) adding to the sample an anti-FactorC3b antibody labeled with a first moiety and an anti-Factor Ba antibodylabeled with a second moiety, wherein one of the moieties is a donor,and the other moiety is an acceptor; (B) providing a light source toexcite the donor in the sample; and (C) measuring the donor fluorescenceemission intensity from the sample, and/or the acceptor fluorescenceemission intensity from the sample; wherein the activity of Factor D inthe sample is positively correlated with the donor fluorescence emissionintensity from the sample, and/or is negatively correlated with theacceptor fluorescence emission intensity from the sample. In certainembodiments, the step of (C) is performed after a period of time of thestep of (B) that results in a decrease in interfering short-livedbackground signals. In specific embodiments, the methods of measuringthe activity of Factor D further comprise: (D) adding to a controlsample the anti-Factor C3b antibody labeled with the first moiety andthe anti-Factor Ba antibody labeled with the second moiety; (E)providing the same light source to excite the donor in the controlsample; and (F) measuring the donor fluorescence emission intensity fromthe control sample, and/or the acceptor fluorescence emission intensityfrom the control sample; wherein a lower donor fluorescence emissionintensity from the sample relative to the control sample, and/or ahigher FRET acceptor fluorescence emission intensity from the samplerelative to the control sample, indicates a lower activity of Factor Din the sample relative to the control sample. In certain embodiments,the step of (C) is performed after a period of time of the step of (B)that results in a decrease in interfering short-lived backgroundsignals, and the step of (F) is performed after the same period of timeof the step of (E).

In certain embodiments wherein anti-Factor C3b antibody and anti-FactorBa antibody are used, the anti-Factor C3b antibody is biotinylated, andthe first moiety comprises streptavidin, avidin, or neutravidin. In someembodiments, the anti-Factor C3b antibody is biotinylated, and the firstmoiety comprises streptavidin. In certain embodiments, the anti-FactorBa antibody is biotinylated, and the second moiety comprisesstreptavidin, avidin, or neutravidin. In some embodiments, theanti-Factor Ba antibody is biotinylated, and the second moiety comprisesstreptavidin.

In certain embodiments wherein anti-Factor C3b antibody and anti-FactorBa antibody are used, the anti-Factor C3b antibody and the anti-FactorBa antibody used in the methods of measuring the activity of Factor Dquench the activity of Factor D. In such embodiments, the need to addanother quencher is obviated. In certain embodiments wherein anti-FactorC3b antibody and anti-Factor Ba antibody are used, the methods ofmeasuring the activity of Factor D further comprise a step of quenchingthe activity of Factor D in the sample by providing an excessive amountof a quencher to the sample before the step of (a). When a controlsample is used, in certain embodiments, the methods of measuring theactivity of Factor D further comprise a step of quenching the activityof Factor D in the sample by providing an excessive amount of a quencherto the sample before the step of (a), and a step of quenching theactivity of Factor D in the control sample by providing an excessiveamount of the quencher to the control sample before the step of (c). Inspecific embodiments, the quencher is a Factor D inhibitor (for example,an anti-Factor D antibody or an excess amount of EDTA).

The sample can comprise a tissue, a population of cells directedisolated from the subject, a population of cultured cells derived fromthe subject, or a preparation from the tissue, the population of cellsor the population of cultured cells that allows the activity of Factor Dto be measured. When a control sample is used, the control sample ispreferably in the same format as the sample. The control sample can be,but is not limited to, a sample with known Factor D activity or a samplewith no Factor D activity. In specific embodiments, more than onecontrol sample is used in the methods described herein. In certainembodiments, a standard curve has been generated for quantifying theactivity of Factor D in samples without the need to measure a controlsample.

The donor/acceptor pair can be any known in the art, or as described inSection 5.1.

The subject referred to in the methods described herein, can be, but isnot limited to, a human or non-human vertebrate such as a wild, domesticor farm animal. In certain embodiments, the subject is a mammal, e.g., ahuman, a cow, a dog, a cat, a goat, a horse, a sheep, a pig, a rat, or amouse. In a preferred embodiment, the subject is a human. In someembodiments, the subject is a human patient having or suspected ofhaving a disorder associated with increased or decreased Factor Dactivity relative to a normal person, such as age-related maculardegeneration (AMD). In some embodiments, the subject is a human patienthaving or suspected of having a disorder associated with excessive oruncontrolled complement activation. They include: complement activationduring cardiopulmonary bypass operations; complement activation due toischemia-reperfusion following acute myocardial infarction, aneurysm,stroke, hemorrhagic shock, crush injury, multiple organ failure,hypobolemic shock and intestinal ischemia. These disorders associatedwith excessive or uncontrolled complement activation can also includedisease or condition is an inflammatory condition such as severe burns,endotoxemia, septic shock, adult respiratory distress syndrome,hemodialysis; anaphylactic shock, severe asthma, angioedema, Crohn'sdisease, sickle cell anemia, poststreptococcal glomerulonephritis andpancreatitis. The disorder may be the result of an adverse drugreaction, drug allergy, IL-2 induced vascular leakage syndrome orradiographic contrast media allergy. It also includes autoimmune diseasesuch as systemic lupus erythematosus, myasthenia gravis, rheumatoidarthritis, Alzheimer's disease and multiple sclerosis. Complementactivation is also associated with transplant rejection. Complementactivation is also associated with ocular diseases (all ocularconditions and diseases the pathology of which involve complement,including the classical and the alternative pathway of complement), suchas, for example, without limitation, macular degenerative disease, suchas all stages of age-related macular degeneration (AMD), including dryand wet (non-exudative and exudative) forms, diabetic retinopathy andother ischemia-related retinopathies, choroidal neovascularization(CNV), uveitis, diabetic macular edema, pathological myopia, vonHippel-Lindau disease, histoplasmosis of the eye, Central Retinal VeinOcclusion (CRVO), corneal neovascularization, and retinalneovascularization. In one example, complement-associated eye conditionsinclude age-related macular degeneration (AMD), including non-exudative(e.g intermediate dry AMD or geographic atrophy (GA)) and exudative(e.g. wet AMD (choroidal neovascularization (CNV)) AMD, diabeticretinopathy (DR), endophthalmitis and uveitis. In a further example,nonexudative AMD may include the presence of hard drusen, soft drusen,geographic atrophy and/or pigment clumping. In another example,complement-associated eye conditions include age-related maculardegeneration (AMD), including early AMD (e.g. includes multiple small toone or more non-extensive medium sized drusen), intermediate AMD (e.g.includes extensive medium drusen to one or more large drusen) andadvanced AMD (e.g. includes geographic atrophy or advanced wet AMD(CNV). In a further example, intermediate dry AMD may include largeconfluent drusen. In a further example, geographic atrophy may includephotoreceptor and/or Retinal Pigmented Epithelial (RPE) loss. In afurther example, the area of geographic atrophy may be small or largeand/or may be in the macula area or in the peripheral retina. In oneexample, the complement-associated eye condition is intermediate dryAMD. In one example, the complement-associated eye condition isgeographic atrophy. In one example, the complement-associated eyecondition is wet AMD (choroidal neovascularization (CNV)).

In the methods of measuring the activity of Factor B described above,the anti-Factor Ba, anti-Factor Bb, and/or anti-Factor C3b may bereplaced by a peptide, a non-antibody protein, a peptide memetic, anaptamer, a nucleotide (e.g., DNA, RNA, shRNA, miRNA, siRNA, antisenseDNA), or any other molecule that binds to Factor Ba, Factor Bb, oranti-Factor C3b, respectively. Alternatively, the Factor Ba, Factor Bb,and/or Factor C3b may be directed attached to the donor or acceptor (asthe case may be) by direct chemical labeling.

In specific embodiments of the methods of measuring the activity ofFactor D described herein, the Factor B is a recombinantly expressedFactor B. In specific embodiments of the methods of measuring theactivity of Factor D described herein, the Factor B is endogenouslyexpressed Factor B purified from a sample derived from a subject.

The Factor D can be recombinantly expressed or endogenously expressed.In some embodiments, the Factor D is purified from the sample before themeasuring of its activity.

The term “sample” referred to in the methods described herein, can be,but is not limited to, a blood sample or a serum sample.

5.4. Methods of Determining the Potency of Factor D Inhibitor

In another aspect, provided herein are methods of determining thepotency of a Factor D inhibitor in inhibiting Factor D activity,comprising performing a proximity-based measurement assay, wherein theproximity-based measurement assay measures the cleavage of Factor B. Theproximity-based measurement assay can utilize any proximity-basedtechnology known in the art for measuring the binding of a protein pair,as described in Section 5.1. The methods described in this section areuseful, for example, in assessing the quality of anti-Factor Dtherapeutics for quality control in batch manufacturing, and in testingthe potency of selected anti-Factor D therapeutic leads.

In various embodiments, the methods of determining the potency of aFactor D inhibitor comprise: (a) mixing a Factor D inhibitor candidatewith Factor D, Factor B and Factor C3b in a test reaction mix; (b)incubating the test reaction mix; (c) adding to the test reaction mix ananti-Factor Ba antibody labeled with a first moiety and an anti-FactorBb antibody labeled with a second moiety after the step of (b), whereinone of the moieties is a donor, and the other is an acceptor, andwherein a proximity signal generated by the acceptor and/or the donorindicates that Factor Ba and Factor Bb are in proximity; and (d)measuring the value of the proximity signal from the test reaction mix;wherein the potency of the Factor D inhibitor is positively correlatedwith the value of the proximity signal.

In certain aspects of such various embodiments, the methods ofdetermining the potency of a Factor D inhibitor further comprise: (e)mixing a control reaction mix; (f) incubating the control reaction mix;(g) adding to the control reaction mix the anti-Factor Ba antibodylabeled with the first moiety and the anti-Factor Bb antibody labeledwith the second moiety after the step of (f); and (h) measuring thevalue of the proximity signal from the control test reaction mix;wherein a greater value of the proximity signal from the test reactionmix relative to the control reaction mix (e.g., about 10%, 15%, 20%,25%, 30%, 40%, 50%, 60%, 70%, 80%, 90% greater or more, or about 1-fold,1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold,9-fold, 10-fold, 15-fold, 20-fold, 30-fold, 40-fold, 50-fold greater ormore) indicates a greater inhibition of Factor D activity by the FactorD inhibitor in the test reaction mix relative to the control reactionmix.

When the proximity signal generated by the donor and/or the acceptor isbased on energy transfer between the donor and the acceptor upon lightactivation, in various embodiments, the methods of determining thepotency of a Factor D inhibitor comprise: (A) mixing the Factor Dinhibitor with Factor D, Factor B and Factor C3b in a test reaction mix;(B) incubating the test reaction mix; (C) adding to the test reactionmix an anti-Factor Ba antibody labeled with a first moiety and ananti-Factor Bb antibody labeled with a second moiety after the step of(B), wherein one of the moieties is a donor, and the other moiety is anacceptor; (D) providing a light source to excite the donor in the testreaction mix; and (E) measuring the donor fluorescence emissionintensity from the test reaction mix, and/or the acceptor fluorescenceemission intensity from the test reaction mix; wherein the potency ofthe Factor D inhibitor is negatively correlated with the donorfluorescence emission intensity from the test reaction mix, and/or ispositively correlated with the acceptor fluorescence emission intensityfrom the test reaction mix. In specific embodiments, the step of (B) isconducted for about 15 min, 30 min, 45 min, 60 min, 75 min, or 90 min.In some embodiments, the step of (B) is conducted for about 45 min. Incertain embodiments, the step of (E) is performed after a period of timeof the step of (D) that results in a decrease in interfering short-livedbackground signals. In specific embodiments, the methods of determiningthe potency of a Factor D inhibitor further comprise: (F) mixing acontrol reaction mix; (G) incubating the control reaction mix; (H)adding to the control reaction mix the anti-Factor Ba antibody labeledwith the first moiety and the anti-Factor Bb antibody labeled with thesecond moiety after the step of (G); (I) providing the same light sourceto excite the donor in the control reaction mix; and (J) measuring thedonor fluorescence emission intensity from the control reaction mix,and/or the acceptor fluorescence emission intensity from the controlreaction mix; wherein a lower donor fluorescence emission intensity fromthe test reaction mix relative to the control reaction mix, and/or ahigher acceptor fluorescence emission intensity from the test reactionmix relative to the control reaction mix, indicates a greater inhibitionof Factor D activity by the Factor D inhibitor in the test reaction mixrelative to the control reaction mix. In specific embodiments, the stepsof (B) and (G) are conducted for about 15 min, 30 min, 45 min, 60 min,75 min, or 90 min. In some embodiments, the steps of (B) and (G) areconducted for about 45 min. In certain embodiments, the step of (E) isperformed after a period of time of the step of (D) that results in adecrease in interfering short-lived background signals, and the step of(J) is performed after the same period of time of the step of (I).

In certain embodiments, the anti-Factor Ba antibody and the anti-FactorBb antibody used in the method of determining the potency of a Factor Dinhibitor quench the activity of Factor D. In such embodiments, the needto add another quencher specifically is obviated. In certainembodiments, the method of determining the potency of a Factor Dinhibitor further comprise a step of quenching the activity of Factor Din the sample by providing an excessive amount of a quencher to thesample before the step of (c). When a control sample is used, in certainembodiments, the methods of measuring the activity of Factor D furthercomprise a step of quenching the activity of Factor D in the sample byproviding an excessive amount of a quencher to the sample before thestep of (c), and a step of quenching the activity of Factor D in thecontrol sample by providing an excessive amount of the quencher to thecontrol sample before the step of (g). In specific embodiments, thequencher is a Factor D inhibitor (for example, an anti-Factor D antibodyor an excess amount of EDTA).

In certain embodiments, the anti-Factor Ba antibody is biotinylated, andthe first moiety comprises streptavidin, avidin, or neutravidin. In someembodiments, the anti-Factor Ba antibody is biotinylated, and the firstmoiety comprises streptavidin. In certain embodiments, the anti-FactorBb antibody is biotinylated, and the second moiety comprisesstreptavidin, avidin, or neutravidin. In some embodiments, theanti-Factor Bb antibody is biotinylated, and the second moiety comprisesstreptavidin.

In other various embodiments, the methods of determining the potency ofa Factor D inhibitor comprise: (a) mixing a Factor D inhibitor candidatewith Factor D, Factor B and Factor C3b in a test reaction mix; (b)incubating the test reaction mix; (c) adding to the test reaction mix ananti-Factor C3b antibody labeled with a first moiety and an anti-FactorBa antibody labeled with a second moiety after the step of (b), whereinone of the moieties is a donor, and the other is an acceptor, andwherein a proximity signal generated by the acceptor and/or the donorindicates that Factor C3b and Factor Ba are in proximity; and (d)measuring the value of the proximity signal from the test reaction mix;wherein the potency of the Factor D inhibitor is positively correlatedwith the value of the proximity signal.

In certain aspects of such other various embodiments, the methods ofdetermining the potency of a Factor D inhibitor further comprise: (e)mixing a control reaction mix; (f) incubating the control reaction mix;(g) adding to the control reaction mix the anti-Factor C3b antibodylabeled with the first moiety and the anti-Factor Ba antibody labeledwith the second moiety after the step of (f); and (h) measuring thevalue of the proximity signal from the control test reaction mix;wherein a greater value of the proximity signal from the test reactionmix relative to the control reaction mix (e.g., about 10%, 15%, 20%,25%, 30%, 40%, 50%, 60%, 70%, 80%, 90% greater or more, or about 1-fold,1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold,9-fold, 10-fold, 15-fold, 20-fold, 30-fold, 40-fold, 50-fold greater ormore) indicates a greater inhibition of Factor D activity by the FactorD inhibitor in the test reaction mix relative to the control reactionmix.

When the proximity signal generated by the donor and/or the acceptor isbased on energy transfer between the donor and the acceptor upon lightactivation, in various embodiments, the methods of determining thepotency of a Factor D inhibitor comprise: (A) mixing the Factor Dinhibitor with Factor D, Factor B and Factor C3b in a test reaction mix;(B) incubating the test reaction mix; (C) adding to the test reactionmix an anti-Factor C3b antibody labeled with a first moiety and ananti-Factor Ba antibody labeled with a second moiety after the step of(B), wherein one of the moieties is a donor, and the other moiety is anacceptor; (D) providing a light source to excite the donor in the testreaction mix; and (E) measuring the donor fluorescence emissionintensity from the test reaction mix, and/or the acceptor fluorescenceemission intensity from the test reaction mix; wherein the potency ofthe Factor D inhibitor is negatively correlated with the donorfluorescence emission intensity from the test reaction mix, and/or ispositively correlated with the acceptor fluorescence emission intensityfrom the test reaction mix. In specific embodiments, the step of (B) isconducted for about 15 min, 30 min, 45 min, 60 min, 75 min, or 90 min.In some embodiments, the step of (B) is conducted for about 45 min. Incertain embodiments, the step of (E) is performed after a period of timeof the step of (D) that results in a decrease in interfering short-livedbackground signals. In specific embodiments, the methods of determiningthe potency of a Factor D inhibitor further comprise: (F) mixing acontrol reaction mix; (G) incubating the control reaction mix; (H)adding to the control reaction mix the anti-Factor C3b antibody labeledwith the first moiety and the anti-Factor Ba antibody labeled with thesecond moiety after the step of (G); (I) providing said light source toexcite the donor in the control reaction mix; and (J) measuring thedonor fluorescence emission intensity from the control reaction mix,and/or the acceptor fluorescence emission intensity from the controlreaction mix; wherein a lower donor fluorescence emission intensity fromthe test reaction mix relative to the control reaction mix, and/or ahigher acceptor fluorescence emission intensity from the test reactionmix relative to the control reaction mix, indicates a greater inhibitionof Factor D activity by the Factor D inhibitor in the test reaction mixrelative to the control reaction mix. In specific embodiments, the stepsof (B) and (G) are conducted for about 15 min, 30 min, 45 min, 60 min,75 min, or 90 min. In some embodiments, the steps of (B) and (G) areconducted for about 45 min. In certain embodiments, the step of (E) isperformed after a period of time of the step of (D) that results in adecrease in interfering short-lived background signals, and the step of(J) is performed after the same period of time of the step of (I).

In certain embodiments wherein anti-Factor C3b antibody and anti-FactorBa antibody are used, the anti-Factor C3b antibody is biotinylated, andthe first moiety comprises streptavidin, avidin, or neutravidin. In someembodiments, the anti-Factor C3b antibody is biotinylated, and the firstmoiety comprises streptavidin. In certain embodiments, the anti-FactorBa antibody is biotinylated, and the second moiety comprisesstreptavidin, avidin, or neutravidin. In some embodiments, theanti-Factor Ba antibody is biotinylated, and the second moiety comprisesstreptavidin.

In certain embodiments wherein anti-Factor C3b antibody and anti-FactorBa antibody are used, the anti-Factor C3b antibody and the anti-FactorBa antibody used in the method of determining the potency of a Factor Dinhibitor quench the activity of Factor D. In such embodiments, the needto add another quencher specifically is obviated. In certain embodimentswherein anti-Factor C3b antibody and anti-Factor Ba antibody are used,the method of determining the potency of a Factor D inhibitor furthercomprise a step of quenching the activity of Factor D in the sample byproviding an excessive amount of a quencher to the sample before thestep of (c). When a control sample is used, in certain embodiments, themethod of determining the potency of a Factor D inhibitor furthercomprise a step of quenching the activity of Factor D in the sample byproviding an excessive amount of a quencher to the sample before thestep of (c), and a step of quenching the activity of Factor D in thecontrol sample by providing an excessive amount of the quencher to thecontrol sample before the step of (g). In specific embodiments, thequencher is a Factor D inhibitor (for example, an anti-Factor D antibodyor an excess amount of EDTA).

The control reaction mix can comprise, for example, a different Factor Dinhibitor with known potency (e.g., 100% potency) or no Factor Dinhibitor, but contains everything else essentially the same as the testreaction mix. A quencher as described above can be used as a differentFactor D inhibitor in the control reaction mix. In specific embodiments,more than one control reaction mix is used in the methods describedherein. In certain embodiments, a standard curve has been generated forquantifying the potency of Factor D inhibitors in samples without theneed to measure a control reaction mix.

The donor/acceptor pair can be any known in the art, or as described inSection 5.1.

The Factor D inhibitor can be any pharmaceutical agent that reduces orblocks the activity of Factor D.

In specific embodiments, the Factor D inhibitor is an antibody or anantigen-binding fragment thereof, for example, an antibody or anantigen-binding fragment thereof that binds to Factor D (see forexample, International Patent Application Publication No. WO1999/042133, International Patent Application Publication No. WO2007/056227, International Patent Application Publication No. WO2008/055206, International Patent Application Publication No. WO2008/147883, and International Patent Application Publication No. WO2009/134711, the disclosures of which are hereby incorporated byreference herein in their entireties). In some embodiments, the antibodyis a murine antibody. In other embodiments, the antibody is a humanizedantibody. In specific embodiments, the antibody is a bispecific antibody(e.g., a bispecific antibody that binds to Factor D and HTRA1). In someembodiments, the antibody is lampalizumab (see, International PatentApplication Publication No. WO 2009/134711, the disclosure of which ishereby incorporated by reference herein in its entirety).

In some embodiments, the antibody comprises one, two, three, four, fiveor six of the following HVRs: (i) an HVR-H1 comprising the amino acidsequence of SEQ ID NO: 1; (ii) an HVR-H2 comprising the amino acidsequence of SEQ ID NO: 2, SEQ ID NO: 3, or SEQ ID NO: 4; (iii) an HVR-H3comprising the amino acid sequence of SEQ ID NO: 5, SEQ ID NO:6, SEQ IDNO: 7, or SEQ ID NO: 8; (iv) an HVR-L1 comprising the amino acidsequence of SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12,SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, or SEQ IDNO: 17; (v) an HVR-L2 comprising the amino acid sequence of SEQ ID NO:18; or (vi) an HVR-L3 comprising the amino acid sequence of SEQ ID NO:19 or SEQ ID NO: 20 (see Table 1).

In some embodiments, the antibody comprises one, two, three, four, fiveor six of the following HVRs: (i) an HVR-H1 comprising the amino acidsequence of SEQ ID NO: 85; (ii) an HVR-H2 comprising the amino acidsequence of SEQ ID NO: 86, SEQ ID NO: 87, SEQ ID NO: 88, SEQ ID NO: 89,SEQ ID NO: 90, SEQ ID NO: 91, SEQ ID NO: 92, SEQ ID NO: 93, or SEQ IDNO: 94; (iii) an HVR-H3 comprising the amino acid sequence of SEQ ID NO:95; (iv) an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 96;(v) an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 97, SEQID NO: 98, or SEQ ID NO: 99; or (vi) an HVR-L3 comprising the amino acidsequence of SEQ ID NO: 100 or SEQ ID NO: 101 (see Table 2).

TABLE 1 HVR amino acid sequences (in accordance with Kabat + Chothia HVRdefinitions) of anti-Factor D antibodies Antibody HVR-H1 HVR-H2 HVR-H3HVR-L1 HVR-L2 HVR-L3 AFD WT GYTFTNYGMN WINTYTGET EGGVNN ITSTDIDDDMNGGNTLRP LQSDSLPYT SEQ ID NO: 1 TYADDFKG SEQ ID NO: 5 SEQ ID NO: 9SEQ ID NO: 18 SEQ ID NO: 19 SEQ ID NO: 2 AFD.v1 GYTFTNYGMN WINTYTGETEGGVNN ITSTSIDDDMN GGNTLRP LQSDSLPYT SEQ ID NO: 1 TYADDFKG SEQ ID NO: 5SEQ ID NO: 10 SEQ ID NO: 18 SEQ ID NO: 19 SEQ ID NO: 2 AFD.v2 GYTFTNYGMNWINTYTGET EGGVNN ITSTDIEDDMN GGNTLRP LQSDSLPYT SEQ ID NO: 1 TYADDFKGSEQ ID NO: 5 SEQ ID NO: 11 SEQ ID NO: 18 SEQ ID NO: 19 SEQ ID NO: 2AFD.v3 GYTFTNYGMN WINTYTGET EGGVNN ITSTDIDSDMN GGNTLRP LQSDSLPYTSEQ ID NO: 1 TYADDFKG SEQ ID NO: 5 SEQ ID NO: 12 SEQ ID NO: 18SEQ ID NO: 19 SEQ ID NO: 2 AFD.v4 GYTFTNYGMN WINTYTGET EGGVNNITSTDIDDSMN GGNTLRP LQSDSLPYT SEQ ID NO: 1 TYADDFKG SEQ ID NO: 5SEQ ID NO: 13 SEQ ID NO: 18 SEQ ID NO: 19 SEQ ID NO: 2 AFD.v5 GYTFTNYGMNWINTYTGET EGGVNN ITSTSIDSSMN GGNTLRP LQSDSLPYT SEQ ID NO: 1 TYADDFKGSEQ ID NO: 5 SEQ ID NO: 14 SEQ ID NO: 18 SEQ ID NO: 19 SEQ ID NO: 2AFD.v6 GYTFTNYGMN WINTYTGET EGGVNN ITSTDIESDMN GGNTLRP LQSDSLPYTSEQ ID NO: 1 TYAEDFKG SEQ ID NO: 5 SEQ ID NO: 15 SEQ ID NO: 18SEQ ID NO: 19 SEQ ID NO: 3 AFD.v7 GYTFTNYGMN WINTYTGET EGGVNNITSTDIESDMN GGNTLRP LQSESLPYT SEQ ID NO: 1 TYAEDFKG SEQ ID NO: 5SEQ ID NO: 15 SEQ ID NO: 18 SEQ ID NO: 20 SEQ ID NO: 3 AFD.v8 GYTFTNYGMNWINTYTGET EGGVNN ITSTSIESDMN GGNTLRP LQSDSLPYT SEQ ID NO: 1 TYAEDFKGSEQ ID NO: 5 SEQ ID NO: 16 SEQ ID NO: 18 SEQ ID NO: 19 SEQ ID NO: 3AFD.v9 GYTFTNYGMN WINTYTGET EGGVNN ITSTSIESDMS GGNTLRP LQSDSLPYTSEQ ID NO: 1 TYAEDFKG SEQ ID NO: 5 SEQ ID NO: 17 SEQ ID NO: 18SEQ ID NO: 19 SEQ ID NO: 3 AFD .v10 GYTFTNYGMN WINTYTGET EGGVNNITSTSIESDMN GGNTLRP LQSESLPYT SEQ ID NO: 1 TYAEDFKG SEQ ID NO: 5SEQ ID NO: 16 SEQ ID NO: 18 SEQ ID NO: 20 SEQ ID NO: 3 AFD.v11GYTFTNYGMN WISTYTGET EGGVNN ITSTSIESDMN GGNTLRP LQSDSLPYT SEQ ID NO: 1TYAEDFKG SEQ ID NO: 5 SEQ ID NO: 16 SEQ ID NO: 18 SEQ ID NO: 19SEQ ID NO: 4 AFD.v12 GYTFTNYGMN WINTYTGET EGGVDN ITSTSIESDMN GGNTLRPLQSDSLPYT SEQ ID NO: 1 TYAEDFKG SEQ ID NO: 6 SEQ ID NO: 16 SEQ ID NO: 18SEQ ID NO: 19 SEQ ID NO: 3 AFD.v13 GYTFTNYGMN WINTYTGET EGGVQNITSTSIESDMN GGNTLRP LQSDSLPYT SEQ ID NO: 1 TYAEDFKG SEQ ID NO: 7SEQ ID NO: 16 SEQ ID NO: 18 SEQ ID NO: 19 SEQ ID NO: 3 AFD.v14GYTFTNYGMN WINTYTGET EGGVSN ITSTSIESDMN GGNTLRP LQSDSLPYT SEQ ID NO: 1TYAEDFKG SEQ ID NO: 3 SEQ ID NO: 8 SEQ ID NO: 16 SEQ ID NO: 18SEQ ID NO: 19 AFD .v 15 GYTFTNYGMN WINTYTGET EGGVSN ITSTSIESDMN GGNTLRPLQSDSLPYT SEQ ID NO: 1 TYAEDFKG SEQ ID NO: 8 SEQ ID NO: 16 SEQ ID NO: 18SEQ ID NO: 20 SEQ ID NO: 3

TABLE 2HVR amino acid sequences (in accordance with Kabat HVR definitions) ofadditional anti-Factor D antibodies Antibody HVR-H1 HVR-H2 HVR-H3 HVR-L1HVR-L2 HVR-L3 murine SYYMY EINPTNGGTN EGGFAY KASQNVDTDVA SASSRYSQQYNNYPLT AFD SEQ ID NO: 85 FNEKFKS SEQ ID NO: 95 SEQ ID NO: 96SEQ ID NO: 97 SEQ ID NO: 100 SEQ ID NO: 86 huAFD. SYYMY EINPTSGGTNEGGFAY KASQNVDTDVA SASSRYS QQYNNYPLT v2.0 SEQ ID NO: 85 FNEKFKSSEQ ID NO: 95 SEQ ID NO: 96 SEQ ID NO: 97 SEQ ID NO: 100 SEQ ID NO: 87huAFD. SYYMY EINPTSGGTN EGGFAY KASQNVDTDVA SASSRYS QQYNNYPLT v2.1SEQ ID NO: 85 FNEKFKS SEQ ID NO: 95 SEQ ID NO: 96 SEQ ID NO: 97SEQ ID NO: 100 SEQ ID NO: 87 huAFD. SYYMY EINPYSGUIN EGGFAY KASQNVDTDVASASSRYS QQYNNYPLT v2.3 SEQ ID NO: 85 FNEKFKS SEQ ID NO: 95 SEQ ID NO: 96SEQ ID NO: 97 SEQ ID NO: 100 SEQ ID NO: 88 huAFD. SYYMY EINPTNGGTNEGGFAY KASQNVDTDVA SASSRYS QQYNNYPLT v1 SEQ ID NO: 85 FNEKFKSSEQ ID NO: 95 SEQ ID NO: 96 SEQ ID NO: 97 SEQ ID NO: 100 SEQ ID NO: 86huAFD. SYYMY EINPTQGGTN EGGFAY KASQNVDTDVA SASSRYS QQYNNYPLT v1.1SEQ ID NO: 85 FNEKFKS SEQ ID NO: 95 SEQ ID NO: 96 SEQ ID NO: 97SEQ ID NO: 100 SEQ ID NO: 89 huAFD. SYYMY EINPTSGDTN EGGFAY KASQNVDTDVASASSRYS QQYNNYPLT v2.2 SEQ ID NO: 85 FNEKFKS SEQ ID NO: 95 SEQ ID NO: 96SEQ ID NO: 97 SEQ ID NO: 100 SEQ ID NO: 90 huAFD. SYYMY EINPTSGETNEGGFAY KASQNVDTDVA SASSRYS QQYNNYPLT v2.4 SEQ ID NO: 85 FNEKFKSSEQ ID NO: 95 SEQ ID NO: 96 SEQ ID NO: 97 SEQ ID NO: 100 SEQ ID NO: 91huAFD. SYYMY EINPYSGGTN EGGFAY KASQNVDTDVA SASSRYS QQYNNYPLT v2.5SEQ ID NO: 85 FNEKFKS SEQ ID NO: 95 SEQ ID NO: 96 SEQ ID NO: 97SEQ ID NO: 100 SEQ ID NO: 92 huAFD. SYYMY EINPTSGGTN EGGFAY KASQNVDTDVASASSRYS QQYNNYPLT v2.6 SEQ ID NO: 85 FNEKFKS SEQ ID NO: 95 SEQ ID NO: 96SEQ ID NO: 97 SEQ ID NO: 100 SEQ ID NO: 87 huAFD. SYYMY EINPTSGGTNEGGFAY KASQNVDTDVA SASSRYS QQYNNYPLT v2.7 SEQ ID NO: 85 FNEKFKSSEQ ID NO: 95 SEQ ID NO: 96 SEQ ID NO: 97 SEQ ID NO: 100 SEQ ID NO: 87huAFD. SYYMY EINPTSGGTN EGGFAY KASQNVDTDVA SASSRYS QQYNNYPLT v2.8SEQ ID NO: 85 FNEKFKS SEQ ID NO: 95 SEQ ID NO: 96 SEQ ID NO: 97SEQ ID NO: 100 SEQ ID NO: 87 huAFD. SYYMY WINPTSGGTN EGGFAY KASQNVDTDVASASSRYS QQYNNYPLT v2.9 SEQ ID NO: 85 FNEKFKS SEQ ID NO: 95 SEQ ID NO: 96SEQ ID NO: 97 SEQ ID NO: 100 SEQ ID NO: 93 huAFD. SYYMY EINPTSGGTNEGGFAY KASQNVDTDVA SASSRKS QQYNNYPLT v2.10 SEQ ID NO: 85 FNEKFKSSEQ ID NO: 95 SEQ ID NO: 96 SEQ ID NO: 98 SEQ ID NO: 100 SEQ ID NO: 87huAFD. SYYMY EINPTSGGTN EGGFAY KASQNVDTDVA SASSRRS QQYNNYPLT v2.11SEQ ID NO: 85 FNEKFKS SEQ ID NO: 95 SEQ ID NO: 96 SEQ ID NO: 99SEQ ID NO: 100 SEQ ID NO: 87 huAFD. SYYMY EINPYSGGTN EGGFAY KASQNVDTDVASASSRYS QQYNNYPLT v2.12 SEQ ID NO: 85 FNEKFKS SEQ ID NO: 95SEQ ID NO: 96 SEQ ID NO: 97 SEQ ID NO: 100 SEQ ID NO: 92 huAFD. SYYMYEINPTSGGTN EGGFAY KASQNVDTDVA SASSRYS QQYENYPLT v2.13 SEQ ID NO: 85FNEKFKS SEQ ID NO: 95 SEQ ID NO: 96 SEQ ID NO: 97 SEQ ID NO: 101SEQ ID NO: 87 huAFD. SYYMY EINPTSGETN EGGFAY KASQNVDTDVA SASSRYSQQYNNYPLT v2.14 SEQ ID NO: 85 FNEKFKS SEQ ID NO: 95 SEQ ID NO: 96SEQ ID NO: 97 SEQ ID NO: 101 SEQ ID NO: 91 huAFD. SYYMY EINPYSGETNEGGFAY KASQNVDTDVA SASSRYS QQYNNYPLT v2.15 SEQ ID NO: 85 FNEKFKSSEQ ID NO: 95 SEQ ID NO: 96 SEQ ID NO: 97 SEQ ID NO: 100 SEQ ID NO: 94

In some embodiments, the antibody comprises an HVR-H1 comprising theamino acid sequence of SEQ ID NO: 1, an HVR-H2 comprising the amino acidsequence of SEQ ID NO: 2, and an HVR-H3 comprising the amino acidsequence of SEQ ID NO: 5.

In some embodiments, the antibody comprises an HVR-H1 comprising theamino acid sequence of SEQ ID NO: 1, an HVR-H2 comprising the amino acidsequence of SEQ ID NO: 3, and an HVR-H3 comprising the amino acidsequence of SEQ ID NO: 5.

In some embodiments, the antibody comprises an HVR-H1 comprising theamino acid sequence of SEQ ID NO: 1, an HVR-H2 comprising the amino acidsequence of SEQ ID NO: 4, and an HVR-H3 comprising the amino acidsequence of SEQ ID NO: 5.

In some embodiments, the antibody comprises an HVR-H1 comprising theamino acid sequence of SEQ ID NO: 1, an HVR-H2 comprising the amino acidsequence of SEQ ID NO: 3, and an HVR-H3 comprising the amino acidsequence of SEQ ID NO: 6.

In some embodiments, the antibody comprises an HVR-H1 comprising theamino acid sequence of SEQ ID NO: 1, an HVR-H2 comprising the amino acidsequence of SEQ ID NO: 3, and an HVR-H3 comprising the amino acidsequence of SEQ ID NO: 7.

In some embodiments, the antibody comprises an HVR-H1 comprising theamino acid sequence of SEQ ID NO: 1, an HVR-H2 comprising the amino acidsequence of SEQ ID NO: 3, and an HVR-H3 comprising the amino acidsequence of SEQ ID NO: 8.

In some embodiments, the antibody comprises an HVR-L1 comprising theamino acid sequence of SEQ ID NO: 9, an HVR-L2 comprising the amino acidsequence of SEQ ID NO: 18, and an HVR-L3 comprising the amino acidsequence of SEQ ID NO: 19.

In some embodiments, the antibody comprises an HVR-L1 comprising theamino acid sequence of SEQ ID NO: 10, an HVR-L2 comprising the aminoacid sequence of SEQ ID NO: 18, and an HVR-L3 comprising the amino acidsequence of SEQ ID NO: 19.

In some embodiments, the antibody comprises an HVR-L1 comprising theamino acid sequence of SEQ ID NO: 11, an HVR-L2 comprising the aminoacid sequence of SEQ ID NO: 18, and an HVR-L3 comprising the amino acidsequence of SEQ ID NO: 19.

In some embodiments, the antibody comprises an HVR-L1 comprising theamino acid sequence of SEQ ID NO: 12, an HVR-L2 comprising the aminoacid sequence of SEQ ID NO: 18, and an HVR-L3 comprising the amino acidsequence of SEQ ID NO: 19.

In some embodiments, the antibody comprises an HVR-L1 comprising theamino acid sequence of SEQ ID NO: 13, an HVR-L2 comprising the aminoacid sequence of SEQ ID NO: 18, and an HVR-L3 comprising the amino acidsequence of SEQ ID NO: 19.

In some embodiments, the antibody comprises an HVR-L1 comprising theamino acid sequence of SEQ ID NO: 14, an HVR-L2 comprising the aminoacid sequence of SEQ ID NO: 18, and an HVR-L3 comprising the amino acidsequence of SEQ ID NO: 19.

In some embodiments, the antibody comprises an HVR-L1 comprising theamino acid sequence of SEQ ID NO: 15, an HVR-L2 comprising the aminoacid sequence of SEQ ID NO: 18, and an HVR-L3 comprising the amino acidsequence of SEQ ID NO: 19.

In some embodiments, the antibody comprises an HVR-L1 comprising theamino acid sequence of SEQ ID NO: 15, an HVR-L2 comprising the aminoacid sequence of SEQ ID NO: 18, and an HVR-L3 comprising the amino acidsequence of SEQ ID NO: 20.

In some embodiments, the antibody comprises an HVR-L1 comprising theamino acid sequence of SEQ ID NO: 16, an HVR-L2 comprising the aminoacid sequence of SEQ ID NO: 18, and an HVR-L3 comprising the amino acidsequence of SEQ ID NO: 19.

In some embodiments, the antibody comprises an HVR-L1 comprising theamino acid sequence of SEQ ID NO: 17, an HVR-L2 comprising the aminoacid sequence of SEQ ID NO: 18, and an HVR-L3 comprising the amino acidsequence of SEQ ID NO: 19.

In some embodiments, the antibody comprises an HVR-L1 comprising theamino acid sequence of SEQ ID NO: 16, an HVR-L2 comprising the aminoacid sequence of SEQ ID NO: 18, and an HVR-L3 comprising the amino acidsequence of SEQ ID NO: 20.

In some embodiments, the antibody comprises an HVR-H1 comprising theamino acid sequence of SEQ ID NO: 1, an HVR-H2 comprising the amino acidsequence of SEQ ID NO: 2, an HVR-H3 comprising the amino acid sequenceof SEQ ID NO: 5, an HVR-L1 comprising the amino acid sequence of SEQ IDNO: 9, an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 18,and an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 19.

In some embodiments, the antibody comprises an HVR-H1 comprising theamino acid sequence of SEQ ID NO: 1, an HVR-H2 comprising the amino acidsequence of SEQ ID NO: 2, an HVR-H3 comprising the amino acid sequenceof SEQ ID NO: 5, an HVR-L1 comprising the amino acid sequence of SEQ IDNO: 10, an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 18,and an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 19.

In some embodiments, the antibody comprises an HVR-H1 comprising theamino acid sequence of SEQ ID NO: 1, an HVR-H2 comprising the amino acidsequence of SEQ ID NO: 2, an HVR-H3 comprising the amino acid sequenceof SEQ ID NO: 5, an HVR-L1 comprising the amino acid sequence of SEQ IDNO: 11, an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 18,and an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 19.

In some embodiments, the antibody comprises an HVR-H1 comprising theamino acid sequence of SEQ ID NO: 1, an HVR-H2 comprising the amino acidsequence of SEQ ID NO: 2, an HVR-H3 comprising the amino acid sequenceof SEQ ID NO: 5, an HVR-L1 comprising the amino acid sequence of SEQ IDNO: 12, an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 18,and an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 19.

In some embodiments, the antibody comprises an HVR-H1 comprising theamino acid sequence of SEQ ID NO: 1, an HVR-H2 comprising the amino acidsequence of SEQ ID NO: 2, an HVR-H3 comprising the amino acid sequenceof SEQ ID NO: 5, an HVR-L1 comprising the amino acid sequence of SEQ IDNO: 13, an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 18,and an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 19.

In some embodiments, the antibody comprises an HVR-H1 comprising theamino acid sequence of SEQ ID NO: 1, an HVR-H2 comprising the amino acidsequence of SEQ ID NO: 2, an HVR-H3 comprising the amino acid sequenceof SEQ ID NO: 5, an HVR-L1 comprising the amino acid sequence of SEQ IDNO: 14, an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 18,and an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 19.

In some embodiments, the antibody comprises an HVR-H1 comprising theamino acid sequence of SEQ ID NO: 1, an HVR-H2 comprising the amino acidsequence of SEQ ID NO: 3, an HVR-H3 comprising the amino acid sequenceof SEQ ID NO: 5, an HVR-L1 comprising the amino acid sequence of SEQ IDNO: 15, an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 18,and an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 19.

In some embodiments, the antibody comprises an HVR-H1 comprising theamino acid sequence of SEQ ID NO: 1, an HVR-H2 comprising the amino acidsequence of SEQ ID NO: 3, an HVR-H3 comprising the amino acid sequenceof SEQ ID NO: 5, an HVR-L1 comprising the amino acid sequence of SEQ IDNO: 15, an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 18,and an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 20.

In some embodiments, the antibody comprises an HVR-H1 comprising theamino acid sequence of SEQ ID NO: 1, an HVR-H2 comprising the amino acidsequence of SEQ ID NO: 3, an HVR-H3 comprising the amino acid sequenceof SEQ ID NO: 5, an HVR-L1 comprising the amino acid sequence of SEQ IDNO: 16, an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 18,and an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 19.

In some embodiments, the antibody comprises an HVR-H1 comprising theamino acid sequence of SEQ ID NO: 1, an HVR-H2 comprising the amino acidsequence of SEQ ID NO: 3, an HVR-H3 comprising the amino acid sequenceof SEQ ID NO: 5, an HVR-L1 comprising the amino acid sequence of SEQ IDNO: 17, an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 18,and an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 19.

In some embodiments, the antibody comprises an HVR-H1 comprising theamino acid sequence of SEQ ID NO: 1, an HVR-H2 comprising the amino acidsequence of SEQ ID NO: 3, an HVR-H3 comprising the amino acid sequenceof SEQ ID NO: 5, an HVR-L1 comprising the amino acid sequence of SEQ IDNO: 16, an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 18,and an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 20.

In some embodiments, the antibody comprises an HVR-H1 comprising theamino acid sequence of SEQ ID NO: 1, an HVR-H2 comprising the amino acidsequence of SEQ ID NO: 4, an HVR-H3 comprising the amino acid sequenceof SEQ ID NO: 5, an HVR-L1 comprising the amino acid sequence of SEQ IDNO: 16, an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 18,and an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 19.

In some embodiments, the antibody comprises an HVR-H1 comprising theamino acid sequence of SEQ ID NO: 1, an HVR-H2 comprising the amino acidsequence of SEQ ID NO: 3, an HVR-H3 comprising the amino acid sequenceof SEQ ID NO: 6, an HVR-L1 comprising the amino acid sequence of SEQ IDNO: 16, an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 18,and an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 19.

In some embodiments, the antibody comprises an HVR-H1 comprising theamino acid sequence of SEQ ID NO: 1, an HVR-H2 comprising the amino acidsequence of SEQ ID NO: 3, an HVR-H3 comprising the amino acid sequenceof SEQ ID NO: 7, an HVR-L1 comprising the amino acid sequence of SEQ IDNO: 16, an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 18,and an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 19.

In some embodiments, the antibody comprises an HVR-H1 comprising theamino acid sequence of SEQ ID NO: 1, an HVR-H2 comprising the amino acidsequence of SEQ ID NO: 3, an HVR-H3 comprising the amino acid sequenceof SEQ ID NO: 8, an HVR-L1 comprising the amino acid sequence of SEQ IDNO: 16, an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 18,and an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 19.

In some embodiments, the antibody comprises an HVR-H1 comprising theamino acid sequence of SEQ ID NO: 1, an HVR-H2 comprising the amino acidsequence of SEQ ID NO: 3, an HVR-H3 comprising the amino acid sequenceof SEQ ID NO: 8, an HVR-L1 comprising the amino acid sequence of SEQ IDNO: 16, an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 18,and an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 20.

In some embodiments, the antibody comprises an HVR-H1 comprising theamino acid sequence of SEQ ID NO: 85, an HVR-H2 comprising the aminoacid sequence of SEQ ID NO: 86, and an HVR-H3 comprising the amino acidsequence of SEQ ID NO: 95.

In some embodiments, the antibody comprises an HVR-H1 comprising theamino acid sequence of SEQ ID NO: 85, an HVR-H2 comprising the aminoacid sequence of SEQ ID NO: 87, and an HVR-H3 comprising the amino acidsequence of SEQ ID NO: 95.

In some embodiments, the antibody comprises an HVR-H1 comprising theamino acid sequence of SEQ ID NO: 85, an HVR-H2 comprising the aminoacid sequence of SEQ ID NO: 88, and an HVR-H3 comprising the amino acidsequence of SEQ ID NO: 95.

In some embodiments, the antibody comprises an HVR-H1 comprising theamino acid sequence of SEQ ID NO: 85, an HVR-H2 comprising the aminoacid sequence of SEQ ID NO: 89, and an HVR-H3 comprising the amino acidsequence of SEQ ID NO: 95.

In some embodiments, the antibody comprises an HVR-H1 comprising theamino acid sequence of SEQ ID NO: 85, an HVR-H2 comprising the aminoacid sequence of SEQ ID NO: 90, and an HVR-H3 comprising the amino acidsequence of SEQ ID NO: 95.

In some embodiments, the antibody comprises an HVR-H1 comprising theamino acid sequence of SEQ ID NO: 85, an HVR-H2 comprising the aminoacid sequence of SEQ ID NO: 91, and an HVR-H3 comprising the amino acidsequence of SEQ ID NO: 95.

In some embodiments, the antibody comprises an HVR-H1 comprising theamino acid sequence of SEQ ID NO: 85, an HVR-H2 comprising the aminoacid sequence of SEQ ID NO: 92, and an HVR-H3 comprising the amino acidsequence of SEQ ID NO: 95.

In some embodiments, the antibody comprises an HVR-H1 comprising theamino acid sequence of SEQ ID NO: 85, an HVR-H2 comprising the aminoacid sequence of SEQ ID NO: 93, and an HVR-H3 comprising the amino acidsequence of SEQ ID NO: 95.

In some embodiments, the antibody comprises an HVR-H1 comprising theamino acid sequence of SEQ ID NO: 85, an HVR-H2 comprising the aminoacid sequence of SEQ ID NO: 94, and an HVR-H3 comprising the amino acidsequence of SEQ ID NO: 95.

In some embodiments, the antibody comprises an HVR-L1 comprising theamino acid sequence of SEQ ID NO: 96, an HVR-L2 comprising the aminoacid sequence of SEQ ID NO: 97, and an HVR-L3 comprising the amino acidsequence of SEQ ID NO: 100.

In some embodiments, the antibody comprises an HVR-L1 comprising theamino acid sequence of SEQ ID NO: 96, an HVR-L2 comprising the aminoacid sequence of SEQ ID NO: 98, and an HVR-L3 comprising the amino acidsequence of SEQ ID NO: 100.

In some embodiments, the antibody comprises an HVR-L1 comprising theamino acid sequence of SEQ ID NO: 96, an HVR-L2 comprising the aminoacid sequence of SEQ ID NO: 99, and an HVR-L3 comprising the amino acidsequence of SEQ ID NO: 100.

In some embodiments, the antibody comprises an HVR-L1 comprising theamino acid sequence of SEQ ID NO: 96, an HVR-L2 comprising the aminoacid sequence of SEQ ID NO: 97, and an HVR-L3 comprising the amino acidsequence of SEQ ID NO: 101.

In some embodiments, the antibody comprises an HVR-H1 comprising theamino acid sequence of SEQ ID NO: 85, an HVR-H2 comprising the aminoacid sequence of SEQ ID NO: 86, an HVR-H3 comprising the amino acidsequence of SEQ ID NO: 95, an HVR-L1 comprising the amino acid sequenceof SEQ ID NO: 96, an HVR-L2 comprising the amino acid sequence of SEQ IDNO: 97, and an HVR-L3 comprising the amino acid sequence of SEQ ID NO:100.

In some embodiments, the antibody comprises an HVR-H1 comprising theamino acid sequence of SEQ ID NO: 85, an HVR-H2 comprising the aminoacid sequence of SEQ ID NO: 87, an HVR-H3 comprising the amino acidsequence of SEQ ID NO: 95, an HVR-L1 comprising the amino acid sequenceof SEQ ID NO: 96, an HVR-L2 comprising the amino acid sequence of SEQ IDNO: 97, and an HVR-L3 comprising the amino acid sequence of SEQ ID NO:100.

In some embodiments, the antibody comprises an HVR-H1 comprising theamino acid sequence of SEQ ID NO: 85, an HVR-H2 comprising the aminoacid sequence of SEQ ID NO: 88, an HVR-H3 comprising the amino acidsequence of SEQ ID NO: 95, an HVR-L1 comprising the amino acid sequenceof SEQ ID NO: 96, an HVR-L2 comprising the amino acid sequence of SEQ IDNO: 97, and an HVR-L3 comprising the amino acid sequence of SEQ ID NO:100.

In some embodiments, the antibody comprises an HVR-H1 comprising theamino acid sequence of SEQ ID NO: 85, an HVR-H2 comprising the aminoacid sequence of SEQ ID NO: 89, an HVR-H3 comprising the amino acidsequence of SEQ ID NO: 95, an HVR-L1 comprising the amino acid sequenceof SEQ ID NO: 96, an HVR-L2 comprising the amino acid sequence of SEQ IDNO: 97, and an HVR-L3 comprising the amino acid sequence of SEQ ID NO:100.

In some embodiments, the antibody comprises an HVR-H1 comprising theamino acid sequence of SEQ ID NO: 85, an HVR-H2 comprising the aminoacid sequence of SEQ ID NO: 90, an HVR-H3 comprising the amino acidsequence of SEQ ID NO: 95, an HVR-L1 comprising the amino acid sequenceof SEQ ID NO: 96, an HVR-L2 comprising the amino acid sequence of SEQ IDNO: 97, and an HVR-L3 comprising the amino acid sequence of SEQ ID NO:100.

In some embodiments, the antibody comprises an HVR-H1 comprising theamino acid sequence of SEQ ID NO: 85, an HVR-H2 comprising the aminoacid sequence of SEQ ID NO: 91, an HVR-H3 comprising the amino acidsequence of SEQ ID NO: 95, an HVR-L1 comprising the amino acid sequenceof SEQ ID NO: 96, an HVR-L2 comprising the amino acid sequence of SEQ IDNO: 97, and an HVR-L3 comprising the amino acid sequence of SEQ ID NO:100.

In some embodiments, the antibody comprises an HVR-H1 comprising theamino acid sequence of SEQ ID NO: 85, an HVR-H2 comprising the aminoacid sequence of SEQ ID NO: 92, an HVR-H3 comprising the amino acidsequence of SEQ ID NO: 95, an HVR-L1 comprising the amino acid sequenceof SEQ ID NO: 96, an HVR-L2 comprising the amino acid sequence of SEQ IDNO: 97, and an HVR-L3 comprising the amino acid sequence of SEQ ID NO:100.

In some embodiments, the antibody comprises an HVR-H1 comprising theamino acid sequence of SEQ ID NO: 85, an HVR-H2 comprising the aminoacid sequence of SEQ ID NO: 93, an HVR-H3 comprising the amino acidsequence of SEQ ID NO: 95, an HVR-L1 comprising the amino acid sequenceof SEQ ID NO: 96, an HVR-L2 comprising the amino acid sequence of SEQ IDNO: 97, and an HVR-L3 comprising the amino acid sequence of SEQ ID NO:100.

In some embodiments, the antibody comprises an HVR-H1 comprising theamino acid sequence of SEQ ID NO: 85, an HVR-H2 comprising the aminoacid sequence of SEQ ID NO: 87, an HVR-H3 comprising the amino acidsequence of SEQ ID NO: 95, an HVR-L1 comprising the amino acid sequenceof SEQ ID NO: 96, an HVR-L2 comprising the amino acid sequence of SEQ IDNO: 98, and an HVR-L3 comprising the amino acid sequence of SEQ ID NO:100.

In some embodiments, the antibody comprises an HVR-H1 comprising theamino acid sequence of SEQ ID NO: 85, an HVR-H2 comprising the aminoacid sequence of SEQ ID NO: 87, an HVR-H3 comprising the amino acidsequence of SEQ ID NO: 95, an HVR-L1 comprising the amino acid sequenceof SEQ ID NO: 96, an HVR-L2 comprising the amino acid sequence of SEQ IDNO: 99, and an HVR-L3 comprising the amino acid sequence of SEQ ID NO:100.

In some embodiments, the antibody comprises an HVR-H1 comprising theamino acid sequence of SEQ ID NO: 85, an HVR-H2 comprising the aminoacid sequence of SEQ ID NO: 87, an HVR-H3 comprising the amino acidsequence of SEQ ID NO: 95, an HVR-L1 comprising the amino acid sequenceof SEQ ID NO: 96, an HVR-L2 comprising the amino acid sequence of SEQ IDNO: 97, and an HVR-L3 comprising the amino acid sequence of SEQ ID NO:101.

In some embodiments, the antibody comprises an HVR-H1 comprising theamino acid sequence of SEQ ID NO: 85, an HVR-H2 comprising the aminoacid sequence of SEQ ID NO: 94, an HVR-H3 comprising the amino acidsequence of SEQ ID NO: 95, an HVR-L1 comprising the amino acid sequenceof SEQ ID NO: 96, an HVR-L2 comprising the amino acid sequence of SEQ IDNO: 97, and an HVR-L3 comprising the amino acid sequence of SEQ ID NO:100.

In some embodiments, the antibody comprises a heavy chain variabledomain having the amino acid sequence of SEQ ID NO: 21. In someembodiments, the antibody comprises a heavy chain variable domain havingat least 90% sequence identity to the amino acid sequence of SEQ ID NO:21. See Table 3.

In some embodiments, the antibody comprises a light chain variabledomain having the amino acid sequence of SEQ ID NO: 22. In someembodiments, the antibody comprises a light chain variable domain havingat least 90% sequence identity to the amino acid sequence of SEQ ID NO:22. See Table 3.

In some embodiments, the antibody comprises a heavy chain variabledomain having the amino acid sequence of SEQ ID NO: 21, and a lightchain variable domain having the amino acid sequence of SEQ ID NO: 22.In some embodiments, the antibody comprises a heavy chain variabledomain having at least 90% sequence identity to the amino acid sequenceof SEQ ID NO: 21, and a light chain variable domain having at least 90%sequence identity to the amino acid sequence of SEQ ID NO: 22. See Table3.

In some embodiments, the antibody comprises a heavy chain variabledomain having the amino acid sequence of SEQ ID NO: 23. In someembodiments, the antibody comprises a heavy chain variable domain havingat least 90% sequence identity to the amino acid sequence of SEQ ID NO:23. See Table 3.

In some embodiments, the antibody comprises a light chain variabledomain having the amino acid sequence of SEQ ID NO: 24. In someembodiments, the antibody comprises a light chain variable domain havingat least 90% sequence identity to the amino acid sequence of SEQ ID NO:24. See Table 3.

In some embodiments, the antibody comprises a heavy chain variabledomain having the amino acid sequence of SEQ ID NO: 23, and a lightchain variable domain having the amino acid sequence of SEQ ID NO: 24.In some embodiments, the antibody comprises a heavy chain variabledomain having at least 90% sequence identity to the amino acid sequenceof SEQ ID NO: 23, and a light chain variable domain having at least 90%sequence identity to the amino acid sequence of SEQ ID NO: 24. See Table3.

In some embodiments, the antibody comprises a heavy chain variabledomain having the amino acid sequence of SEQ ID NO: 25. In someembodiments, the antibody comprises a heavy chain variable domain havingat least 90% sequence identity to the amino acid sequence of SEQ ID NO:25. See Table 3.

In some embodiments, the antibody comprises a light chain variabledomain having the amino acid sequence of SEQ ID NO: 26. In someembodiments, the antibody comprises a light chain variable domain havingat least 90% sequence identity to the amino acid sequence of SEQ ID NO:26. See Table 3.

In some embodiments, the antibody comprises a heavy chain variabledomain having the amino acid sequence of SEQ ID NO: 25, and a lightchain variable domain having the amino acid sequence of SEQ ID NO: 26.In some embodiments, the antibody comprises a heavy chain variabledomain having at least 90% sequence identity to the amino acid sequenceof SEQ ID NO: 25, and a light chain variable domain having at least 90%sequence identity to the amino acid sequence of SEQ ID NO: 26. See Table3.

In some embodiments, the antibody comprises a heavy chain variabledomain having the amino acid sequence of SEQ ID NO: 27. In someembodiments, the antibody comprises a heavy chain variable domain havingat least 90% sequence identity to the amino acid sequence of SEQ ID NO:27. See Table 3.

In some embodiments, the antibody comprises a light chain variabledomain having the amino acid sequence of SEQ ID NO: 28. In someembodiments, the antibody comprises a light chain variable domain havingat least 90% sequence identity to the amino acid sequence of SEQ ID NO:28. See Table 3.

In some embodiments, the antibody comprises a heavy chain variabledomain having the amino acid sequence of SEQ ID NO: 27, and a lightchain variable domain having the amino acid sequence of SEQ ID NO: 28.In some embodiments, the antibody comprises a heavy chain variabledomain having at least 90% sequence identity to the amino acid sequenceof SEQ ID NO: 27, and a light chain variable domain having at least 90%sequence identity to the amino acid sequence of SEQ ID NO: 28. See Table3.

In some embodiments, the antibody comprises a heavy chain variabledomain having the amino acid sequence of SEQ ID NO: 29. In someembodiments, the antibody comprises a heavy chain variable domain havingat least 90% sequence identity to the amino acid sequence of SEQ ID NO:29. See Table 3.

In some embodiments, the antibody comprises a light chain variabledomain having the amino acid sequence of SEQ ID NO: 30. In someembodiments, the antibody comprises a light chain variable domain havingat least 90% sequence identity to the amino acid sequence of SEQ ID NO:30. See Table 3.

In some embodiments, the antibody comprises a heavy chain variabledomain having the amino acid sequence of SEQ ID NO: 29, and a lightchain variable domain having the amino acid sequence of SEQ ID NO: 30.In some embodiments, the antibody comprises a heavy chain variabledomain having at least 90% sequence identity to the amino acid sequenceof SEQ ID NO: 29, and a light chain variable domain having at least 90%sequence identity to the amino acid sequence of SEQ ID NO: 30. See Table3.

In some embodiments, the antibody comprises a heavy chain variabledomain having the amino acid sequence of SEQ ID NO: 31. In someembodiments, the antibody comprises a heavy chain variable domain havingat least 90% sequence identity to the amino acid sequence of SEQ ID NO:31. See Table 3.

In some embodiments, the antibody comprises a light chain variabledomain having the amino acid sequence of SEQ ID NO: 32. In someembodiments, the antibody comprises a light chain variable domain havingat least 90% sequence identity to the amino acid sequence of SEQ ID NO:32. See Table 3.

In some embodiments, the antibody comprises a heavy chain variabledomain having the amino acid sequence of SEQ ID NO: 31, and a lightchain variable domain having the amino acid sequence of SEQ ID NO: 32.In some embodiments, the antibody comprises a heavy chain variabledomain having at least 90% sequence identity to the amino acid sequenceof SEQ ID NO: 31, and a light chain variable domain having at least 90%sequence identity to the amino acid sequence of SEQ ID NO: 32. See Table3.

In some embodiments, the antibody comprises a heavy chain variabledomain having the amino acid sequence of SEQ ID NO: 33. In someembodiments, the antibody comprises a heavy chain variable domain havingat least 90% sequence identity to the amino acid sequence of SEQ ID NO:33. See Table 3.

In some embodiments, the antibody comprises a light chain variabledomain having the amino acid sequence of SEQ ID NO: 34. In someembodiments, the antibody comprises a light chain variable domain havingat least 90% sequence identity to the amino acid sequence of SEQ ID NO:34. See Table 3.

In some embodiments, the antibody comprises a heavy chain variabledomain having the amino acid sequence of SEQ ID NO: 33, and a lightchain variable domain having the amino acid sequence of SEQ ID NO: 34.In some embodiments, the antibody comprises a heavy chain variabledomain having at least 90% sequence identity to the amino acid sequenceof SEQ ID NO: 33, and a light chain variable domain having at least 90%sequence identity to the amino acid sequence of SEQ ID NO: 34. See Table3.

In some embodiments, the antibody comprises a heavy chain variabledomain having the amino acid sequence of SEQ ID NO: 35. In someembodiments, the antibody comprises a heavy chain variable domain havingat least 90% sequence identity to the amino acid sequence of SEQ ID NO:35. See Table 3.

In some embodiments, the antibody comprises a light chain variabledomain having the amino acid sequence of SEQ ID NO: 36. In someembodiments, the antibody comprises a light chain variable domain havingat least 90% sequence identity to the amino acid sequence of SEQ ID NO:36. See Table 3.

In some embodiments, the antibody comprises a heavy chain variabledomain having the amino acid sequence of SEQ ID NO: 35, and a lightchain variable domain having the amino acid sequence of SEQ ID NO: 36.In some embodiments, the antibody comprises a heavy chain variabledomain having at least 90% sequence identity to the amino acid sequenceof SEQ ID NO: 35, and a light chain variable domain having at least 90%sequence identity to the amino acid sequence of SEQ ID NO: 36. See Table3.

In some embodiments, the antibody comprises a heavy chain variabledomain having the amino acid sequence of SEQ ID NO: 37. In someembodiments, the antibody comprises a heavy chain variable domain havingat least 90% sequence identity to the amino acid sequence of SEQ ID NO:37. See Table 3.

In some embodiments, the antibody comprises a light chain variabledomain having the amino acid sequence of SEQ ID NO: 38. In someembodiments, the antibody comprises a light chain variable domain havingat least 90% sequence identity to the amino acid sequence of SEQ ID NO:38. See Table 3.

In some embodiments, the antibody comprises a heavy chain variabledomain having the amino acid sequence of SEQ ID NO: 37, and a lightchain variable domain having the amino acid sequence of SEQ ID NO: 38.In some embodiments, the antibody comprises a heavy chain variabledomain having at least 90% sequence identity to the amino acid sequenceof SEQ ID NO: 37, and a light chain variable domain having at least 90%sequence identity to the amino acid sequence of SEQ ID NO: 38. See Table3.

In some embodiments, the antibody comprises a heavy chain variabledomain having the amino acid sequence of SEQ ID NO: 39. In someembodiments, the antibody comprises a heavy chain variable domain havingat least 90% sequence identity to the amino acid sequence of SEQ ID NO:39. See Table 3.

In some embodiments, the antibody comprises a light chain variabledomain having the amino acid sequence of SEQ ID NO: 40. In someembodiments, the antibody comprises a light chain variable domain havingat least 90% sequence identity to the amino acid sequence of SEQ ID NO:40. See Table 3.

In some embodiments, the antibody comprises a heavy chain variabledomain having the amino acid sequence of SEQ ID NO: 39, and a lightchain variable domain having the amino acid sequence of SEQ ID NO: 40.In some embodiments, the antibody comprises a heavy chain variabledomain having at least 90% sequence identity to the amino acid sequenceof SEQ ID NO: 39, and a light chain variable domain having at least 90%sequence identity to the amino acid sequence of SEQ ID NO: 40. See Table3.

In some embodiments, the antibody comprises a heavy chain variabledomain having the amino acid sequence of SEQ ID NO: 41. In someembodiments, the antibody comprises a heavy chain variable domain havingat least 90% sequence identity to the amino acid sequence of SEQ ID NO:41. See Table 3.

In some embodiments, the antibody comprises a light chain variabledomain having the amino acid sequence of SEQ ID NO: 42. In someembodiments, the antibody comprises a light chain variable domain havingat least 90% sequence identity to the amino acid sequence of SEQ ID NO:42. See Table 3.

In some embodiments, the antibody comprises a heavy chain variabledomain having the amino acid sequence of SEQ ID NO: 41, and a lightchain variable domain having the amino acid sequence of SEQ ID NO: 42.In some embodiments, the antibody comprises a heavy chain variabledomain having at least 90% sequence identity to the amino acid sequenceof SEQ ID NO: 41, and a light chain variable domain having at least 90%sequence identity to the amino acid sequence of SEQ ID NO: 42. See Table3.

In some embodiments, the antibody comprises a heavy chain variabledomain having the amino acid sequence of SEQ ID NO: 43. In someembodiments, the antibody comprises a heavy chain variable domain havingat least 90% sequence identity to the amino acid sequence of SEQ ID NO:43. See Table 3.

In some embodiments, the antibody comprises a light chain variabledomain having the amino acid sequence of SEQ ID NO: 44. In someembodiments, the antibody comprises a light chain variable domain havingat least 90% sequence identity to the amino acid sequence of SEQ ID NO:44. See Table 3.

In some embodiments, the antibody comprises a heavy chain variabledomain having the amino acid sequence of SEQ ID NO: 43, and a lightchain variable domain having the amino acid sequence of SEQ ID NO: 44.In some embodiments, the antibody comprises a heavy chain variabledomain having at least 90% sequence identity to the amino acid sequenceof SEQ ID NO: 43, and a light chain variable domain having at least 90%sequence identity to the amino acid sequence of SEQ ID NO: 44. See Table3.

In some embodiments, the antibody comprises a heavy chain variabledomain having the amino acid sequence of SEQ ID NO: 45. In someembodiments, the antibody comprises a heavy chain variable domain havingat least 90% sequence identity to the amino acid sequence of SEQ ID NO:45. See Table 3.

In some embodiments, the antibody comprises a light chain variabledomain having the amino acid sequence of SEQ ID NO: 46. In someembodiments, the antibody comprises a light chain variable domain havingat least 90% sequence identity to the amino acid sequence of SEQ ID NO:46. See Table 3.

In some embodiments, the antibody comprises a heavy chain variabledomain having the amino acid sequence of SEQ ID NO: 45, and a lightchain variable domain having the amino acid sequence of SEQ ID NO: 46.In some embodiments, the antibody comprises a heavy chain variabledomain having at least 90% sequence identity to the amino acid sequenceof SEQ ID NO: 45, and a light chain variable domain having at least 90%sequence identity to the amino acid sequence of SEQ ID NO: 46. See Table3.

In some embodiments, the antibody comprises a heavy chain variabledomain having the amino acid sequence of SEQ ID NO: 47. In someembodiments, the antibody comprises a heavy chain variable domain havingat least 90% sequence identity to the amino acid sequence of SEQ ID NO:47. See Table 3.

In some embodiments, the antibody comprises a light chain variabledomain having the amino acid sequence of SEQ ID NO: 48. In someembodiments, the antibody comprises a light chain variable domain havingat least 90% sequence identity to the amino acid sequence of SEQ ID NO:48. See Table 3.

In some embodiments, the antibody comprises a heavy chain variabledomain having the amino acid sequence of SEQ ID NO: 47, and a lightchain variable domain having the amino acid sequence of SEQ ID NO: 48.In some embodiments, the antibody comprises a heavy chain variabledomain having at least 90% sequence identity to the amino acid sequenceof SEQ ID NO: 47, and a light chain variable domain having at least 90%sequence identity to the amino acid sequence of SEQ ID NO: 48. See Table3.

In some embodiments, the antibody comprises a heavy chain variabledomain having the amino acid sequence of SEQ ID NO: 49. In someembodiments, the antibody comprises a heavy chain variable domain havingat least 90% sequence identity to the amino acid sequence of SEQ ID NO:49. See Table 3.

In some embodiments, the antibody comprises a light chain variabledomain having the amino acid sequence of SEQ ID NO: 50. In someembodiments, the antibody comprises a light chain variable domain havingat least 90% sequence identity to the amino acid sequence of SEQ ID NO:50. See Table 3.

In some embodiments, the antibody comprises a heavy chain variabledomain having the amino acid sequence of SEQ ID NO: 49, and a lightchain variable domain having the amino acid sequence of SEQ ID NO: 50.In some embodiments, the antibody comprises a heavy chain variabledomain having at least 90% sequence identity to the amino acid sequenceof SEQ ID NO: 49, and a light chain variable domain having at least 90%sequence identity to the amino acid sequence of SEQ ID NO: 50. See Table3.

In some embodiments, the antibody comprises a heavy chain variabledomain having the amino acid sequence of SEQ ID NO: 51. In someembodiments, the antibody comprises a heavy chain variable domain havingat least 90% sequence identity to the amino acid sequence of SEQ ID NO:51. See Table 3.

In some embodiments, the antibody comprises a light chain variabledomain having the amino acid sequence of SEQ ID NO: 52. In someembodiments, the antibody comprises a light chain variable domain havingat least 90% sequence identity to the amino acid sequence of SEQ ID NO:52. See Table 3.

In some embodiments, the antibody comprises a heavy chain variabledomain having the amino acid sequence of SEQ ID NO: 51, and a lightchain variable domain having the amino acid sequence of SEQ ID NO: 52.In some embodiments, the antibody comprises a heavy chain variabledomain having at least 90% sequence identity to the amino acid sequenceof SEQ ID NO: 51, and a light chain variable domain having at least 90%sequence identity to the amino acid sequence of SEQ ID NO: 52. See Table3.

TABLE 3Heavy chain and light chain variable domain amino acid sequences of anti-Factor D antibodies SEQ ID AFD WT Heavy ChainEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 21 Variable RegionWINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGG VNNWGQGTLVTVSSSEQ ID AFD WT Light ChainDIQVTQSPSSLSASVGDRVTITCITSTDIDDDMNWYQQKPGKVPKLLISGGNT NO: 22Variable Region LRPGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCLQSDSLPYTFGQGTKVEIKSEQ ID AFD.v1 Heavy ChainEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 23 Variable RegionWINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGG VNNWGQGTLVTVSSSEQ ID AFD.v1 Light ChainDIQVTQSPSSLSASVGDRVTITCITSTSIDDDMNWYQQKPGKVPKLLISGGNT NO: 24Variable Region LRPGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCLQSDSLPYTFGQGTKVEIKSEQ ID AFD.v2 Heavy ChainEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 25 Variable RegionWINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGG VNNWGQGTLVTVSSSEQ ID AFD.v2 Light ChainDIQVTQSPSSLSASVGDRVTITCITSTDIEDDMNWYQQKPGKVPKLLISGGNT NO: 26Variable Region LRPGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCLQSDSLPYTFGQGTKVEIKSEQ ID AFD.v3 Heavy ChainEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 27 Variable RegionWINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGG VNNWGQGTLVTVSSSEQ ID AFD.v3 Light ChainDIQVTQSPSSLSASVGDRVTITCITSTDIDSDMNWYQQKPGKVPKLLISGGNT NO: 28Variable Region LRPGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCLQSDSLPYTFGQGTKVEIKSEQ ID AFD.v4 Heavy ChainEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 29 Variable RegionWINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGG VNNWGQGTLVTVSSSEQ ID AFD.v4 Light ChainDIQVTQSPSSLSASVGDRVTITCITSTDIDDSMNWYQQKPGKVPKLLISGGNT NO: 30Variable Region LRPGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCLQSDSLPYTFGQGTKVEIKSEQ ID AFD.v5 Heavy ChainEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 31 Variable RegionWINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGG VNNWGQGTLVTVSSSEQ ID AFD.v5 Light ChainDIQVTQSPSSLSASVGDRVTITCITSTSIDSSMNWYQQKPGKVPKLLISGGNTL NO: 32Variable Region RPGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCLQSDSLPYTFGQGTKVEIKSEQ ID AFD.v6 Heavy ChainEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 33 Variable RegionWINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGG VNNWGQGTLVTVSSSEQ ID AFD.v6 Light ChainDIQVTQSPSSLSASVGDRVTITCITSTDIESDMNWYQQKPGKVPKLLISGGNT NO: 34Variable Region LRPGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCLQSDSLPYTFGQGTKVEIKSEQ ID AFD.v7 Heavy ChainEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 35 Variable RegionWINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGG VNNWGQGTLVTVSSSEQ ID AFD.v7 Light ChainDIQVTQSPSSLSASVGDRVTITCITSTDIESDMNWYQQKPGKVPKLLISGGNT NO: 36Variable Region LRPGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCLQSESLPYTFGQGTKVEIKSEQ ID AFD.v8 Heavy ChainEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 37 Variable RegionWINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGG VNNWGQGTLVTVSSSEQ ID AFD.v8 Light ChainDIQVTQSPSSLSASVGDRVTITCITSTSIESDMNWYQQKPGKVPKLLISGGNTL NO: 38Variable Region RPGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCLQSDSLPYTFGQGTKVEIKSEQ ID AFD.v9 Heavy ChainEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 39 Variable RegionWINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGG VNNWGQGTLVTVSSSEQ ID AFD.v9 Light ChainDIQVTQSPSSLSASVGDRVTITCITSTSIESDMSWYQQKPGKVPKLLISGGNTL NO: 40Variable Region RPGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCLQSDSLPYTFGQGTKVEIKSEQ ID AFD.v10 Heavy ChainEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 41 Variable RegionWINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGG VNNWGQGTLVTVSSSEQ ID AFD.v10 Light ChainDIQVTQSPSSLSASVGDRVTITCITSTSIESDMNWYQQKPGKVPKLLISGGNTL NO: 42Variable Region RPGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCLQSESLPYTFGQGTKVEIKSEQ ID AFD.v11 Heavy ChainEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 43 Variable RegionWISTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGG VNNWGQGTLVTVSSSEQ ID AFD.v11 Light ChainDIQVTQSPSSLSASVGDRVTITCITSTSIESDMNWYQQKPGKVPKLLISGGNTL NO: 44Variable Region RPGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCLQSDSLPYTFGQGTKVEIKSEQ ID AFD.v12 Heavy ChainEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 45 Variable RegionWINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGG VDNWGQGTLVTVSSSEQ ID AFD.v12 Light ChainDIQVTQSPSSLSASVGDRVTITCITSTSIESDMNWYQQKPGKVPKLLISGGNTL NO: 46Variable Region RPGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCLQSDSLPYTFGQGTKVEIKSEQ ID AFD.v13 Heavy ChainEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 47 Variable RegionWINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGG VQNWGQGTLVTVSSSEQ ID AFD.v13 Light ChainDIQVTQSPSSLSASVGDRVTITCITSTSIESDMNWYQQKPGKVPKLLISGGNTL NO: 48Variable Region RPGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCLQSDSLPYTFGQGTKVEIKSEQ ID AFD.v14 Heavy ChainEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 49 Variable RegionWINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGG VSNWGQGTLVTVSSSEQ ID AFD.v14 Light ChainDIQVTQSPSSLSASVGDRVTITCITSTSIESDMNWYQQKPGKVPKLLISGGNTL NO: 50Variable Region RPGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCLQSDSLPYTFGQGTKVEIKSEQ ID AFD.v15 Heavy ChainEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 51 Variable RegionWINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGG VSNWGQGTLVTVSSSEQ ID AFD.v15 Light ChainDIQVTQSPSSLSASVGDRVTITCITSTSIESDMNWYQQKPGKVPKLLISGGNTL NO: 52Variable Region RPGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCLQSESLPYTFGQGTKVEIK

In some embodiments, the antibody comprises a heavy chain variabledomain having the amino acid sequence of SEQ ID NO: 102. In someembodiments, the antibody comprises a heavy chain variable domain havingat least 90% sequence identity to the amino acid sequence of SEQ ID NO:102. See Table 4.

In some embodiments, the antibody comprises a light chain variabledomain having the amino acid sequence of SEQ ID NO: 103. In someembodiments, the antibody comprises a light chain variable domain havingat least 90% sequence identity to the amino acid sequence of SEQ ID NO:103. See Table 4.

In some embodiments, the antibody comprises a heavy chain variabledomain having the amino acid sequence of SEQ ID NO: 102, and a lightchain variable domain having the amino acid sequence of SEQ ID NO: 103.In some embodiments, the antibody comprises a heavy chain variabledomain having at least 90% sequence identity to the amino acid sequenceof SEQ ID NO: 102, and a light chain variable domain having at least 90%sequence identity to the amino acid sequence of SEQ ID NO: 103. SeeTable 4.

In some embodiments, the antibody comprises a heavy chain variabledomain having the amino acid sequence of SEQ ID NO: 104. In someembodiments, the antibody comprises a heavy chain variable domain havingat least 90% sequence identity to the amino acid sequence of SEQ ID NO:104. See Table 4.

In some embodiments, the antibody comprises a light chain variabledomain having the amino acid sequence of SEQ ID NO: 105. In someembodiments, the antibody comprises a light chain variable domain havingat least 90% sequence identity to the amino acid sequence of SEQ ID NO:105. See Table 4.

In some embodiments, the antibody comprises a heavy chain variabledomain having the amino acid sequence of SEQ ID NO: 104, and a lightchain variable domain having the amino acid sequence of SEQ ID NO: 105.In some embodiments, the antibody comprises a heavy chain variabledomain having at least 90% sequence identity to the amino acid sequenceof SEQ ID NO: 104, and a light chain variable domain having at least 90%sequence identity to the amino acid sequence of SEQ ID NO: 105. SeeTable 4.

In some embodiments, the antibody comprises a heavy chain variabledomain having the amino acid sequence of SEQ ID NO: 106. In someembodiments, the antibody comprises a heavy chain variable domain havingat least 90% sequence identity to the amino acid sequence of SEQ ID NO:106. See Table 4.

In some embodiments, the antibody comprises a light chain variabledomain having the amino acid sequence of SEQ ID NO: 107. In someembodiments, the antibody comprises a light chain variable domain havingat least 90% sequence identity to the amino acid sequence of SEQ ID NO:107. See Table 4.

In some embodiments, the antibody comprises a heavy chain variabledomain having the amino acid sequence of SEQ ID NO: 106, and a lightchain variable domain having the amino acid sequence of SEQ ID NO: 107.In some embodiments, the antibody comprises a heavy chain variabledomain having at least 90% sequence identity to the amino acid sequenceof SEQ ID NO: 106, and a light chain variable domain having at least 90%sequence identity to the amino acid sequence of SEQ ID NO: 107. SeeTable 4.

In some embodiments, the antibody comprises a heavy chain variabledomain having the amino acid sequence of SEQ ID NO: 108. In someembodiments, the antibody comprises a heavy chain variable domain havingat least 90% sequence identity to the amino acid sequence of SEQ ID NO:108. See Table 4.

In some embodiments, the antibody comprises a light chain variabledomain having the amino acid sequence of SEQ ID NO: 109. In someembodiments, the antibody comprises a light chain variable domain havingat least 90% sequence identity to the amino acid sequence of SEQ ID NO:109. See Table 4.

In some embodiments, the antibody comprises a heavy chain variabledomain having the amino acid sequence of SEQ ID NO: 108, and a lightchain variable domain having the amino acid sequence of SEQ ID NO: 109.In some embodiments, the antibody comprises a heavy chain variabledomain having at least 90% sequence identity to the amino acid sequenceof SEQ ID NO: 108, and a light chain variable domain having at least 90%sequence identity to the amino acid sequence of SEQ ID NO: 109. SeeTable 4.

In some embodiments, the antibody comprises a heavy chain variabledomain having the amino acid sequence of SEQ ID NO: 110. In someembodiments, the antibody comprises a heavy chain variable domain havingat least 90% sequence identity to the amino acid sequence of SEQ ID NO:110. See Table 4.

In some embodiments, the antibody comprises a light chain variabledomain having the amino acid sequence of SEQ ID NO: 111. In someembodiments, the antibody comprises a light chain variable domain havingat least 90% sequence identity to the amino acid sequence of SEQ ID NO:111. See Table 4.

In some embodiments, the antibody comprises a heavy chain variabledomain having the amino acid sequence of SEQ ID NO: 110, and a lightchain variable domain having the amino acid sequence of SEQ ID NO: 111.In some embodiments, the antibody comprises a heavy chain variabledomain having at least 90% sequence identity to the amino acid sequenceof SEQ ID NO: 110, and a light chain variable domain having at least 90%sequence identity to the amino acid sequence of SEQ ID NO: 111. SeeTable 4.

In some embodiments, the antibody comprises a heavy chain variabledomain having the amino acid sequence of SEQ ID NO: 112. In someembodiments, the antibody comprises a heavy chain variable domain havingat least 90% sequence identity to the amino acid sequence of SEQ ID NO:112. See Table 4.

In some embodiments, the antibody comprises a light chain variabledomain having the amino acid sequence of SEQ ID NO: 113. In someembodiments, the antibody comprises a light chain variable domain havingat least 90% sequence identity to the amino acid sequence of SEQ ID NO:113. See Table 4.

In some embodiments, the antibody comprises a heavy chain variabledomain having the amino acid sequence of SEQ ID NO: 112, and a lightchain variable domain having the amino acid sequence of SEQ ID NO: 113.In some embodiments, the antibody comprises a heavy chain variabledomain having at least 90% sequence identity to the amino acid sequenceof SEQ ID NO: 112, and a light chain variable domain having at least 90%sequence identity to the amino acid sequence of SEQ ID NO: 113. SeeTable 4.

In some embodiments, the antibody comprises a heavy chain variabledomain having the amino acid sequence of SEQ ID NO: 114. In someembodiments, the antibody comprises a heavy chain variable domain havingat least 90% sequence identity to the amino acid sequence of SEQ ID NO:114. See Table 4.

In some embodiments, the antibody comprises a light chain variabledomain having the amino acid sequence of SEQ ID NO: 115. In someembodiments, the antibody comprises a light chain variable domain havingat least 90% sequence identity to the amino acid sequence of SEQ ID NO:115. See Table 4.

In some embodiments, the antibody comprises a heavy chain variabledomain having the amino acid sequence of SEQ ID NO: 114, and a lightchain variable domain having the amino acid sequence of SEQ ID NO: 115.In some embodiments, the antibody comprises a heavy chain variabledomain having at least 90% sequence identity to the amino acid sequenceof SEQ ID NO: 114, and a light chain variable domain having at least 90%sequence identity to the amino acid sequence of SEQ ID NO: 115. SeeTable 4.

In some embodiments, the antibody comprises a heavy chain variabledomain having the amino acid sequence of SEQ ID NO: 116. In someembodiments, the antibody comprises a heavy chain variable domain havingat least 90% sequence identity to the amino acid sequence of SEQ ID NO:116. See Table 4.

In some embodiments, the antibody comprises a light chain variabledomain having the amino acid sequence of SEQ ID NO: 117. In someembodiments, the antibody comprises a light chain variable domain havingat least 90% sequence identity to the amino acid sequence of SEQ ID NO:117. See Table 4.

In some embodiments, the antibody comprises a heavy chain variabledomain having the amino acid sequence of SEQ ID NO: 116, and a lightchain variable domain having the amino acid sequence of SEQ ID NO: 117.In some embodiments, the antibody comprises a heavy chain variabledomain having at least 90% sequence identity to the amino acid sequenceof SEQ ID NO: 116, and a light chain variable domain having at least 90%sequence identity to the amino acid sequence of SEQ ID NO: 117. SeeTable 4.

In some embodiments, the antibody comprises a heavy chain variabledomain having the amino acid sequence of SEQ ID NO: 118. In someembodiments, the antibody comprises a heavy chain variable domain havingat least 90% sequence identity to the amino acid sequence of SEQ ID NO:118. See Table 4.

In some embodiments, the antibody comprises a light chain variabledomain having the amino acid sequence of SEQ ID NO: 119. In someembodiments, the antibody comprises a light chain variable domain havingat least 90% sequence identity to the amino acid sequence of SEQ ID NO:119. See Table 4.

In some embodiments, the antibody comprises a heavy chain variabledomain having the amino acid sequence of SEQ ID NO: 118, and a lightchain variable domain having the amino acid sequence of SEQ ID NO: 119.In some embodiments, the antibody comprises a heavy chain variabledomain having at least 90% sequence identity to the amino acid sequenceof SEQ ID NO: 118, and a light chain variable domain having at least 90%sequence identity to the amino acid sequence of SEQ ID NO: 119. SeeTable 4.

In some embodiments, the antibody comprises a heavy chain variabledomain having the amino acid sequence of SEQ ID NO: 120. In someembodiments, the antibody comprises a heavy chain variable domain havingat least 90% sequence identity to the amino acid sequence of SEQ ID NO:120. See Table 4.

In some embodiments, the antibody comprises a light chain variabledomain having the amino acid sequence of SEQ ID NO: 121. In someembodiments, the antibody comprises a light chain variable domain havingat least 90% sequence identity to the amino acid sequence of SEQ ID NO:121. See Table 4.

In some embodiments, the antibody comprises a heavy chain variabledomain having the amino acid sequence of SEQ ID NO: 120, and a lightchain variable domain having the amino acid sequence of SEQ ID NO: 121.In some embodiments, the antibody comprises a heavy chain variabledomain having at least 90% sequence identity to the amino acid sequenceof SEQ ID NO: 120, and a light chain variable domain having at least 90%sequence identity to the amino acid sequence of SEQ ID NO: 121. SeeTable 4.

In some embodiments, the antibody comprises a heavy chain variabledomain having the amino acid sequence of SEQ ID NO: 122. In someembodiments, the antibody comprises a heavy chain variable domain havingat least 90% sequence identity to the amino acid sequence of SEQ ID NO:122. See Table 4.

In some embodiments, the antibody comprises a light chain variabledomain having the amino acid sequence of SEQ ID NO: 123. In someembodiments, the antibody comprises a light chain variable domain havingat least 90% sequence identity to the amino acid sequence of SEQ ID NO:123. See Table 4.

In some embodiments, the antibody comprises a heavy chain variabledomain having the amino acid sequence of SEQ ID NO: 122, and a lightchain variable domain having the amino acid sequence of SEQ ID NO: 123.In some embodiments, the antibody comprises a heavy chain variabledomain having at least 90% sequence identity to the amino acid sequenceof SEQ ID NO: 122, and a light chain variable domain having at least 90%sequence identity to the amino acid sequence of SEQ ID NO: 123. SeeTable 4.

In some embodiments, the antibody comprises a heavy chain variabledomain having the amino acid sequence of SEQ ID NO: 124. In someembodiments, the antibody comprises a heavy chain variable domain havingat least 90% sequence identity to the amino acid sequence of SEQ ID NO:124. See Table 4.

In some embodiments, the antibody comprises a light chain variabledomain having the amino acid sequence of SEQ ID NO: 125. In someembodiments, the antibody comprises a light chain variable domain havingat least 90% sequence identity to the amino acid sequence of SEQ ID NO:125. See Table 4.

In some embodiments, the antibody comprises a heavy chain variabledomain having the amino acid sequence of SEQ ID NO: 124, and a lightchain variable domain having the amino acid sequence of SEQ ID NO: 125.In some embodiments, the antibody comprises a heavy chain variabledomain having at least 90% sequence identity to the amino acid sequenceof SEQ ID NO: 124, and a light chain variable domain having at least 90%sequence identity to the amino acid sequence of SEQ ID NO: 125. SeeTable 4.

In some embodiments, the antibody comprises a heavy chain variabledomain having the amino acid sequence of SEQ ID NO: 126. In someembodiments, the antibody comprises a heavy chain variable domain havingat least 90% sequence identity to the amino acid sequence of SEQ ID NO:126. See Table 4.

In some embodiments, the antibody comprises a light chain variabledomain having the amino acid sequence of SEQ ID NO: 127. In someembodiments, the antibody comprises a light chain variable domain havingat least 90% sequence identity to the amino acid sequence of SEQ ID NO:127. See Table 4.

In some embodiments, the antibody comprises a heavy chain variabledomain having the amino acid sequence of SEQ ID NO: 126, and a lightchain variable domain having the amino acid sequence of SEQ ID NO: 127.In some embodiments, the antibody comprises a heavy chain variabledomain having at least 90% sequence identity to the amino acid sequenceof SEQ ID NO: 126, and a light chain variable domain having at least 90%sequence identity to the amino acid sequence of SEQ ID NO: 127. SeeTable 4.

In some embodiments, the antibody comprises a heavy chain variabledomain having the amino acid sequence of SEQ ID NO: 128. In someembodiments, the antibody comprises a heavy chain variable domain havingat least 90% sequence identity to the amino acid sequence of SEQ ID NO:128. See Table 4.

In some embodiments, the antibody comprises a light chain variabledomain having the amino acid sequence of SEQ ID NO: 129. In someembodiments, the antibody comprises a light chain variable domain havingat least 90% sequence identity to the amino acid sequence of SEQ ID NO:129. See Table 4.

In some embodiments, the antibody comprises a heavy chain variabledomain having the amino acid sequence of SEQ ID NO: 128, and a lightchain variable domain having the amino acid sequence of SEQ ID NO: 129.In some embodiments, the antibody comprises a heavy chain variabledomain having at least 90% sequence identity to the amino acid sequenceof SEQ ID NO: 128, and a light chain variable domain having at least 90%sequence identity to the amino acid sequence of SEQ ID NO: 129. SeeTable 4.

In some embodiments, the antibody comprises a heavy chain variabledomain having the amino acid sequence of SEQ ID NO: 130. In someembodiments, the antibody comprises a heavy chain variable domain havingat least 90% sequence identity to the amino acid sequence of SEQ ID NO:130. See Table 4.

In some embodiments, the antibody comprises a light chain variabledomain having the amino acid sequence of SEQ ID NO: 131. In someembodiments, the antibody comprises a light chain variable domain havingat least 90% sequence identity to the amino acid sequence of SEQ ID NO:131. See Table 4.

In some embodiments, the antibody comprises a heavy chain variabledomain having the amino acid sequence of SEQ ID NO: 130, and a lightchain variable domain having the amino acid sequence of SEQ ID NO: 131.In some embodiments, the antibody comprises a heavy chain variabledomain having at least 90% sequence identity to the amino acid sequenceof SEQ ID NO: 130, and a light chain variable domain having at least 90%sequence identity to the amino acid sequence of SEQ ID NO: 131. SeeTable 4.

In some embodiments, the antibody comprises a heavy chain variabledomain having the amino acid sequence of SEQ ID NO: 132. In someembodiments, the antibody comprises a heavy chain variable domain havingat least 90% sequence identity to the amino acid sequence of SEQ ID NO:132. See Table 4.

In some embodiments, the antibody comprises a light chain variabledomain having the amino acid sequence of SEQ ID NO: 133. In someembodiments, the antibody comprises a light chain variable domain havingat least 90% sequence identity to the amino acid sequence of SEQ ID NO:133. See Table 4.

In some embodiments, the antibody comprises a heavy chain variabledomain having the amino acid sequence of SEQ ID NO: 132, and a lightchain variable domain having the amino acid sequence of SEQ ID NO: 133.In some embodiments, the antibody comprises a heavy chain variabledomain having at least 90% sequence identity to the amino acid sequenceof SEQ ID NO: 132, and a light chain variable domain having at least 90%sequence identity to the amino acid sequence of SEQ ID NO: 133. SeeTable 4.

In some embodiments, the antibody comprises a heavy chain variabledomain having the amino acid sequence of SEQ ID NO: 134. In someembodiments, the antibody comprises a heavy chain variable domain havingat least 90% sequence identity to the amino acid sequence of SEQ ID NO:134. See Table 4.

In some embodiments, the antibody comprises a light chain variabledomain having the amino acid sequence of SEQ ID NO: 135. In someembodiments, the antibody comprises a light chain variable domain havingat least 90% sequence identity to the amino acid sequence of SEQ ID NO:135. See Table 4.

In some embodiments, the antibody comprises a heavy chain variabledomain having the amino acid sequence of SEQ ID NO: 134, and a lightchain variable domain having the amino acid sequence of SEQ ID NO: 135.In some embodiments, the antibody comprises a heavy chain variabledomain having at least 90% sequence identity to the amino acid sequenceof SEQ ID NO: 134, and a light chain variable domain having at least 90%sequence identity to the amino acid sequence of SEQ ID NO: 135. SeeTable 4.

In some embodiments, the antibody comprises a heavy chain variabledomain having the amino acid sequence of SEQ ID NO: 136. In someembodiments, the antibody comprises a heavy chain variable domain havingat least 90% sequence identity to the amino acid sequence of SEQ ID NO:136. See Table 4.

In some embodiments, the antibody comprises a light chain variabledomain having the amino acid sequence of SEQ ID NO: 137. In someembodiments, the antibody comprises a light chain variable domain havingat least 90% sequence identity to the amino acid sequence of SEQ ID NO:137. See Table 4.

In some embodiments, the antibody comprises a heavy chain variabledomain having the amino acid sequence of SEQ ID NO: 136, and a lightchain variable domain having the amino acid sequence of SEQ ID NO: 137.In some embodiments, the antibody comprises a heavy chain variabledomain having at least 90% sequence identity to the amino acid sequenceof SEQ ID NO: 136, and a light chain variable domain having at least 90%sequence identity to the amino acid sequence of SEQ ID NO: 137. SeeTable 4.

In some embodiments, the antibody comprises a heavy chain variabledomain having the amino acid sequence of SEQ ID NO: 138. In someembodiments, the antibody comprises a heavy chain variable domain havingat least 90% sequence identity to the amino acid sequence of SEQ ID NO:138. See Table 4.

In some embodiments, the antibody comprises a light chain variabledomain having the amino acid sequence of SEQ ID NO: 139. In someembodiments, the antibody comprises a light chain variable domain havingat least 90% sequence identity to the amino acid sequence of SEQ ID NO:139. See Table 4.

In some embodiments, the antibody comprises a heavy chain variabledomain having the amino acid sequence of SEQ ID NO: 138, and a lightchain variable domain having the amino acid sequence of SEQ ID NO: 139.In some embodiments, the antibody comprises a heavy chain variabledomain having at least 90% sequence identity to the amino acid sequenceof SEQ ID NO: 138, and a light chain variable domain having at least 90%sequence identity to the amino acid sequence of SEQ ID NO: 139. SeeTable 4.

TABLE 4Heavy chain and light chain variable domain amino acid sequences ofadditional anti-Factor D antibodies SEQ ID murine AFD HeavyQVQLQQSGAELVKPGASVKLSCKASGYTFTSYYMYWVKERPGQGLEWIGEI NO: 102Chain Variable RegionNPTNGGTNFNEKFKSKATLTVDTSSNTAYMQLSSLTSEDSAVYYCAREGGF AYWGQGTLVTVSA SEQ IDmurine AFD Light DIVMTQSQKFMSTSVGDRVSVTCKASQNVDTDVAWFQQKPGQSPRGLIYSANO: 103 Chain Variable RegionSSRYSGVPDRFTGSGSGTDFTLTISNVQSEDLAEYFCQQYNNYPLTFGSGTK VEIK SEQ IDhuAFD.v2.0 Heavy EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGENO: 104 Chain Variable RegionINPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFA YWGQGTLVTVSSSEQ ID huAFD.v2.0 LightDIQMTQSPSSLSASVGDRVTITCKASQNVDTDVAWFQQKPGKAPKGLIYSAS NO: 105Chain Variable RegionSRYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNNYPLTFGQGTKVE IK SEQ IDhuAFD.v2.1 Heavy EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGENO: 106 Chain Variable RegionINPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFA YWGQGTLVTVSSSEQ ID huAFD.v2.1 LightDIQMTQSPSSLSASVGDRVTITCKASQNVDTDVAWFQQKPGKAPKGLIRSAS NO: 107Chain Variable RegionSRYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNNYPLTFGQGTKVE IK SEQ IDhuAFD.v2.3 Heavy EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGENO: 108 Chain Variable RegionINPYSGDTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFA YWGQGTLVTVSSSEQ ID huAFD.v2.3 LightDIQMTQSPSSLSASVGDRVTITCKASQNVDTDVAWFQQKPGKAPKGLIRSAS NO: 109Chain Variable RegionSRYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNNYPLTFGQGTKVE IK SEQ IDhuAFD.v1 Heavy EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGENO: 110 Chain Variable RegionINPTNGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGF AYWGQGTLVTVSSSEQ ID huAFD.v1 Light ChainDIQMTQSPSSLSASVGDRVTITCKASQNVDTDVAWFQQKPGKAPKGLIYSAS NO: 111Variable Region SRYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNNYPLTFGQGTKVE IKSEQ ID huAFD.v1.1 HeavyEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 112Chain Variable RegionINPTQGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGF AYWGQGTLVTVSSSEQ ID huAFD.v1.1 LightDIQMTQSPSSLSASVGDRVTITCKASQNVDTDVAWFQQKPGKAPKGLIYSAS NO: 113Chain Variable RegionSRYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNNYPLTFGQGTKVE IK SEQ IDhuAFD.v2.2 Heavy EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGENO: 114 Chain Variable RegionINPTSGDTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFA YWGQGTLVTVSSSEQ ID huAFD.v2.2 LightDIQMTQSPSSLSASVGDRVTITCKASQNVDTDVAWFQQKPGKAPKGLIYSAS NO: 115Chain Variable RegionSRYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNNYPLTFGQGTKVE IK SEQ IDhuAFD.v2.4 Heavy EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGENO: 116 Chain Variable RegionINPTSGETNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFA YWGQGTLVTVSSSEQ ID huAFD.v2.4 LightDIQMTQSPSSLSASVGDRVTITCKASQNVDTDVAWFQQKPGKAPKGLIYSAS NO: 117Chain Variable RegionSRYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNNYPLTFGQGTKVE IK SEQ IDhuAFD.v2.5 Heavy EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGENO: 118 Chain Variable RegionINPYSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFA YWGQGTLVTVSSSEQ ID huAFD.v2.5 LightDIQMTQSPSSLSASVGDRVTITCKASQNVDTDVAWFQQKPGKAPKGLIYSAS NO: 119Chain Variable RegionSRYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNNYPLTFGQGTKVE IK SEQ IDhuAFD.v2.6 Heavy EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGENO: 120 Chain Variable RegionINPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFA YWGQGTLVTVSSSEQ ID huAFD.v2.6 LightDIQMTQSPSSLSASVGDRVTITCKASQNVDTDVAWFQQKPGKAPKGLISSAS NO: 121Chain Variable RegionSRYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNNYPLTFGQGTKVE IK SEQ IDhuAFD.v2.7 Heavy EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGENO: 122 Chain Variable RegionINPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFA YWGQGTLVTVSSSEQ ID huAFD.v2.7 LightDIQMTQSPSSLSASVGDRVTITCKASQNVDTDVAWFQQKPGKAPKGLIKSAS NO: 123Chain Variable RegionSRYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNNYPLTFGQGTKVE IK SEQ IDhuAFD.v2.8 Heavy EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGENO: 124 Chain Variable RegionINPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFA YWGQGTLVTVSSSEQ ID huAFD.v2.8 LightDIQMTQSPSSLSASVGDRVTITCKASQNVDTDVAWFQQKPGKAPKGLIQSAS NO: 125Chain Variable RegionSRYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNNYPLTFGQGTKVE IK SEQ IDhuAFD.v2.9 Heavy EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGNO: 126 Chain Variable RegionWINPTSGGTNFNEKFKSRATLTVDTSTSTAYELSSLRSEDTAVYYCAREGG FAYWGQGTLVTVSSSEQ ID huAFD.v2.9 LightDIQMTQSPSSLSASVGDRVTITCKASQNVDTDVAWFQQKPGKAPKGLIYSAS NO: 127Chain Variable RegionSRYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNNYPLTFGQGTKVE IK SEQ IDhuAFD.v2.10 Heavy EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGENO: 128 Chain Variable RegionINPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFA YWGQGTLVTVSSSEQ ID huAFD.v2.10 LightDIQMTQSPSSLSASVGDRVTITCKASQNVDTDVAWFQQKPGKAPKGLIYSAS NO: 129Chain Variable RegionSRKSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNNYPLTFGQGTKVE IK SEQ IDhuAFD.v2.11 Heavy EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGENO: 130 Chain Variable RegionINPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFA YWGQGTLVTVSSSEQ ID huAFD.v2.11 LightDIQMTQSPSSLSASVGDRVTITCKASQNVDTDVAWFQQKPGKAPKGLIYSAS NO: 131Chain Variable RegionSRRSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNNYPLTFGQGTKVE IK SEQ IDhuAFD.v2.12 Heavy EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGENO: 132 Chain Variable RegionINPYSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFA YWGQGTLVTVSSSEQ ID huAFD.v2.12 LightDIQMTQSPSSLSASVGDRVTITCKASQNVDTDVAWFQQKPGKAPKGLIRSAS NO: 133Chain Variable RegionSRYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNNYPLTFGQGTKVE IK SEQ IDhuAFD.v2.13 Heavy EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGENO: 134 Chain Variable RegionINPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFA YWGQGTLVTVSSSEQ ID huAFD.v2.13 LightDIQMTQSPSSLSASVGDRVTITCKASQNVDTDVAWFQQKPGKAPKGLIRSAS NO: 135Chain Variable RegionSRYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYENYPLTFGQGTKVE IK SEQ IDhuAFD.v2.14 Heavy EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGENO: 136 Chain Variable RegionINPTSGETNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFA YWGQGTLVTVSSSEQ ID huAFD.v2.14 LightDIQMTQSPSSLSASVGDRVTITCKASQNVDTDVAWFQQKPGKAPKGLIRSAS NO: 137Chain Variable RegionSRYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNNYPLTFGQGTKVE IK SEQ IDhuAFD.v2.15 Heavy EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGENO: 138 Chain Variable RegionINPYSGETNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFA YWGQGTLVTVSSSEQ ID huAFD.v2.15 LightDIQMTQSPSSLSASVGDRVTITCKASQNVDTDVAWFQQKPGKAPKGLIRSAS NO: 139Chain Variable RegionSRYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNNYPLTFGQGTKVE IK

In some embodiments, the antibody comprises a heavy chain having theamino acid sequence of SEQ ID NO: 53. In some embodiments, the antibodycomprises a heavy chain having at least 90% sequence identity to theamino acid sequence of SEQ ID NO: 53. See Table 5.

In some embodiments, the antibody comprises a light chain having theamino acid sequence of SEQ ID NO: 54. In some embodiments, the antibodycomprises a light chain having at least 90% sequence identity to theamino acid sequence of SEQ ID NO: 54. See Table 5.

In some embodiments, the antibody comprises a heavy chain having theamino acid sequence of SEQ ID NO: 53, and a light chain having the aminoacid sequence of SEQ ID NO: 54. In some embodiments, the antibodycomprises a heavy chain having at least 90% sequence identity to theamino acid sequence of SEQ ID NO: 53, and a light chain having at least90% sequence identity to the amino acid sequence of SEQ ID NO: 54. SeeTable 5.

In some embodiments, the antibody comprises a heavy chain having theamino acid sequence of SEQ ID NO: 55. In some embodiments, the antibodycomprises a heavy chain having at least 90% sequence identity to theamino acid sequence of SEQ ID NO: 55. See Table 5.

In some embodiments, the antibody comprises a light chain having theamino acid sequence of SEQ ID NO: 56. In some embodiments, the antibodycomprises a light chain having at least 90% sequence identity to theamino acid sequence of SEQ ID NO: 56. See Table 5.

In some embodiments, the antibody comprises a heavy chain having theamino acid sequence of SEQ ID NO: 55, and a light chain having the aminoacid sequence of SEQ ID NO: 56. In some embodiments, the antibodycomprises a heavy chain having at least 90% sequence identity to theamino acid sequence of SEQ ID NO: 55, and a light chain having at least90% sequence identity to the amino acid sequence of SEQ ID NO: 56. SeeTable 5.

In some embodiments, the antibody comprises a heavy chain having theamino acid sequence of SEQ ID NO: 57. In some embodiments, the antibodycomprises a heavy chain having at least 90% sequence identity to theamino acid sequence of SEQ ID NO: 57. See Table 5.

In some embodiments, the antibody comprises a light chain having theamino acid sequence of SEQ ID NO: 58. In some embodiments, the antibodycomprises a light chain having at least 90% sequence identity to theamino acid sequence of SEQ ID NO: 58. See Table 5.

In some embodiments, the antibody comprises a heavy chain having theamino acid sequence of SEQ ID NO: 57, and a light chain having the aminoacid sequence of SEQ ID NO: 58. In some embodiments, the antibodycomprises a heavy chain having at least 90% sequence identity to theamino acid sequence of SEQ ID NO: 57, and a light chain having at least90% sequence identity to the amino acid sequence of SEQ ID NO: 58. SeeTable 5.

In some embodiments, the antibody comprises a heavy chain having theamino acid sequence of SEQ ID NO: 59. In some embodiments, the antibodycomprises a heavy chain having at least 90% sequence identity to theamino acid sequence of SEQ ID NO: 59. See Table 5.

In some embodiments, the antibody comprises a light chain having theamino acid sequence of SEQ ID NO: 60. In some embodiments, the antibodycomprises a light chain having at least 90% sequence identity to theamino acid sequence of SEQ ID NO: 60. See Table 5.

In some embodiments, the antibody comprises a heavy chain having theamino acid sequence of SEQ ID NO: 59, and a light chain having the aminoacid sequence of SEQ ID NO: 60. In some embodiments, the antibodycomprises a heavy chain having at least 90% sequence identity to theamino acid sequence of SEQ ID NO: 59, and a light chain having at least90% sequence identity to the amino acid sequence of SEQ ID NO: 60. SeeTable 5.

In some embodiments, the antibody comprises a heavy chain having theamino acid sequence of SEQ ID NO: 61. In some embodiments, the antibodycomprises a heavy chain having at least 90% sequence identity to theamino acid sequence of SEQ ID NO: 61. See Table 5.

In some embodiments, the antibody comprises a light chain having theamino acid sequence of SEQ ID NO: 62. In some embodiments, the antibodycomprises a light chain having at least 90% sequence identity to theamino acid sequence of SEQ ID NO: 62. See Table 5.

In some embodiments, the antibody comprises a heavy chain having theamino acid sequence of SEQ ID NO: 61, and a light chain having the aminoacid sequence of SEQ ID NO: 62. In some embodiments, the antibodycomprises a heavy chain having at least 90% sequence identity to theamino acid sequence of SEQ ID NO: 61, and a light chain having at least90% sequence identity to the amino acid sequence of SEQ ID NO: 62. SeeTable 5.

In some embodiments, the antibody comprises a heavy chain having theamino acid sequence of SEQ ID NO: 63. In some embodiments, the antibodycomprises a heavy chain having at least 90% sequence identity to theamino acid sequence of SEQ ID NO: 63. See Table 5.

In some embodiments, the antibody comprises a light chain having theamino acid sequence of SEQ ID NO: 64. In some embodiments, the antibodycomprises a light chain having at least 90% sequence identity to theamino acid sequence of SEQ ID NO: 64. See Table 5.

In some embodiments, the antibody comprises a heavy chain having theamino acid sequence of SEQ ID NO: 63, and a light chain having the aminoacid sequence of SEQ ID NO: 64. In some embodiments, the antibodycomprises a heavy chain having at least 90% sequence identity to theamino acid sequence of SEQ ID NO: 63, and a light chain having at least90% sequence identity to the amino acid sequence of SEQ ID NO: 64. SeeTable 5.

In some embodiments, the antibody comprises a heavy chain having theamino acid sequence of SEQ ID NO: 65. In some embodiments, the antibodycomprises a heavy chain having at least 90% sequence identity to theamino acid sequence of SEQ ID NO: 65. See Table 5.

In some embodiments, the antibody comprises a light chain having theamino acid sequence of SEQ ID NO: 66. In some embodiments, the antibodycomprises a light chain having at least 90% sequence identity to theamino acid sequence of SEQ ID NO: 66. See Table 5.

In some embodiments, the antibody comprises a heavy chain having theamino acid sequence of SEQ ID NO: 65, and a light chain having the aminoacid sequence of SEQ ID NO: 66. In some embodiments, the antibodycomprises a heavy chain having at least 90% sequence identity to theamino acid sequence of SEQ ID NO: 65, and a light chain having at least90% sequence identity to the amino acid sequence of SEQ ID NO: 66. SeeTable 5.

In some embodiments, the antibody comprises a heavy chain having theamino acid sequence of SEQ ID NO: 67. In some embodiments, the antibodycomprises a heavy chain having at least 90% sequence identity to theamino acid sequence of SEQ ID NO: 67. See Table 5.

In some embodiments, the antibody comprises a light chain having theamino acid sequence of SEQ ID NO: 68. In some embodiments, the antibodycomprises a light chain having at least 90% sequence identity to theamino acid sequence of SEQ ID NO: 68. See Table 5.

In some embodiments, the antibody comprises a heavy chain having theamino acid sequence of SEQ ID NO: 67, and a light chain having the aminoacid sequence of SEQ ID NO:

68. In some embodiments, the antibody comprises a heavy chain having atleast 90% sequence identity to the amino acid sequence of SEQ ID NO: 67,and a light chain having at least 90% sequence identity to the aminoacid sequence of SEQ ID NO: 68. See Table 5.

In some embodiments, the antibody comprises a heavy chain having theamino acid sequence of SEQ ID NO: 69. In some embodiments, the antibodycomprises a heavy chain having at least 90% sequence identity to theamino acid sequence of SEQ ID NO: 69. See Table 5.

In some embodiments, the antibody comprises a light chain having theamino acid sequence of SEQ ID NO: 70. In some embodiments, the antibodycomprises a light chain having at least 90% sequence identity to theamino acid sequence of SEQ ID NO: 70. See Table 5.

In some embodiments, the antibody comprises a heavy chain having theamino acid sequence of SEQ ID NO: 69, and a light chain having the aminoacid sequence of SEQ ID NO: 70. In some embodiments, the antibodycomprises a heavy chain having at least 90% sequence identity to theamino acid sequence of SEQ ID NO: 69, and a light chain having at least90% sequence identity to the amino acid sequence of SEQ ID NO: 70. SeeTable 5.

In some embodiments, the antibody comprises a heavy chain having theamino acid sequence of SEQ ID NO: 71. In some embodiments, the antibodycomprises a heavy chain having at least 90% sequence identity to theamino acid sequence of SEQ ID NO: 71. See Table 5.

In some embodiments, the antibody comprises a light chain having theamino acid sequence of SEQ ID NO: 72. In some embodiments, the antibodycomprises a light chain having at least 90% sequence identity to theamino acid sequence of SEQ ID NO: 72. See Table 5.

In some embodiments, the antibody comprises a heavy chain having theamino acid sequence of SEQ ID NO: 71, and a light chain having the aminoacid sequence of SEQ ID NO: 72. In some embodiments, the antibodycomprises a heavy chain having at least 90% sequence identity to theamino acid sequence of SEQ ID NO: 71, and a light chain having at least90% sequence identity to the amino acid sequence of SEQ ID NO: 72. SeeTable 5.

In some embodiments, the antibody comprises a heavy chain having theamino acid sequence of SEQ ID NO: 73. In some embodiments, the antibodycomprises a heavy chain having at least 90% sequence identity to theamino acid sequence of SEQ ID NO: 73. See Table 5.

In some embodiments, the antibody comprises a light chain having theamino acid sequence of SEQ ID NO: 74. In some embodiments, the antibodycomprises a light chain having at least 90% sequence identity to theamino acid sequence of SEQ ID NO: 74. See Table 5.

In some embodiments, the antibody comprises a heavy chain having theamino acid sequence of SEQ ID NO: 73, and a light chain having the aminoacid sequence of SEQ ID NO: 74. In some embodiments, the antibodycomprises a heavy chain having at least 90% sequence identity to theamino acid sequence of SEQ ID NO: 73, and a light chain having at least90% sequence identity to the amino acid sequence of SEQ ID NO: 74. SeeTable 5.

In some embodiments, the antibody comprises a heavy chain having theamino acid sequence of SEQ ID NO: 75. In some embodiments, the antibodycomprises a heavy chain having at least 90% sequence identity to theamino acid sequence of SEQ ID NO: 75. See Table 5.

In some embodiments, the antibody comprises a light chain having theamino acid sequence of SEQ ID NO: 76. In some embodiments, the antibodycomprises a light chain having at least 90% sequence identity to theamino acid sequence of SEQ ID NO: 76. See Table 5.

In some embodiments, the antibody comprises a heavy chain having theamino acid sequence of SEQ ID NO: 75, and a light chain having the aminoacid sequence of SEQ ID NO: 76. In some embodiments, the antibodycomprises a heavy chain having at least 90% sequence identity to theamino acid sequence of SEQ ID NO: 75, and a light chain having at least90% sequence identity to the amino acid sequence of SEQ ID NO: 76. SeeTable 5.

In some embodiments, the antibody comprises a heavy chain having theamino acid sequence of SEQ ID NO: 77. In some embodiments, the antibodycomprises a heavy chain having at least 90% sequence identity to theamino acid sequence of SEQ ID NO: 77. See Table 5.

In some embodiments, the antibody comprises a light chain having theamino acid sequence of SEQ ID NO: 78. In some embodiments, the antibodycomprises a light chain having at least 90% sequence identity to theamino acid sequence of SEQ ID NO: 78. See Table 5.

In some embodiments, the antibody comprises a heavy chain having theamino acid sequence of SEQ ID NO: 77, and a light chain having the aminoacid sequence of SEQ ID NO:

78. In some embodiments, the antibody comprises a heavy chain having atleast 90% sequence identity to the amino acid sequence of SEQ ID NO: 77,and a light chain having at least 90% sequence identity to the aminoacid sequence of SEQ ID NO: 78. See Table 5.

In some embodiments, the antibody comprises a heavy chain having theamino acid sequence of SEQ ID NO: 79. In some embodiments, the antibodycomprises a heavy chain having at least 90% sequence identity to theamino acid sequence of SEQ ID NO: 79. See Table 5.

In some embodiments, the antibody comprises a light chain having theamino acid sequence of SEQ ID NO: 80. In some embodiments, the antibodycomprises a light chain having at least 90% sequence identity to theamino acid sequence of SEQ ID NO: 80. See Table 5.

In some embodiments, the antibody comprises a heavy chain having theamino acid sequence of SEQ ID NO: 79, and a light chain having the aminoacid sequence of SEQ ID NO: 80. In some embodiments, the antibodycomprises a heavy chain having at least 90% sequence identity to theamino acid sequence of SEQ ID NO: 79, and a light chain having at least90% sequence identity to the amino acid sequence of SEQ ID NO: 80. SeeTable 5.

In some embodiments, the antibody comprises a heavy chain having theamino acid sequence of SEQ ID NO: 81. In some embodiments, the antibodycomprises a heavy chain having at least 90% sequence identity to theamino acid sequence of SEQ ID NO: 81. See Table 5.

In some embodiments, the antibody comprises a light chain having theamino acid sequence of SEQ ID NO: 82. In some embodiments, the antibodycomprises a light chain having at least 90% sequence identity to theamino acid sequence of SEQ ID NO: 82. See Table 5.

In some embodiments, the antibody comprises a heavy chain having theamino acid sequence of SEQ ID NO: 81, and a light chain having the aminoacid sequence of SEQ ID NO: 82. In some embodiments, the antibodycomprises a heavy chain having at least 90% sequence identity to theamino acid sequence of SEQ ID NO: 81, and a light chain having at least90% sequence identity to the amino acid sequence of SEQ ID NO: 82. SeeTable 5.

In some embodiments, the antibody comprises a heavy chain having theamino acid sequence of SEQ ID NO: 83. In some embodiments, the antibodycomprises a heavy chain having at least 90% sequence identity to theamino acid sequence of SEQ ID NO: 83. See Table 5.

In some embodiments, the antibody comprises a light chain having theamino acid sequence of SEQ ID NO: 84. In some embodiments, the antibodycomprises a light chain having at least 90% sequence identity to theamino acid sequence of SEQ ID NO: 84. See Table 5.

In some embodiments, the antibody comprises a heavy chain having theamino acid sequence of SEQ ID NO: 83, and a light chain having the aminoacid sequence of SEQ ID NO: 84. In some embodiments, the antibodycomprises a heavy chain having at least 90% sequence identity to theamino acid sequence of SEQ ID NO: 83, and a light chain having at least90% sequence identity to the amino acid sequence of SEQ ID NO: 84. SeeTable 5.

TABLE 5Heavy chain and light chain amino acid sequences of anti-Factor Dantibodies SEQ ID AFD WT Heavy ChainEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 53WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSATKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDKTHTSEQ ID AFD WT Light ChainDIQVTQSPSSLSASVGDRVTITCITSTDIDDDMNWYQQKPGKVPKLLISGGNT NO: 54LRPGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCLQSDSLPYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVIEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFN RGEC SEQ IDAFD.v1 Heavy Chain EVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMGNO: 55 WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDKTHTSEQ ID AFD.v1 Light ChainDIQVTQSPSSLSASVGDRVTITCITSTSIDDDMNWYQQKPGKVPKLLISGGNT NO: 56LRPGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCLQSDSLPYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVIEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFN RGEC SEQ IDAFD.v2 Heavy Chain EVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMGNO: 57 WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDKTHTSEQ ID AFD.v2 Light ChainDIQVTQSPSSLSASVGDRVTITCITSTDIEDDMNWYQQKPGKVPKLLISGGNT NO: 58LRPGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCLQSDSLPYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVIEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFN RGEC SEQ IDAFD.v3 Heavy Chain EVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMGNO: 59 WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDKTHTSEQ ID AFD.v3 Light ChainDIQVTQSPSSLSASVGDRVTITCITSTDIDSDMNWYQQKPGKVPKLLISGGNT NO: 60LRPGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCLQSDSLPYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVIEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFN RGEC SEQ IDAFD.v4 Heavy Chain EVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMGNO: 61 WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDKTHTSEQ ID AFD.v4 Light ChainDIQVTQSPSSLSASVGDRVTITCITSTDIDDSMNWYQQKPGKVPKLLISGGNT NO: 62LRPGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCLQSDSLPYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVIEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFN RGEC SEQ IDAFD.v5 Heavy Chain EVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMGNO: 63 WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDKTHTSEQ ID AFD.v5 Light ChainDIQVTQSPSSLSASVGDRVTITCITSTSIDSSMNWYQQKPGKVPKLLISGGNTL NO: 64RPGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCLQSDSLPYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVIEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFN RGEC SEQ IDAFD.v6 Heavy Chain EVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMGNO: 65 WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDKTHTSEQ ID AFD.v6 Light ChainDIQVTQSPSSLSASVGDRVTITCITSTDIESDMNWYQQKPGKVPKLLISGGNT NO: 66LRPGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCLQSDSLPYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVIEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFN RGEC SEQ IDAFD.v7 Heavy Chain EVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMGNO: 67 WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDKTHTSEQ ID AFD.v7 Light ChainDIQVTQSPSSLSASVGDRVTITCITSTDIESDMNWYQQKPGKVPKLLISGGNT NO: 68LRPGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCLQSESLPYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVIEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFN RGEC SEQ IDAFD.v8 Heavy Chain EVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMGNO: 69 WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDKTHTSEQ ID AFD.v8 Light ChainDIQVTQSPSSLSASVGDRVTITCITSTSIESDMNWYQQKPGKVPKLLISGGNTL NO: 70RPGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCLQSDSLPYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVIEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFN RGEC SEQ IDAFD.v9 Heavy Chain EVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMGNO: 71 WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDKTHTSEQ ID AFD.v9 Light ChainDIQVTQSPSSLSASVGDRVTITCITSTSIESDMSWYQQKPGKVPKLLISGGNTL NO: 72RPGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCLQSDSLPYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVIEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFN RGEC SEQ IDAFD.v10 Heavy Chain EVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMGNO: 73 WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDKTHTSEQ ID AFD.v10 Light ChainDIQVTQSPSSLSASVGDRVTITCITSTSIESDMNWYQQKPGKVPKLLISGGNTL NO: 74RPGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCLQSESLPYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR GEC SEQ IDAFD.v11 Heavy Chain EVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMGNO: 75 WISTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDKTHTSEQ ID AFD.v11 Light ChainDIQVTQSPSSLSASVGDRVTITCITSTSIESDMNWYQQKPGKVPKLLISGGNTL NO: 76RPGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCLQSDSLPYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVIEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFN RGEC SEQ IDAFD.v12 Heavy Chain EVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMGNO: 77 WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVDNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDKTHTSEQ ID AFD.v12 Light ChainDIQVTQSPSSLSASVGDRVTITCITSTSIESDMNWYQQKPGKVPKLLISGGNTL NO: 78RPGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCLQSDSLPYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVIEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFN RGEC SEQ IDAFD.v13 Heavy Chain EVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMGNO: 79 WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVQNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDKTHTSEQ ID AFD.v13 Light ChainDIQVTQSPSSLSASVGDRVTITCITSTSIESDMNWYQQKPGKVPKLLISGGNTL NO: 80RPGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCLQSDSLPYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVIEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFN RGEC SEQ IDAFD.v14 Heavy Chain EVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMGNO: 81 WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVSNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDKTHTSEQ ID AFD.v14 Light ChainDIQVTQSPSSLSASVGDRVTITCITSTSIESDMNWYQQKPGKVPKLLISGGNTL NO: 82RPGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCLQSDSLPYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVIEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFN RGEC SEQ IDAFD.v15 Heavy Chain EVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMGNO: 83 WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVSNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDKTHTSEQ ID AFD.v15 Light ChainDIQVTQSPSSLSASVGDRVTITCITSTSIESDMNWYQQKPGKVPKLLISGGNTL NO: 84RPGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCLQSESLPYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR GEC

In some embodiments, the antibody comprises a heavy chain having theamino acid sequence of SEQ ID NO: 140. In some embodiments, the antibodycomprises a heavy chain having at least 90% sequence identity to theamino acid sequence of SEQ ID NO: 140. See Table 6.

In some embodiments, the antibody comprises a light chain having theamino acid sequence of SEQ ID NO: 141. In some embodiments, the antibodycomprises a light chain having at least 90% sequence identity to theamino acid sequence of SEQ ID NO: 141. See Table 6.

In some embodiments, the antibody comprises a heavy chain having theamino acid sequence of SEQ ID NO: 140, and a light chain having theamino acid sequence of SEQ ID NO: 141. In some embodiments, the antibodycomprises a heavy chain having at least 90% sequence identity to theamino acid sequence of SEQ ID NO: 140, and a light chain having at least90% sequence identity to the amino acid sequence of SEQ ID NO: 141. SeeTable 6.

In some embodiments, the antibody comprises a heavy chain having theamino acid sequence of SEQ ID NO: 142. In some embodiments, the antibodycomprises a heavy chain having at least 90% sequence identity to theamino acid sequence of SEQ ID NO: 142. See Table 6.

In some embodiments, the antibody comprises a light chain having theamino acid sequence of SEQ ID NO: 143. In some embodiments, the antibodycomprises a light chain having at least 90% sequence identity to theamino acid sequence of SEQ ID NO: 143. See Table 6.

In some embodiments, the antibody comprises a heavy chain having theamino acid sequence of SEQ ID NO: 142, and a light chain having theamino acid sequence of SEQ ID NO: 143. In some embodiments, the antibodycomprises a heavy chain having at least 90% sequence identity to theamino acid sequence of SEQ ID NO: 142, and a light chain having at least90% sequence identity to the amino acid sequence of SEQ ID NO: 143. SeeTable 6.

In some embodiments, the antibody comprises a heavy chain having theamino acid sequence of SEQ ID NO: 144. In some embodiments, the antibodycomprises a heavy chain having at least 90% sequence identity to theamino acid sequence of SEQ ID NO: 144. See Table 6.

In some embodiments, the antibody comprises a light chain having theamino acid sequence of SEQ ID NO: 145. In some embodiments, the antibodycomprises a light chain having at least 90% sequence identity to theamino acid sequence of SEQ ID NO: 145. See Table 6.

In some embodiments, the antibody comprises a heavy having the aminoacid sequence of SEQ ID NO: 144, and a light chain having the amino acidsequence of SEQ ID NO: 145. In some embodiments, the antibody comprisesa heavy chain having at least 90% sequence identity to the amino acidsequence of SEQ ID NO: 144, and a light chain having at least 90%sequence identity to the amino acid sequence of SEQ ID NO: 145. SeeTable 6.

In some embodiments, the antibody comprises a heavy chain having theamino acid sequence of SEQ ID NO: 146. In some embodiments, the antibodycomprises a heavy chain having at least 90% sequence identity to theamino acid sequence of SEQ ID NO: 146. See Table 6.

In some embodiments, the antibody comprises a light chain having theamino acid sequence of SEQ ID NO: 147. In some embodiments, the antibodycomprises a light chain having at least 90% sequence identity to theamino acid sequence of SEQ ID NO: 147. See Table 6.

In some embodiments, the antibody comprises a heavy chain having theamino acid sequence of SEQ ID NO: 146, and a light chain having theamino acid sequence of SEQ ID NO: 147. In some embodiments, the antibodycomprises a heavy chain having at least 90% sequence identity to theamino acid sequence of SEQ ID NO: 146, and a light chain having at least90% sequence identity to the amino acid sequence of SEQ ID NO: 147. SeeTable 6.

In some embodiments, the antibody comprises a heavy chain having theamino acid sequence of SEQ ID NO: 148. In some embodiments, the antibodycomprises a heavy chain having at least 90% sequence identity to theamino acid sequence of SEQ ID NO: 148. See Table 6.

In some embodiments, the antibody comprises a light chain having theamino acid sequence of SEQ ID NO: 149. In some embodiments, the antibodycomprises a light chain having at least 90% sequence identity to theamino acid sequence of SEQ ID NO: 149. See Table 6.

In some embodiments, the antibody comprises a heavy chain having theamino acid sequence of SEQ ID NO: 148, and a light chain having theamino acid sequence of SEQ ID NO: 149. In some embodiments, the antibodycomprises a heavy chain having at least 90% sequence identity to theamino acid sequence of SEQ ID NO: 148, and a light chain having at least90% sequence identity to the amino acid sequence of SEQ ID NO: 149. SeeTable 6.

In some embodiments, the antibody comprises a heavy chain having theamino acid sequence of SEQ ID NO: 150. In some embodiments, the antibodycomprises a heavy chain having at least 90% sequence identity to theamino acid sequence of SEQ ID NO: 150. See Table 6.

In some embodiments, the antibody comprises a light chain having theamino acid sequence of SEQ ID NO: 151. In some embodiments, the antibodycomprises a light chain having at least 90% sequence identity to theamino acid sequence of SEQ ID NO: 151. See Table 6.

In some embodiments, the antibody comprises a heavy chain having theamino acid sequence of SEQ ID NO: 150, and a light chain having theamino acid sequence of SEQ ID NO: 151. In some embodiments, the antibodycomprises a heavy chain having at least 90% sequence identity to theamino acid sequence of SEQ ID NO: 150, and a light chain having at least90% sequence identity to the amino acid sequence of SEQ ID NO: 151. SeeTable 6.

In some embodiments, the antibody comprises a heavy chain having theamino acid sequence of SEQ ID NO: 152. In some embodiments, the antibodycomprises a heavy chain having at least 90% sequence identity to theamino acid sequence of SEQ ID NO: 152. See Table 6.

In some embodiments, the antibody comprises a light chain having theamino acid sequence of SEQ ID NO: 153. In some embodiments, the antibodycomprises a light chain having at least 90% sequence identity to theamino acid sequence of SEQ ID NO: 153. See Table 6.

In some embodiments, the antibody comprises a heavy chain having theamino acid sequence of SEQ ID NO: 152, and a light chain having theamino acid sequence of SEQ ID NO: 153. In some embodiments, the antibodycomprises a heavy chain having at least 90% sequence identity to theamino acid sequence of SEQ ID NO: 152, and a light chain having at least90% sequence identity to the amino acid sequence of SEQ ID NO: 153. SeeTable 6.

In some embodiments, the antibody comprises a heavy chain having theamino acid sequence of SEQ ID NO: 154. In some embodiments, the antibodycomprises a heavy chain having at least 90% sequence identity to theamino acid sequence of SEQ ID NO: 154. See Table 6.

In some embodiments, the antibody comprises a light chain having theamino acid sequence of SEQ ID NO: 155. In some embodiments, the antibodycomprises a light chain having at least 90% sequence identity to theamino acid sequence of SEQ ID NO: 155. See Table 6.

In some embodiments, the antibody comprises a heavy chain having theamino acid sequence of SEQ ID NO: 154, and a light chain having theamino acid sequence of SEQ ID NO: 155. In some embodiments, the antibodycomprises a heavy chain having at least 90% sequence identity to theamino acid sequence of SEQ ID NO: 154, and a light chain having at least90% sequence identity to the amino acid sequence of SEQ ID NO: 155. SeeTable 6.

In some embodiments, the antibody comprises a heavy chain having theamino acid sequence of SEQ ID NO: 156. In some embodiments, the antibodycomprises a heavy chain having at least 90% sequence identity to theamino acid sequence of SEQ ID NO: 156. See Table 6.

In some embodiments, the antibody comprises a light chain having theamino acid sequence of SEQ ID NO: 157. In some embodiments, the antibodycomprises a light chain having at least 90% sequence identity to theamino acid sequence of SEQ ID NO: 157. See Table 6.

In some embodiments, the antibody comprises a heavy chain having theamino acid sequence of SEQ ID NO: 156, and a light chain having theamino acid sequence of SEQ ID NO: 157. In some embodiments, the antibodycomprises a heavy chain having at least 90% sequence identity to theamino acid sequence of SEQ ID NO: 156, and a light chain having at least90% sequence identity to the amino acid sequence of SEQ ID NO: 157. SeeTable 6.

In some embodiments, the antibody comprises a heavy chain having theamino acid sequence of SEQ ID NO: 158. In some embodiments, the antibodycomprises a heavy chain having at least 90% sequence identity to theamino acid sequence of SEQ ID NO: 158. See Table 6.

In some embodiments, the antibody comprises a light chain having theamino acid sequence of SEQ ID NO: 159. In some embodiments, the antibodycomprises a light chain having at least 90% sequence identity to theamino acid sequence of SEQ ID NO: 159. See Table 6.

In some embodiments, the antibody comprises a heavy chain having theamino acid sequence of SEQ ID NO: 158, and a light chain having theamino acid sequence of SEQ ID NO: 159. In some embodiments, the antibodycomprises a heavy chain having at least 90% sequence identity to theamino acid sequence of SEQ ID NO: 158, and a light chain having at least90% sequence identity to the amino acid sequence of SEQ ID NO: 159. SeeTable 6.

In some embodiments, the antibody comprises a heavy chain having theamino acid sequence of SEQ ID NO: 160. In some embodiments, the antibodycomprises a heavy chain having at least 90% sequence identity to theamino acid sequence of SEQ ID NO: 160. See Table 6.

In some embodiments, the antibody comprises a light chain having theamino acid sequence of SEQ ID NO: 161. In some embodiments, the antibodycomprises a light chain having at least 90% sequence identity to theamino acid sequence of SEQ ID NO: 161. See Table 6.

In some embodiments, the antibody comprises a heavy chain having theamino acid sequence of SEQ ID NO: 160, and a light chain having theamino acid sequence of SEQ ID NO: 161. In some embodiments, the antibodycomprises a heavy chain having at least 90% sequence identity to theamino acid sequence of SEQ ID NO: 160, and a light chain having at least90% sequence identity to the amino acid sequence of SEQ ID NO: 161. SeeTable 6.

In some embodiments, the antibody comprises a heavy chain having theamino acid sequence of SEQ ID NO: 162. In some embodiments, the antibodycomprises a heavy chain having at least 90% sequence identity to theamino acid sequence of SEQ ID NO: 162. See Table 6.

In some embodiments, the antibody comprises a light chain having theamino acid sequence of SEQ ID NO: 163. In some embodiments, the antibodycomprises a light chain having at least 90% sequence identity to theamino acid sequence of SEQ ID NO: 163. See Table 6.

In some embodiments, the antibody comprises a heavy chain having theamino acid sequence of SEQ ID NO: 162, and a light chain having theamino acid sequence of SEQ ID NO: 163. In some embodiments, the antibodycomprises a heavy chain having at least 90% sequence identity to theamino acid sequence of SEQ ID NO: 162, and a light chain having at least90% sequence identity to the amino acid sequence of SEQ ID NO: 163. SeeTable 6.

In some embodiments, the antibody comprises a heavy chain having theamino acid sequence of SEQ ID NO: 164. In some embodiments, the antibodycomprises a heavy chain having at least 90% sequence identity to theamino acid sequence of SEQ ID NO: 164. See Table 6.

In some embodiments, the antibody comprises a light chain having theamino acid sequence of SEQ ID NO: 165. In some embodiments, the antibodycomprises a light chain having at least 90% sequence identity to theamino acid sequence of SEQ ID NO: 165. See Table 6.

In some embodiments, the antibody comprises a heavy chain having theamino acid sequence of SEQ ID NO: 164, and a light chain having theamino acid sequence of SEQ ID NO: 165. In some embodiments, the antibodycomprises a heavy chain having at least 90% sequence identity to theamino acid sequence of SEQ ID NO: 164, and a light chain having at least90% sequence identity to the amino acid sequence of SEQ ID NO: 165. SeeTable 6.

In some embodiments, the antibody comprises a heavy chain having theamino acid sequence of SEQ ID NO: 166. In some embodiments, the antibodycomprises a heavy chain having at least 90% sequence identity to theamino acid sequence of SEQ ID NO: 166. See Table 6.

In some embodiments, the antibody comprises a light chain having theamino acid sequence of SEQ ID NO: 167. In some embodiments, the antibodycomprises a light chain having at least 90% sequence identity to theamino acid sequence of SEQ ID NO: 167. See Table 6.

In some embodiments, the antibody comprises a heavy chain having theamino acid sequence of SEQ ID NO: 166, and a light chain having theamino acid sequence of SEQ ID NO: 167. In some embodiments, the antibodycomprises a heavy chain having at least 90% sequence identity to theamino acid sequence of SEQ ID NO: 166, and a light chain having at least90% sequence identity to the amino acid sequence of SEQ ID NO: 167. SeeTable 6.

In some embodiments, the antibody comprises a heavy chain having theamino acid sequence of SEQ ID NO: 168. In some embodiments, the antibodycomprises a heavy chain having at least 90% sequence identity to theamino acid sequence of SEQ ID NO: 168. See Table 6.

In some embodiments, the antibody comprises a light chain having theamino acid sequence of SEQ ID NO: 169. In some embodiments, the antibodycomprises a light chain having at least 90% sequence identity to theamino acid sequence of SEQ ID NO: 169. See Table 6.

In some embodiments, the antibody comprises a heavy chain having theamino acid sequence of SEQ ID NO: 168, and a light chain having theamino acid sequence of SEQ ID NO:

169. In some embodiments, the antibody comprises a heavy chain having atleast 90% sequence identity to the amino acid sequence of SEQ ID NO:168, and a light chain having at least 90% sequence identity to theamino acid sequence of SEQ ID NO: 169. See Table 6.

In some embodiments, the antibody comprises a heavy chain having theamino acid sequence of SEQ ID NO: 170. In some embodiments, the antibodycomprises a heavy chain having at least 90% sequence identity to theamino acid sequence of SEQ ID NO: 170. See Table 6.

In some embodiments, the antibody comprises a light chain having theamino acid sequence of SEQ ID NO: 171. In some embodiments, the antibodycomprises a light chain having at least 90% sequence identity to theamino acid sequence of SEQ ID NO: 171. See Table 6.

In some embodiments, the antibody comprises a heavy chain having theamino acid sequence of SEQ ID NO: 170, and a light chain having theamino acid sequence of SEQ ID NO: 171. In some embodiments, the antibodycomprises a heavy chain having at least 90% sequence identity to theamino acid sequence of SEQ ID NO: 170, and a light chain having at least90% sequence identity to the amino acid sequence of SEQ ID NO: 171. SeeTable 6.

In some embodiments, the antibody comprises a heavy chain having theamino acid sequence of SEQ ID NO: 172. In some embodiments, the antibodycomprises a heavy chain having at least 90% sequence identity to theamino acid sequence of SEQ ID NO: 172. See Table 6.

In some embodiments, the antibody comprises a light chain having theamino acid sequence of SEQ ID NO: 173. In some embodiments, the antibodycomprises a light chain having at least 90% sequence identity to theamino acid sequence of SEQ ID NO: 173. See Table 6.

In some embodiments, the antibody comprises a heavy chain having theamino acid sequence of SEQ ID NO: 172, and a light chain having theamino acid sequence of SEQ ID NO: 173. In some embodiments, the antibodycomprises a heavy chain having at least 90% sequence identity to theamino acid sequence of SEQ ID NO: 172, and a light chain having at least90% sequence identity to the amino acid sequence of SEQ ID NO: 173. SeeTable 6.

In some embodiments, the antibody comprises a heavy chain having theamino acid sequence of SEQ ID NO: 174. In some embodiments, the antibodycomprises a heavy chain having at least 90% sequence identity to theamino acid sequence of SEQ ID NO: 174. See Table 6.

In some embodiments, the antibody comprises a light chain having theamino acid sequence of SEQ ID NO: 175. In some embodiments, the antibodycomprises a light chain having at least 90% sequence identity to theamino acid sequence of SEQ ID NO: 175. See Table 6.

In some embodiments, the antibody comprises a heavy chain having theamino acid sequence of SEQ ID NO: 174, and a light chain having theamino acid sequence of SEQ ID NO: 175. In some embodiments, the antibodycomprises a heavy chain having at least 90% sequence identity to theamino acid sequence of SEQ ID NO: 174, and a light chain having at least90% sequence identity to the amino acid sequence of SEQ ID NO: 175. SeeTable 6.

TABLE 6Heavy chain and light chain amino acid sequences of additional anti-FactorD antibodies SEQ ID huAFD.v2.0 HeavyEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 140 ChainINPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCDKTHTSEQ ID huAFD.v2.0 LightDIQMTQSPSSLSASVGDRVTITCKASQNVDTDVAWFQQKPGKAPKGLIYSAS NO: 141 ChainSRYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNNYPLTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSF NRGEC SEQ IDhuAFD.v2.1 Heavy EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGENO: 142 Chain INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCDKTHTSEQ ID huAFD.v2.1 LightDIQMTQSPSSLSASVGDRVTITCKASQNVDTDVAWFQQKPGKAPKGLIRSAS NO: 143 ChainSRYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNNYPLTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSF NRGEC SEQ IDhuAFD.v2.3 Heavy EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGENO: 144 Chain INPYSGDTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSN TKVDKKVEPKSCDKTHTSEQ ID huAFD.v2.3 LightDIQMTQSPSSLSASVGDRVTITCKASQNVDTDVAWFQQKPGKAPKGLIRSAS NO: 145 ChainSRYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNNYPLTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSF NRGEC SEQ IDhuAFD.v1 Heavy EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGENO: 146 Chain INPTNGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSN TKVDKKVEPKSCDKTHTSEQ ID huAFD.v1 LightDIQMTQSPSSLSASVGDRVTITCKASQNVDTDVAWFQQKPGKAPKGLIYSAS NO: 147 ChainSRYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNNYPLTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSF NRGEC SEQ IDhuAFD.v1.1 Heavy EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGENO: 148 Chain INPTQGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSN TKVDKKVEPKSCDKTHTSEQ ID huAFD.v1.1 LightDIQMTQSPSSLSASVGDRVTITCKASQNVDTDVAWFQQKPGKAPKGLIYSAS NO: 149 ChainSRYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNNYPLTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSF NRGEC SEQ IDhuAFD.v2.2 Heavy EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGENO: 150 Chain INPTSGDTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCDKTHTSEQ ID huAFD.v2.2 LightDIQMTQSPSSLSASVGDRVTITCKASQNVDTDVAWFQQKPGKAPKGLIYSAS NO: 151 ChainSRYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNNYPLTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSF NRGEC SEQ IDhuAFD.v2.4 Heavy EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGENO: 152 Chain INPTSGETNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCDKTHTSEQ ID huAFD.v2.4 LightDIQMTQSPSSLSASVGDRVTITCKASQNVDTDVAWFQQKPGKAPKGLIYSAS NO: 153 ChainSRYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNNYPLTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSF NRGEC SEQ IDhuAFD.v2.5 Heavy EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGENO: 154 Chain INPYSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSN TKVDKKVEPKSCDKTHTSEQ ID huAFD.v2.5 LightDIQMTQSPSSLSASVGDRVTITCKASQNVDTDVAWFQQKPGKAPKGLIYSAS NO: 155 ChainSRYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNNYPLTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSF NRGEC SEQ IDhuAFD.v2.6 Heavy EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGENO: 156 Chain INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCDKTHTSEQ ID huAFD.v2.6 LightDIQMTQSPSSLSASVGDRVTITCKASQNVDTDVAWFQQKPGKAPKGLISSAS NO: 157 ChainSRYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNNYPLTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSF NRGEC SEQ IDhuAFD.v2.7 Heavy EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGENO: 158 Chain INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCDKTHTSEQ ID huAFD.v2.7 LightDIQMTQSPSSLSASVGDRVTITCKASQNVDTDVAWFQQKPGKAPKGLIKSAS NO: 159 ChainSRYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNNYPLTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSF NRGEC SEQ IDhuAFD.v2.8 Heavy EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGENO: 160 Chain INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCDKTHTSEQ ID huAFD.v2.8 LightDIQMTQSPSSLSASVGDRVTITCKASQNVDTDVAWFQQKPGKAPKGLIQSAS NO: 161 ChainSRYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNNYPLTFGQGTKVENSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSF NRGEC SEQ IDhuAFD.v2.9 Heavy EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGNO: 162 Chain WINPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDKTHTSEQ ID huAFD.v2.9 LightDIQMTQSPSSLSASVGDRVTITCKASQNVDTDVAWFQQKPGKAPKGLIYSAS NO: 163 ChainSRYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNNYPLTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSF NRGEC SEQ IDhuAFD.v2.10 Heavy EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGENO: 164 Chain INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCDKTHTSEQ ID huAFD.v2.10 LightDIQMTQSPSSLSASVGDRVTITCKASQNVDTDVAWFQQKPGKAPKGLIYSAS NO: 165 ChainSRKSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNNYPLTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSF NRGEC SEQ IDhuAFD.v2.11 Heavy EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGENO: 166 Chain INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCDKTHTSEQ ID huAFD.v2.11 LightDIQMTQSPSSLSASVGDRVTITCKASQNVDTDVAWFQQKPGKAPKGLIYSAS NO: 167 ChainSRRSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNNYPLTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSF NRGEC SEQ IDhuAFD.v2.12 Heavy EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGENO: 168 Chain INPYSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSN TKVDKKVEPKSCDKTHTSEQ ID huAFD.v2.12 LightDIQMTQSPSSLSASVGDRVTITCKASQNVDTDVAWFQQKPGKAPKGLIRSAS NO: 169 ChainSRYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNNYPLTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSF NRGEC SEQ IDhuAFD.v2.13 Heavy EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGENO: 170 Chain INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCDKTHTSEQ ID huAFD.v2.13 LightDIQMTQSPSSLSASVGDRVTITCKASQNVDTDVAWFQQKPGKAPKGLIRSAS NO: 171 ChainSRYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYENYPLTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSF NRGEC SEQ IDhuAFD.v2.14 Heavy EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGENO: 172 Chain INPTSGETNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCDKTHTSEQ ID huAFD.v2.14 LightDIQMTQSPSSLSASVGDRVTITCKASQNVDTDVAWFQQKPGKAPKGLIRSAS NO: 173 ChainSRYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNNYPLTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSF NRGEC SEQ IDhuAFD.v2.15 Heavy EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGENO: 174 Chain INPYSGETNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCDKTHTSEQ ID huAFD.v2.15 LightDIQMTQSPSSLSASVGDRVTITCKASQNVDTDVAWFQQKPGKAPKGLIRSAS NO: 175 ChainSRYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNNYPLTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSF NRGEC

The antibody and antigen-binding fragments described herein can also befurther covalently modified by conjugating the antibody orantigen-binding fragments to one of a variety of non-proteinaciouspolymer molecules. The antibody-polymer conjugates can be made using anysuitable technique for derivatizing antibody with polymers, and are notlimited to conjugates utilizing any particular type of linkage betweenan antibody or antibody fragment and a polymer.

In one aspect, the conjugates include species wherein a polymer iscovalently attached to a specific site or specific sites on the parentalantibody, i.e. polymer attachment is targeted to a particular region ora particular amino acid residue or residues in the parental antibody orantibody fragment. Site specific conjugation of polymers is mostcommonly achieved by attachment to cysteine residues in the parentalantibody or antibody fragment. In such embodiments, the couplingchemistry can, for example, utilize the free sulfhydryl group of acysteine residue not in a disulfide bridge in the parental antibody. Thepolymer can be activated with any functional group that is capable ofreacting specifically with the free sulfhydryl or thiol group(s) on theparental antibody, such as maleimide, sulfhydryl, thiol, triflate,tesylate, aziridine, exirane, and 5-pyridyl functional groups. Thepolymer can be coupled to the parental antibody using any protocolsuitable for the chemistry of the coupling system selected, such as theprotocols and systems described in U.S. Pat. Nos. 4,179,337; 7,122,636,and Jevsevar et al. (2010) Biotech. J. 5:113-128.

In some embodiments, one or more cysteine residue(s) naturally presentin the parental antibody is (are) used as attachment site(s) for polymerconjugation. In some embodiments, one or more cysteine residue(s) is(are) engineered into a selected site or sites in the parental antibodyfor the purpose of providing a specific attachment site or sites forpolymer. Cysteine engineered antibodies have been described previously(U.S. Pat. Pub. No. 2007/0092940 and Junutula, J. R., et al, J. ImmunolMethods, Vol. 332(1-2), pp. 41-52 (2008), all herein incorporated byreference in their entirety). In some embodiments, cysteine engineeredantibodies can be parental antibodies. These are useful for generatingantibody fragments having a free cysteine in a particular location,typically in a constant region, e.g., CL or CH1. A parent antibodyengineered to contain a cysteine may be referred to as a “ThioMab” andFab fragments produced from such cysteine engineered antibodies,regardless of the method of production, may be referred as “ThioMabs” or“ThioFabs.” As described previously (see, e.g., U.S. Pat. Pub. No.2007/0092940 and Junutula, J. R., et al, J. Immunol Methods, Vol.332(1-2), pp. 41-52 (2008)), mutants with replaced (“engineered”)cysteine (Cys) residues are evaluated for the reactivity of the newlyintroduced, engineered cysteine thiol groups. The thiol reactivity valueis a relative, numerical term in the range of 0 to 1.0 and can bemeasured for any cysteine engineered antibody. In addition to having areactive thiol group, ThioMabs should be selected such that they retainantigen binding capability. The design, selection, and preparation ofcysteine engineered antibodies were described in detail previously (see,e.g., WO 2011/069104, which is herein incorporated by reference).Engineered cysteines are preferably introduced into the constant domainsof heavy or light chains. As such, the cysteine engineered antibodieswill preferably retain the antigen binding capability of their wildtype, parent antibody counterparts and, as such, are capable of bindingspecifically, to antigens.

In one aspect, the invention encompasses antibody-polymer conjugates,wherein the antibody is a Fab fragment, and the polymer is attached toone or more cysteine residue in the light or heavy chain of the Fabfragment that would ordinarily form the inter-chain disulfide bondlinking the light and heavy chains. In some embodiments, one or morecysteine residue(s) naturally present in the hinge region of theantibody is (are) used to attach the polymer. In some embodiments, oneor more cysteine residues is (are) engineered into the hinge region ofthe Fab fragment for the purpose of providing a specific attachment siteor sites for polymer.

In another aspect, the invention encompasses antibody-polymerconjugates, wherein the antibody is a Fab-C or Fab′ fragment, and thepolymer attachment is targeted to the hinge region of the Fab-C or Fab′fragment. In some embodiments, one or more cysteine residue(s) naturallypresent in the hinge region of the antibody is (are) used to attach thepolymer. In some embodiments, one or more cysteine residues is (are)added to the C-terminus of the Fab fragment for the purpose of providinga specific attachment site or sites for polymer.

In another aspect, the invention encompasses antibody-polymerconjugates, wherein the antibody is a F(ab′)2 fragment, and the polymerattachment is targeted to the hinge region of the F(ab′)2 fragment. Insome embodiments, one or more cysteine residue(s) naturally present inthe hinge region of the antibody is (are) used to attach the polymer. Insome embodiments, one or more cysteine residues is (are) engineered intothe hinge region of the F(ab′)2 fragment for the purpose of providing aspecific attachment site or sites for polymer.

In some embodiments, the anti-Factor D antibody (e.g., Fab fragment,Fab′ fragment, or F(ab′)2 fragment) is modified by adding one cysteineat the C′-terminal end of the heavy chain for the purpose of providingone attachment site for polymer conjugation. In some embodiments, theanti-Factor D antibody (e.g., Fab fragment, Fab′ fragment, or F(ab′)2fragment) is modified by adding four additional residues,Cys-Pro-Pro-Cys, at the C′-terminal end of the heavy chain for thepurpose of providing two attachment sites for polymer conjugation. Insome embodiments, the anti-Factor D antibody (e.g., Fab fragment, Fab′fragment, or F(ab′)2 fragment) is modified by adding four additionalresidues, Cys-Pro-Pro-Ser, at the C′-terminal end of the heavy chain forthe purpose of providing one attachment site for polymer conjugation. Insome embodiments, the anti-Factor D antibody (e.g., Fab fragment, Fab′fragment, or F(ab′)2 fragment) is modified by adding four additionalresidues, Ser-Pro-Pro-Cys, at the C′-terminal end of the heavy chain forthe purpose of providing one attachment site for polymer conjugation. Insome embodiments, the anti-Factor D antibody (e.g., Fab fragment, Fab′fragment, or F(ab′)2 fragment) is modified by adding four additionalresidues, Ala-Pro-Pro-Cys, at the C′-terminal end of the heavy chain forthe purpose of providing one attachment site for polymer conjugation. Insome embodiments, the anti-Factor D antibody (e.g., Fab fragment, Fab′fragment, or F(ab′)2 fragment) is modified by adding four additionalresidues, Ser-Gly-Gly-Cys, at the C′-terminal end of the heavy chain forthe purpose of providing one attachment site for polymer conjugation. Inspecific embodiments, the polymer conjugation is PEG polymerconjugation.

One commonly used antibody conjugation is PEGylation, wherein one ormore polyethylene glycol (PEG) polymers are covalently attached to theantibody's constant region. See U.S. Pat. Nos. 4,179,337; 7,122,636. PEGpolymers of different sizes (e.g., from about 500 D to about 300,000 D)and shapes (e.g., linear or branched) have been known and widely used inthe field. The polymers useful for the present invention may be obtainedcommercially (e.g., from Nippon Oil and Fats; Nektar Therapeutics;Creative PEGWorks) or prepared from commercially available startingmaterials using conventional chemical procedures. PEGylation changes thephysical and chemical properties of the antibody drug, and may resultsin improved pharmacokinetic behaviors such as improved stability,decreased immunogenicity, extended circulating life as well as increasedresidence time.

In some embodiments, the antibody (e.g., a Fab fragment, a Fab′fragment, a Fab-C fragment or a F(ab′)2 fragment) comprises a heavychain having the amino acid sequence of SEQ ID NO: 176. In someembodiments, the antibody (e.g., a Fab fragment, a Fab′ fragment, aFab-C fragment or a F(ab′)2 fragment) comprises a heavy chain having atleast 90% sequence identity to the amino acid sequence of SEQ ID NO:176. In some embodiments, the antibody (e.g., a Fab′ fragment, a Fab-Cfragment or a F(ab′)2 fragment) comprises a heavy chain having the aminoacid sequence of SEQ ID NO: 176, wherein the cysteine at the C′ Terminalend is attached to a polymer (e.g., a PEG polymer). In some embodiments,the antibody (e.g., a Fab′ fragment, a Fab-C fragment or a F(ab′)2fragment) comprises a heavy chain having at least 90% sequence identityto the amino acid sequence of SEQ ID NO: 176, wherein the cysteine atthe C′ Terminal end is attached to a polymer (e.g., a PEG polymer). SeeTable 7.

In some embodiments, the antibody (e.g., a Fab fragment, a Fab′fragment, a Fab-C fragment or a F(ab′)2 fragment) comprises a heavychain having the amino acid sequence of SEQ ID NO: 177. In someembodiments, the antibody (e.g., a Fab fragment, a Fab′ fragment, aFab-C fragment or a F(ab′)2 fragment) comprises a heavy chain having atleast 90% sequence identity to the amino acid sequence of SEQ ID NO:177. In some embodiments, the antibody (e.g., a Fab′ fragment, a Fab-Cfragment or a F(ab′)2 fragment) comprises a heavy chain having the aminoacid sequence of SEQ ID NO: 177, wherein the two cysteines in theCys-Pro-Pro-Cys sequence at the C′ Terminal end are each attached to apolymer (e.g., a PEG polymer). In some embodiments, the antibody (e.g.,a Fab′ fragment, a Fab-C fragment or a F(ab′)2 fragment) comprises aheavy chain having at least 90% sequence identity to the amino acidsequence of SEQ ID NO: 177, wherein the two cysteines in theCys-Pro-Pro-Cys sequence at the C′ Terminal end are each attached to apolymer (e.g., a PEG polymer). See Table 7.

In some embodiments, the antibody (e.g., a Fab fragment, a Fab′fragment, a Fab-C fragment or a F(ab′)2 fragment) comprises a heavychain having the amino acid sequence of SEQ ID NO: 178. In someembodiments, the antibody (e.g., a Fab fragment, a Fab′ fragment, aFab-C fragment or a F(ab′)2 fragment) comprises a heavy chain having atleast 90% sequence identity to the amino acid sequence of SEQ ID NO:178. In some embodiments, the antibody (e.g., a Fab′ fragment, a Fab-Cfragment or a F(ab′)2 fragment) comprises a heavy chain having the aminoacid sequence of SEQ ID NO: 178, wherein the cysteine at the C′ Terminalend is attached to a polymer (e.g., a PEG polymer). In some embodiments,the antibody (e.g., a Fab′ fragment, a Fab-C fragment or a F(ab′)2fragment) comprises a heavy chain having at least 90% sequence identityto the amino acid sequence of SEQ ID NO: 178, wherein the cysteine atthe C′ Terminal end is attached to a polymer (e.g., a PEG polymer). SeeTable 7.

In some embodiments, the antibody (e.g., a Fab fragment, a Fab′fragment, a Fab-C fragment or a F(ab′)2 fragment) comprises a heavychain having the amino acid sequence of SEQ ID NO: 179. In someembodiments, the antibody (e.g., a Fab fragment, a Fab′ fragment, aFab-C fragment or a F(ab′)2 fragment) comprises a heavy chain having atleast 90% sequence identity to the amino acid sequence of SEQ ID NO:179. In some embodiments, the antibody (e.g., a Fab′ fragment, a Fab-Cfragment or a F(ab′)2 fragment) comprises a heavy chain having the aminoacid sequence of SEQ ID NO: 179, wherein the two cysteines in theCys-Pro-Pro-Cys sequence at the C′ Terminal end are each attached to apolymer (e.g., a PEG polymer). In some embodiments, the antibody (e.g.,a Fab′ fragment, a Fab-C fragment or a F(ab′)2 fragment) comprises aheavy chain having at least 90% sequence identity to the amino acidsequence of SEQ ID NO: 179, wherein the two cysteines in theCys-Pro-Pro-Cys sequence at the C′ Terminal end are each attached to apolymer (e.g., a PEG polymer). See Table 7.

TABLE 7Heavy chain and light chain amino acid sequences of cysteine-modified anti-Factor D antibodies SEQ ID Cys-Modified AFD.v8EVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 176 Heavy ChainWINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDKTHTCSEQ ID Cys-Pro-Pro-Cys-EVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 177Modified AFD.v8 WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGHeavy Chain VNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPC SEQ ID Cys-ModifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 178AFD.v14 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVSNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDKTHTCSEQ ID Cys-Pro-Pro-Cys-EVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 179Modified AFD.v14 WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGHeavy Chain VSNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPC

While Fab, Fab′, Fab-C and F(ab′)2 fragments provide the advantage ofsmall size, short serum half-life, and lack of effector function, theytypically include parts of the upper hinge region that can serve asneoepitopes, and are eventually recognized by the immune system andanti-hinge antibodies (AHA) are generated. These pre-existing AHA titersvary from donor to donor and may represent past and current exposure toneoepitopes. AHA can act as surrogate Fc and restore effector functionof proteolytically inactivated antibodies. One reason to use a Fab,Fab′, Fab-C or F(ab′)2 molecule as therapeutic format is to eliminateeffector function. Thus, it is undesired to have effector functionreinstated by pre-existing AHA and risk any potential safety concerns.To evade recognition by pre-existing AHAs, the Fab, Fab′, Fab-C orF(ab′)2 fragments of an IgG2 or IgG4 isotype can be used. Alternatively,the heavy chain of the Fab of an IgG1 isotype can be modified toterminate with Cys-Asp or Cys-Asp-Lys-Thr-His-Leu.

In specific embodiments, the anti-Factor D antibody is a Fab fragment, aFab′ fragment, a Fab-C fragment or a F(ab′)2 fragment of an IgG2isotype. In specific embodiments, the anti-Factor D antibody is a Fabfragment, a Fab′ fragment, a Fab-C fragment or a F(ab′)2 fragment of anIgG4 isotype. In specific embodiments, the anti-Factor D antibody is aFab fragment, a Fab′ fragment, a Fab-C fragment or a F(ab′)2 fragment ofan IgG1 isotype.

In specific embodiments, the anti-Factor D antibody is a Fab fragmentwhose C-terminal of the heavy chain is modified to terminate withCys-Asp (CD), Cys-Asp-Lys (CDK), Cys-Asp-Lys-Thr (CDKT),Cys-Asp-Lys-Thr-His (CDKTH), Cys-Asp-Lys-Thr-His-Thr (CDKTHT), orCys-Asp-Lys-Thr-His-Leu (CDKTHL). In specific embodiments, theanti-Factor D antibody is a Fab fragment whose C-terminal of the heavychain is modified to terminate with Cys-Asp (CD), Cys-Asp-Lys (CDK),Cys-Asp-Lys-Thr (CDKT), Cys-Asp-Lys-Thr-His (CDKTH), orCys-Asp-Lys-Thr-His-Leu (CDKTHL). In specific embodiments, theanti-Factor D antibody is a Fab fragment whose C-terminal of the heavychain is modified to terminate with Cys-Asp (CD) orCys-Asp-Lys-Thr-His-Leu (CDKTHL). In specific embodiments, theanti-Factor D antibody is a Fab fragment whose C-terminal of the heavychain is modified to terminate with Cys-Asp-Lys-Thr-His-X (CDKTHX),wherein X is any amino acid except Thr (T). The cysteine residue(s) maybe attached to a polymer (e.g., a PEG polymer). In specific embodiments,the anti-Factor D antibody is a Fab fragment of an IgG1 isotype.

In specific embodiments, the anti-Factor D antibody is a Fab-C fragmentwhose C-terminal of the heavy chain is modified to terminate withCys-Asp-Lys-Thr-His-Thr-Cys (CDKTHTC). In specific embodiments, theanti-Factor D antibody is a Fab fragment, a Fab′ fragment or a F(ab′)2fragment whose C-terminal of the heavy chain is modified to terminatewith Cys-Asp-Lys-Thr-His-Thr-Cys-Pro-Pro-Cys (CDKTHTCPPC),Cys-Asp-Lys-Thr-His-Thr-Cys-Pro-Pro-Ser (CDKTHTCPPS),Cys-Asp-Lys-Thr-His-Thr-Ser-Pro-Pro-Cys (CDKTHTSPPC),Cys-Asp-Lys-Thr-His-Thr-Ala-Pro-Pro-Cys (CDKTHTAPPC), orCys-Asp-Lys-Thr-His-Thr-Ser-Gly-Gly-Cys (CDKTHTSGGC). In specificembodiments, the anti-Factor D antibody is a Fab fragment whoseC-terminal of the heavy chain is modified to terminate withCys-Tyr-Gly-Pro-Pro-Cys (CYGPPC). One, two, or three of the cysteineresidue(s) (as the case may be) may each be attached to a polymer (e.g.,a PEG polymer). In specific embodiments, the anti-Factor D antibody is aFab fragment, a Fab′ fragment, a Fab-C fragment or a F(ab′)2 fragment ofan IgG1 isotype.

In specific embodiments, the anti-Factor D antibody is a Fab fragmentwhose C-terminal of the heavy chain is modified to terminate withVal-Glu-Arg-Lys (VERK). In specific embodiments, the anti-Factor Dantibody is a Fab-C fragment whose C-terminal of the heavy chain ismodified to terminate with Val-Glu-Arg-Lys-Cys (VERKC). The cysteineresidue may be attached to a polymer (e.g., a PEG polymer). In specificembodiments, the anti-Factor D antibody is a Fab fragment or a Fab-Cfragment of an IgG2 isotype.

In specific embodiments, the anti-Factor D antibody is a Fab fragmentwhose C-terminal of the heavy chain is modified to terminate withLys-Tyr-Gly-Pro-Pro (KYGPP), Lys-Tyr-Gly-Pro (KYGP), Lys-Tyr-Gly (KYG),Lys-Tyr (KY), or Lys (K). In specific embodiments, the anti-Factor Dantibody is a Fab-C fragment whose C-terminal of the heavy chain ismodified to terminate with Lys-Tyr-Gly-Pro-Pro-Cys (KYGPPC). Thecysteine residue may be attached to a polymer (e.g., a PEG polymer). Inspecific embodiments, the anti-Factor D antibody is a Fab fragmentor aFab-C fragment of an IgG4 isotype.

In some embodiments, the anti-Factor D antibody is a Fab fragmentcomprising a heavy chain having the amino acid sequence of SEQ ID NO:180, SEQ ID NO: 181, SEQ ID NO: 182, SEQ ID NO: 183, SEQ ID NO: 184, SEQID NO: 185, SEQ ID NO: 186, SEQ ID NO: 187, SEQ ID NO: 188, SEQ ID NO:189, SEQ ID NO: 190, SEQ ID NO: 191, SEQ ID NO: 192, SEQ ID NO: 193, SEQID NO: 194, SEQ ID NO: 195, SEQ ID NO: 196, SEQ ID NO: 197, SEQ ID NO:198, SEQ ID NO: 199, SEQ ID NO: 200, SEQ ID NO: 201, SEQ ID NO: 202, SEQID NO: 203, SEQ ID NO: 204, SEQ ID NO: 205, SEQ ID NO: 206, SEQ ID NO:207, SEQ ID NO: 208, SEQ ID NO: 209, SEQ ID NO: 210, SEQ ID NO: 211, SEQID NO: 212, or SEQ ID NO: 213. In some embodiments, the anti-Factor Dantibody is a Fab fragment comprising a heavy chain having at least 90%sequence identity to the amino acid sequence of SEQ ID NO: 180, SEQ IDNO: 181, SEQ ID NO: 182, SEQ ID NO: 183, SEQ ID NO: 184, SEQ ID NO: 185,SEQ ID NO: 186, SEQ ID NO: 187, SEQ ID NO: 188, SEQ ID NO: 189, SEQ IDNO: 190, SEQ ID NO: 191, SEQ ID NO: 192, SEQ ID NO: 193, SEQ ID NO: 194,SEQ ID NO: 195, SEQ ID NO: 196, SEQ ID NO: 197, SEQ ID NO: 198, SEQ IDNO: 199, SEQ ID NO: 200, SEQ ID NO: 201, SEQ ID NO: 202, SEQ ID NO: 203,SEQ ID NO: 204, SEQ ID NO: 205, SEQ ID NO: 206, SEQ ID NO: 207, SEQ IDNO: 208, SEQ ID NO: 209, SEQ ID NO: 210, SEQ ID NO: 211, SEQ ID NO: 212,or SEQ ID NO: 213. See Table 8. In specific embodiments, the Fabfragment is of an IgG1 isotype. In specific embodiments, the cysteine inthe Cys-Asp (CD) sequence at the C′ Terminal end is attached to apolymer (e.g., a PEG polymer).

In some embodiments, the anti-Factor D antibody is a Fab fragmentcomprising a heavy chain having the amino acid sequence of SEQ ID NO:214, SEQ ID NO: 215, SEQ ID NO: 216, SEQ ID NO: 217, SEQ ID NO: 218, SEQID NO: 219, SEQ ID NO: 220, SEQ ID NO: 221, SEQ ID NO: 222, SEQ ID NO:223, SEQ ID NO: 224, SEQ ID NO: 225, SEQ ID NO: 226, SEQ ID NO: 227, SEQID NO: 228, SEQ ID NO: 229, SEQ ID NO: 230, SEQ ID NO: 231, SEQ ID NO:232, SEQ ID NO: 233, SEQ ID NO: 234, SEQ ID NO: 235, SEQ ID NO: 236, SEQID NO: 237, SEQ ID NO: 238, SEQ ID NO: 239, SEQ ID NO: 240, SEQ ID NO:241, SEQ ID NO: 242, SEQ ID NO: 243, SEQ ID NO: 244, SEQ ID NO: 245, SEQID NO: 246, or SEQ ID NO: 247. In some embodiments, the anti-Factor Dantibody is a Fab fragment comprising a heavy chain having at least 90%sequence identity to the amino acid sequence of SEQ ID NO: 214, SEQ IDNO: 215, SEQ ID NO: 216, SEQ ID NO: 217, SEQ ID NO: 218, SEQ ID NO: 219,SEQ ID NO: 220, SEQ ID NO: 221, SEQ ID NO: 222, SEQ ID NO: 223, SEQ IDNO: 224, SEQ ID NO: 225, SEQ ID NO: 226, SEQ ID NO: 227, SEQ ID NO: 228,SEQ ID NO: 229, SEQ ID NO: 230, SEQ ID NO: 231, SEQ ID NO: 232, SEQ IDNO: 233, SEQ ID NO: 234, SEQ ID NO: 235, SEQ ID NO: 236, SEQ ID NO: 237,SEQ ID NO: 238, SEQ ID NO: 239, SEQ ID NO: 240, SEQ ID NO: 241, SEQ IDNO: 242, SEQ ID NO: 243, SEQ ID NO: 244, SEQ ID NO: 245, SEQ ID NO: 246,or SEQ ID NO: 247. See Table 8. In specific embodiments, the Fabfragment is of an IgG1 isotype. In specific embodiments, the cysteine inthe Cys-Asp-Lys-Thr-His-Leu (CDKTHL) sequence at the C′ Terminal end isattached to a polymer (e.g., a PEG polymer).

In some embodiments, the anti-Factor D antibody is a Fab fragmentcomprising a heavy chain having the amino acid sequence of SEQ ID NO:248, SEQ ID NO: 249, SEQ ID NO: 250, SEQ ID NO: 251, SEQ ID NO: 252, SEQID NO: 253, SEQ ID NO: 254, SEQ ID NO: 255, SEQ ID NO: 256, SEQ ID NO:257, SEQ ID NO: 258, SEQ ID NO: 259, SEQ ID NO: 260, SEQ ID NO: 261, SEQID NO: 262, SEQ ID NO: 263, SEQ ID NO: 264, SEQ ID NO: 265, SEQ ID NO:266, SEQ ID NO: 267, SEQ ID NO: 268, SEQ ID NO: 269, SEQ ID NO: 270, SEQID NO: 271, SEQ ID NO: 272, SEQ ID NO: 273, SEQ ID NO: 274, SEQ ID NO:275, SEQ ID NO: 276, SEQ ID NO: 277, SEQ ID NO: 278, SEQ ID NO: 279, SEQID NO: 280, or SEQ ID NO: 281. In some embodiments, the anti-Factor Dantibody is a Fab fragment comprising a heavy chain having at least 90%sequence identity to the amino acid sequence of SEQ ID NO: 248, SEQ IDNO: 249, SEQ ID NO: 250, SEQ ID NO: 251, SEQ ID NO: 252, SEQ ID NO: 253,SEQ ID NO: 254, SEQ ID NO: 255, SEQ ID NO: 256, SEQ ID NO: 257, SEQ IDNO: 258, SEQ ID NO: 259, SEQ ID NO: 260, SEQ ID NO: 261, SEQ ID NO: 262,SEQ ID NO: 263, SEQ ID NO: 264, SEQ ID NO: 265, SEQ ID NO: 266, SEQ IDNO: 267, SEQ ID NO: 268, SEQ ID NO: 269, SEQ ID NO: 270, SEQ ID NO: 271,SEQ ID NO: 272, SEQ ID NO: 273, SEQ ID NO: 274, SEQ ID NO: 275, SEQ IDNO: 276, SEQ ID NO: 277, SEQ ID NO: 278, SEQ ID NO: 279, SEQ ID NO: 280,or SEQ ID NO: 281. See Table 8. In specific embodiments, the Fabfragment is of an IgG1 isotype. In specific embodiments, the cysteine inthe Cys-Asp-Lys (CDK) sequence at the C′ Terminal end is attached to apolymer (e.g., a PEG polymer).

In some embodiments, the anti-Factor D antibody is a Fab fragmentcomprising a heavy chain having the amino acid sequence of SEQ ID NO:282, SEQ ID NO: 283, SEQ ID NO: 284, SEQ ID NO: 285, SEQ ID NO: 286, SEQID NO: 287, SEQ ID NO: 288, SEQ ID NO: 289, SEQ ID NO: 290, SEQ ID NO:291, SEQ ID NO: 292, SEQ ID NO: 293, SEQ ID NO: 294, SEQ ID NO: 295, SEQID NO: 296, SEQ ID NO: 297, SEQ ID NO: 298, SEQ ID NO: 299, SEQ ID NO:300, SEQ ID NO: 301, SEQ ID NO: 302, SEQ ID NO: 303, SEQ ID NO: 304, SEQID NO: 305, SEQ ID NO: 306, SEQ ID NO: 307, SEQ ID NO: 308, SEQ ID NO:309, SEQ ID NO: 310, SEQ ID NO: 311, SEQ ID NO: 312, SEQ ID NO: 313, SEQID NO: 314, or SEQ ID NO: 315. In some embodiments, the anti-Factor Dantibody is a Fab fragment comprising a heavy chain having at least 90%sequence identity to the amino acid sequence of SEQ ID NO: 282, SEQ IDNO: 283, SEQ ID NO: 284, SEQ ID NO: 285, SEQ ID NO: 286, SEQ ID NO: 287,SEQ ID NO: 288, SEQ ID NO: 289, SEQ ID NO: 290, SEQ ID NO: 291, SEQ IDNO: 292, SEQ ID NO: 293, SEQ ID NO: 294, SEQ ID NO: 295, SEQ ID NO: 296,SEQ ID NO: 297, SEQ ID NO: 298, SEQ ID NO: 299, SEQ ID NO: 300, SEQ IDNO: 301, SEQ ID NO: 302, SEQ ID NO: 303, SEQ ID NO: 304, SEQ ID NO: 305,SEQ ID NO: 306, SEQ ID NO: 307, SEQ ID NO: 308, SEQ ID NO: 309, SEQ IDNO: 310, SEQ ID NO: 311, SEQ ID NO: 312, SEQ ID NO: 313, SEQ ID NO: 314,or SEQ ID NO: 315. See Table 8. In specific embodiments, the Fabfragment is of an IgG1 isotype. In specific embodiments, the cysteine inthe Cys-Asp-Lys-Thr (CDKT) sequence at the C′ Terminal end is attachedto a polymer (e.g., a PEG polymer).

In some embodiments, the anti-Factor D antibody is a Fab fragmentcomprising a heavy chain having the amino acid sequence of SEQ ID NO:316, SEQ ID NO: 317, SEQ ID NO: 318, SEQ ID NO: 319, SEQ ID NO: 320, SEQID NO: 321, SEQ ID NO: 322, SEQ ID NO: 323, SEQ ID NO: 324, SEQ ID NO:325, SEQ ID NO: 326, SEQ ID NO: 327, SEQ ID NO: 328, SEQ ID NO: 329, SEQID NO: 330, SEQ ID NO: 331, SEQ ID NO: 332, SEQ ID NO: 333, SEQ ID NO:334, SEQ ID NO: 335, SEQ ID NO: 336, SEQ ID NO: 337, SEQ ID NO: 338, SEQID NO: 339, SEQ ID NO: 340, SEQ ID NO: 341, SEQ ID NO: 342, SEQ ID NO:343, SEQ ID NO: 344, SEQ ID NO: 345, SEQ ID NO: 346, SEQ ID NO: 347, SEQID NO: 348, or SEQ ID NO: 349. In some embodiments, the anti-Factor Dantibody is a Fab fragment comprising a heavy chain having at least 90%sequence identity to the amino acid sequence of SEQ ID NO: 316, SEQ IDNO: 317, SEQ ID NO: 318, SEQ ID NO: 319, SEQ ID NO: 320, SEQ ID NO: 321,SEQ ID NO: 322, SEQ ID NO: 323, SEQ ID NO: 324, SEQ ID NO: 325, SEQ IDNO: 326, SEQ ID NO: 327, SEQ ID NO: 328, SEQ ID NO: 329, SEQ ID NO: 330,SEQ ID NO: 331, SEQ ID NO: 332, SEQ ID NO: 333, SEQ ID NO: 334, SEQ IDNO: 335, SEQ ID NO: 336, SEQ ID NO: 337, SEQ ID NO: 338, SEQ ID NO: 339,SEQ ID NO: 340, SEQ ID NO: 341, SEQ ID NO: 342, SEQ ID NO: 343, SEQ IDNO: 344, SEQ ID NO: 345, SEQ ID NO: 346, SEQ ID NO: 347, SEQ ID NO: 348,or SEQ ID NO: 349. See Table 8. In specific embodiments, the Fabfragment is of an IgG1 isotype. In specific embodiments, the cysteine inthe Cys-Asp-Lys-Thr-His (CDKTH) sequence at the C′ Terminal end isattached to a polymer (e.g., a PEG polymer).

In some embodiments, the anti-Factor D antibody is a Fab-C fragmentcomprising a heavy chain having the amino acid sequence of SEQ ID NO:350, SEQ ID NO: 351, SEQ ID NO: 352, SEQ ID NO: 353, SEQ ID NO: 354, SEQID NO: 355, SEQ ID NO: 356, SEQ ID NO: 357, SEQ ID NO: 358, SEQ ID NO:359, SEQ ID NO: 360, SEQ ID NO: 361, SEQ ID NO: 362, SEQ ID NO: 363, SEQID NO: 364, SEQ ID NO: 365, SEQ ID NO: 366, SEQ ID NO: 367, SEQ ID NO:368, SEQ ID NO: 369, SEQ ID NO: 370, SEQ ID NO: 371, SEQ ID NO: 372, SEQID NO: 373, SEQ ID NO: 374, SEQ ID NO: 375, SEQ ID NO: 376, SEQ ID NO:377, SEQ ID NO: 378, SEQ ID NO: 379, SEQ ID NO: 380, SEQ ID NO: 381, SEQID NO: 382, or SEQ ID NO: 383. In some embodiments, the anti-Factor Dantibody is a Fab-C fragment comprising a heavy chain having at least90% sequence identity to the amino acid sequence of SEQ ID NO: 350, SEQID NO: 351, SEQ ID NO: 352, SEQ ID NO: 353, SEQ ID NO: 354, SEQ ID NO:355, SEQ ID NO: 356, SEQ ID NO: 357, SEQ ID NO: 358, SEQ ID NO: 359, SEQID NO: 360, SEQ ID NO: 361, SEQ ID NO: 362, SEQ ID NO: 363, SEQ ID NO:364, SEQ ID NO: 365, SEQ ID NO: 366, SEQ ID NO: 367, SEQ ID NO: 368, SEQID NO: 369, SEQ ID NO: 370, SEQ ID NO: 371, SEQ ID NO: 372, SEQ ID NO:373, SEQ ID NO: 374, SEQ ID NO: 375, SEQ ID NO: 376, SEQ ID NO: 377, SEQID NO: 378, SEQ ID NO: 379, SEQ ID NO: 380, SEQ ID NO: 381, SEQ ID NO:382, or SEQ ID NO: 383. See Table 8. In specific embodiments, the Fab-Cfragment is of an IgG1 isotype. In specific embodiments, the twocysteines in the Cys-Asp-Lys-Thr-His-Thr-Cys (CDKTHTC) sequence at theC′ Terminal end are each attached to a polymer (e.g., a PEG polymer). Inspecific embodiments, the first cysteine in theCys-Asp-Lys-Thr-His-Thr-Cys (CDKTHTC) sequence at the C′ Terminal end isattached to a polymer (e.g., a PEG polymer). In specific embodiments,the second cysteine in the Cys-Asp-Lys-Thr-His-Thr-Cys (CDKTHTC)sequence at the C′ Terminal end is attached to a polymer (e.g., a PEGpolymer).

In some embodiments, the anti-Factor D antibody is a Fab fragment, aFab′ fragment or a F(ab′)2 fragment comprising a heavy chain having theamino acid sequence of SEQ ID NO: 384, SEQ ID NO: 385, SEQ ID NO: 386,SEQ ID NO: 387, SEQ ID NO: 388, SEQ ID NO: 389, SEQ ID NO: 390, SEQ IDNO: 391, SEQ ID NO: 392, SEQ ID NO: 393, SEQ ID NO: 394, SEQ ID NO: 395,SEQ ID NO: 396, SEQ ID NO: 397, SEQ ID NO: 398, SEQ ID NO: 399, SEQ IDNO: 400, SEQ ID NO: 401, SEQ ID NO: 402, SEQ ID NO: 403, SEQ ID NO: 404,SEQ ID NO: 405, SEQ ID NO: 406, SEQ ID NO: 407, SEQ ID NO: 408, SEQ IDNO: 409, SEQ ID NO: 410, SEQ ID NO: 411, SEQ ID NO: 412, SEQ ID NO: 413,SEQ ID NO: 414, SEQ ID NO: 415, SEQ ID NO: 416, or SEQ ID NO: 417. Insome embodiments, the anti-Factor D antibody is a Fab fragment, a Fab′fragment or a F(ab′)2 fragment comprising a heavy chain having at least90% sequence identity to the amino acid sequence of SEQ ID NO: 384, SEQID NO: 385, SEQ ID NO: 386, SEQ ID NO: 387, SEQ ID NO: 388, SEQ ID NO:389, SEQ ID NO: 390, SEQ ID NO: 391, SEQ ID NO: 392, SEQ ID NO: 393, SEQID NO: 394, SEQ ID NO: 395, SEQ ID NO: 396, SEQ ID NO: 397, SEQ ID NO:398, SEQ ID NO: 399, SEQ ID NO: 400, SEQ ID NO: 401, SEQ ID NO: 402, SEQID NO: 403, SEQ ID NO: 404, SEQ ID NO: 405, SEQ ID NO: 406, SEQ ID NO:407, SEQ ID NO: 408, SEQ ID NO: 409, SEQ ID NO: 410, SEQ ID NO: 411, SEQID NO: 412, SEQ ID NO: 413, SEQ ID NO: 414, SEQ ID NO: 415, SEQ ID NO:416, or SEQ ID NO: 417. See Table 8. In specific embodiments, the Fabfragment, Fab′ fragment or F(ab′)2 fragment is of an IgG1 isotype. Inspecific embodiments, the three cysteines in theCys-Asp-Lys-Thr-His-Thr-Cys-Pro-Pro-Cys (CDKTHTCPPC) sequence at the C′Terminal end are each attached to a polymer (e.g., a PEG polymer). Inspecific embodiments, the second cysteine and the third cysteine in theCys-Asp-Lys-Thr-His-Thr-Cys-Pro-Pro-Cys (CDKTHTCPPC) sequence at the C′Terminal end are each attached to a polymer (e.g., a PEG polymer). Inspecific embodiments, the first cysteine and the third cysteine in theCys-Asp-Lys-Thr-His-Thr-Cys-Pro-Pro-Cys (CDKTHTCPPC) sequence at the C′Terminal end are each attached to a polymer (e.g., a PEG polymer). Inspecific embodiments, the first cysteine and the second cysteine in theCys-Asp-Lys-Thr-His-Thr-Cys-Pro-Pro-Cys (CDKTHTCPPC) sequence at the C′Terminal end are each attached to a polymer (e.g., a PEG polymer). Inspecific embodiments, the first cysteine in theCys-Asp-Lys-Thr-His-Thr-Cys-Pro-Pro-Cys (CDKTHTCPPC) sequence at the C′Terminal end is attached to a polymer (e.g., a PEG polymer). In specificembodiments, the second cysteine in theCys-Asp-Lys-Thr-His-Thr-Cys-Pro-Pro-Cys (CDKTHTCPPC) sequence at the C′Terminal end is attached to a polymer (e.g., a PEG polymer). In specificembodiments, the third cysteine in theCys-Asp-Lys-Thr-His-Thr-Cys-Pro-Pro-Cys (CDKTHTCPPC) sequence at the C′Terminal end is attached to a polymer (e.g., a PEG polymer).

In some embodiments, the anti-Factor D antibody is a Fab fragment, aFab′ fragment or a F(ab′)2 fragment comprising a heavy chain having theamino acid sequence of SEQ ID NO: 418, SEQ ID NO: 419, SEQ ID NO: 420,SEQ ID NO: 421, SEQ ID NO: 422, SEQ ID NO: 423, SEQ ID NO: 424, SEQ IDNO: 425, SEQ ID NO: 426, SEQ ID NO: 427, SEQ ID NO: 428, SEQ ID NO: 429,SEQ ID NO: 430, SEQ ID NO: 431, SEQ ID NO: 432, SEQ ID NO: 433, SEQ IDNO: 434, SEQ ID NO: 435, SEQ ID NO: 436, SEQ ID NO: 437, SEQ ID NO: 438,SEQ ID NO: 439, SEQ ID NO: 440, SEQ ID NO: 441, SEQ ID NO: 442, SEQ IDNO: 443, SEQ ID NO: 444, SEQ ID NO: 445, SEQ ID NO: 446, SEQ ID NO: 447,SEQ ID NO: 448, SEQ ID NO: 449, SEQ ID NO: 450, or SEQ ID NO: 451. Insome embodiments, the anti-Factor D antibody is a Fab fragment, a Fab′fragment or a F(ab′)2 fragment comprising a heavy chain having at least90% sequence identity to the amino acid sequence of SEQ ID NO: 418, SEQID NO: 419, SEQ ID NO: 420, SEQ ID NO: 421, SEQ ID NO: 422, SEQ ID NO:423, SEQ ID NO: 424, SEQ ID NO: 425, SEQ ID NO: 426, SEQ ID NO: 427, SEQID NO: 428, SEQ ID NO: 429, SEQ ID NO: 430, SEQ ID NO: 431, SEQ ID NO:432, SEQ ID NO: 433, SEQ ID NO: 434, SEQ ID NO: 435, SEQ ID NO: 436, SEQID NO: 437, SEQ ID NO: 438, SEQ ID NO: 439, SEQ ID NO: 440, SEQ ID NO:441, SEQ ID NO: 442, SEQ ID NO: 443, SEQ ID NO: 444, SEQ ID NO: 445, SEQID NO: 446, SEQ ID NO: 447, SEQ ID NO: 448, SEQ ID NO: 449, SEQ ID NO:450, or SEQ ID NO: 451. See Table 8. In specific embodiments, the Fabfragment, Fab′ fragment or F(ab′)2 fragment is of an IgG1 isotype. Inspecific embodiments, the two cysteines in theCys-Asp-Lys-Thr-His-Thr-Cys-Pro-Pro-Ser (CDKTHTCPPS) sequence at the C′Terminal end are each attached to a polymer (e.g., a PEG polymer). Inspecific embodiments, the first cysteine in theCys-Asp-Lys-Thr-His-Thr-Cys-Pro-Pro-Ser (CDKTHTCPPS) sequence at the C′Terminal end is attached to a polymer (e.g., a PEG polymer). In specificembodiments, the second cysteine in theCys-Asp-Lys-Thr-His-Thr-Cys-Pro-Pro-Ser (CDKTHTCPPS) sequence at the C′Terminal end is attached to a polymer (e.g., a PEG polymer).

In some embodiments, the anti-Factor D antibody is a Fab fragment, aFab′ fragment or a F(ab′)2 fragment comprising a heavy chain having theamino acid sequence of SEQ ID NO: 452, SEQ ID NO: 453, SEQ ID NO: 454,SEQ ID NO: 455, SEQ ID NO: 456, SEQ ID NO: 457, SEQ ID NO: 458, SEQ IDNO: 459, SEQ ID NO: 460, SEQ ID NO: 461, SEQ ID NO: 462, SEQ ID NO: 463,SEQ ID NO: 464, SEQ ID NO: 465, SEQ ID NO: 466, SEQ ID NO: 467, SEQ IDNO: 468, SEQ ID NO: 469, SEQ ID NO: 470, SEQ ID NO: 471, SEQ ID NO: 472,SEQ ID NO: 473, SEQ ID NO: 474, SEQ ID NO: 475, SEQ ID NO: 476, SEQ IDNO: 477, SEQ ID NO: 478, SEQ ID NO: 479, SEQ ID NO: 480, SEQ ID NO: 481,SEQ ID NO: 482, SEQ ID NO: 483, SEQ ID NO: 484, or SEQ ID NO: 485. Insome embodiments, the anti-Factor D antibody is a Fab fragment, a Fab′fragment or a F(ab′)2 fragment comprising a heavy chain having at least90% sequence identity to the amino acid sequence of SEQ ID NO: 452, SEQID NO: 453, SEQ ID NO: 454, SEQ ID NO: 455, SEQ ID NO: 456, SEQ ID NO:457, SEQ ID NO: 458, SEQ ID NO: 459, SEQ ID NO: 460, SEQ ID NO: 461, SEQID NO: 462, SEQ ID NO: 463, SEQ ID NO: 464, SEQ ID NO: 465, SEQ ID NO:466, SEQ ID NO: 467, SEQ ID NO: 468, SEQ ID NO: 469, SEQ ID NO: 470, SEQID NO: 471, SEQ ID NO: 472, SEQ ID NO: 473, SEQ ID NO: 474, SEQ ID NO:475, SEQ ID NO: 476, SEQ ID NO: 477, SEQ ID NO: 478, SEQ ID NO: 479, SEQID NO: 480, SEQ ID NO: 481, SEQ ID NO: 482, SEQ ID NO: 483, SEQ ID NO:484, or SEQ ID NO: 485. See Table 8. In specific embodiments, the Fabfragment, Fab′ fragment or F(ab′)2 fragment is of an IgG1 isotype. Inspecific embodiments, the two cysteines in theCys-Asp-Lys-Thr-His-Thr-Ser-Pro-Pro-Cys (CDKTHTSPPC) sequence at the C′Terminal end are each attached to a polymer (e.g., a PEG polymer). Inspecific embodiments, the first cysteine in theCys-Asp-Lys-Thr-His-Thr-Ser-Pro-Pro-Cys (CDKTHTSPPC) sequence at the C′Terminal end is attached to a polymer (e.g., a PEG polymer). In specificembodiments, the second cysteine in theCys-Asp-Lys-Thr-His-Thr-Ser-Pro-Pro-Cys (CDKTHTSPPC) sequence at the C′Terminal end is attached to a polymer (e.g., a PEG polymer).

In some embodiments, the anti-Factor D antibody is a Fab fragment, aFab′ fragment or a F(ab′)2 fragment comprising a heavy chain having theamino acid sequence of SEQ ID NO: 486, SEQ ID NO: 487, SEQ ID NO: 488,SEQ ID NO: 489, SEQ ID NO: 490, SEQ ID NO: 491, SEQ ID NO: 492, SEQ IDNO: 493, SEQ ID NO: 494, SEQ ID NO: 495, SEQ ID NO: 496, SEQ ID NO: 497,SEQ ID NO: 498, SEQ ID NO: 499, SEQ ID NO: 500, SEQ ID NO: 501, SEQ IDNO: 502, SEQ ID NO: 503, SEQ ID NO: 504, SEQ ID NO: 505, SEQ ID NO: 506,SEQ ID NO: 507, SEQ ID NO: 508, SEQ ID NO: 509, SEQ ID NO: 510, SEQ IDNO: 511, SEQ ID NO: 512, SEQ ID NO: 513, SEQ ID NO: 514, SEQ ID NO: 515,SEQ ID NO: 516, SEQ ID NO: 517, SEQ ID NO: 518, or SEQ ID NO: 519. Insome embodiments, the anti-Factor D antibody is a Fab fragment, a Fab′fragment or a F(ab′)2 fragment comprising a heavy chain having at least90% sequence identity to the amino acid sequence of SEQ ID NO: 486, SEQID NO: 487, SEQ ID NO: 488, SEQ ID NO: 489, SEQ ID NO: 490, SEQ ID NO:491, SEQ ID NO: 492, SEQ ID NO: 493, SEQ ID NO: 494, SEQ ID NO: 495, SEQID NO: 496, SEQ ID NO: 497, SEQ ID NO: 498, SEQ ID NO: 499, SEQ ID NO:500, SEQ ID NO: 501, SEQ ID NO: 502, SEQ ID NO: 503, SEQ ID NO: 504, SEQID NO: 505, SEQ ID NO: 506, SEQ ID NO: 507, SEQ ID NO: 508, SEQ ID NO:509, SEQ ID NO: 510, SEQ ID NO: 511, SEQ ID NO: 512, SEQ ID NO: 513, SEQID NO: 514, SEQ ID NO: 515, SEQ ID NO: 516, SEQ ID NO: 517, SEQ ID NO:518, or SEQ ID NO: 519. See Table 8. In specific embodiments, the Fabfragment, Fab′ fragment or F(ab′)2 fragment is of an IgG1 isotype. Inspecific embodiments, the two cysteines in theCys-Asp-Lys-Thr-His-Thr-Ala-Pro-Pro-Cys (CDKTHTAPPC) sequence at the C′Terminal end are each attached to a polymer (e.g., a PEG polymer). Inspecific embodiments, the first cysteine in theCys-Asp-Lys-Thr-His-Thr-Ala-Pro-Pro-Cys (CDKTHTAPPC) sequence at the C′Terminal end is attached to a polymer (e.g., a PEG polymer). In specificembodiments, the second cysteine in theCys-Asp-Lys-Thr-His-Thr-Ala-Pro-Pro-Cys (CDKTHTAPPC) sequence at the C′Terminal end is attached to a polymer (e.g., a PEG polymer).

In some embodiments, the anti-Factor D antibody is a Fab fragment, aFab′ fragment or a F(ab′)2 fragment comprising a heavy chain having theamino acid sequence of SEQ ID NO: 520, SEQ ID NO: 521, SEQ ID NO: 522,SEQ ID NO: 523, SEQ ID NO: 524, SEQ ID NO: 525, SEQ ID NO: 526, SEQ IDNO: 527, SEQ ID NO: 528, SEQ ID NO: 529, SEQ ID NO: 530, SEQ ID NO: 531,SEQ ID NO: 532, SEQ ID NO: 533, SEQ ID NO: 534, SEQ ID NO: 535, SEQ IDNO: 536, SEQ ID NO: 537, SEQ ID NO: 538, SEQ ID NO: 539, SEQ ID NO: 540,SEQ ID NO: 541, SEQ ID NO: 542, SEQ ID NO: 543, SEQ ID NO: 544, SEQ IDNO: 545, SEQ ID NO: 546, SEQ ID NO: 547, SEQ ID NO: 548, SEQ ID NO: 549,SEQ ID NO: 550, SEQ ID NO: 551, SEQ ID NO: 552, or SEQ ID NO: 553. Insome embodiments, the anti-Factor D antibody is a Fab fragment, a Fab′fragment or a F(ab′)2 fragment comprising a heavy chain having at least90% sequence identity to the amino acid sequence of SEQ ID NO: 520, SEQID NO: 521, SEQ ID NO: 522, SEQ ID NO: 523, SEQ ID NO: 524, SEQ ID NO:525, SEQ ID NO: 526, SEQ ID NO: 527, SEQ ID NO: 528, SEQ ID NO: 529, SEQID NO: 530, SEQ ID NO: 531, SEQ ID NO: 532, SEQ ID NO: 533, SEQ ID NO:534, SEQ ID NO: 535, SEQ ID NO: 536, SEQ ID NO: 537, SEQ ID NO: 538, SEQID NO: 539, SEQ ID NO: 540, SEQ ID NO: 541, SEQ ID NO: 542, SEQ ID NO:543, SEQ ID NO: 544, SEQ ID NO: 545, SEQ ID NO: 546, SEQ ID NO: 547, SEQID NO: 548, SEQ ID NO: 549, SEQ ID NO: 550, SEQ ID NO: 551, SEQ ID NO:552, or SEQ ID NO: 553. See Table 8. In specific embodiments, the Fabfragment, Fab′ fragment or F(ab′)2 fragment is of an IgG1 isotype. Inspecific embodiments, the two cysteines in theCys-Asp-Lys-Thr-His-Thr-Ser-Gly-Gly-Cys (CDKTHTSGGC) sequence at the C′Terminal end are each attached to a polymer (e.g., a PEG polymer). Inspecific embodiments, the first cysteine in theCys-Asp-Lys-Thr-His-Thr-Ser-Gly-Gly-Cys (CDKTHTSGGC) sequence at the C′Terminal end is attached to a polymer (e.g., a PEG polymer). In specificembodiments, the second cysteine in theCys-Asp-Lys-Thr-His-Thr-Ser-Gly-Gly-Cys (CDKTHTSGGC) sequence at the C′Terminal end is attached to a polymer (e.g., a PEG polymer).

In some embodiments, the anti-Factor D antibody is a Fab fragmentcomprising a heavy chain having the amino acid sequence of SEQ ID NO:554, SEQ ID NO: 555, SEQ ID NO: 556, SEQ ID NO: 557, SEQ ID NO: 558, SEQID NO: 559, SEQ ID NO: 560, SEQ ID NO: 561, SEQ ID NO: 562, SEQ ID NO:563, SEQ ID NO: 564, SEQ ID NO: 565, SEQ ID NO: 566, SEQ ID NO: 567, SEQID NO: 568, SEQ ID NO: 569, SEQ ID NO: 570, SEQ ID NO: 571, SEQ ID NO:572, SEQ ID NO: 573, SEQ ID NO: 574, SEQ ID NO: 575, SEQ ID NO: 576, SEQID NO: 577, SEQ ID NO: 578, SEQ ID NO: 579, SEQ ID NO: 580, SEQ ID NO:581, SEQ ID NO: 582, SEQ ID NO: 583, SEQ ID NO: 584, SEQ ID NO: 585, SEQID NO: 586, or SEQ ID NO: 587. In some embodiments, the anti-Factor Dantibody is a Fab fragment comprising a heavy chain having at least 90%sequence identity to the amino acid sequence of SEQ ID NO: 554, SEQ IDNO: 555, SEQ ID NO: 556, SEQ ID NO: 557, SEQ ID NO: 558, SEQ ID NO: 559,SEQ ID NO: 560, SEQ ID NO: 561, SEQ ID NO: 562, SEQ ID NO: 563, SEQ IDNO: 564, SEQ ID NO: 565, SEQ ID NO: 566, SEQ ID NO: 567, SEQ ID NO: 568,SEQ ID NO: 569, SEQ ID NO: 570, SEQ ID NO: 571, SEQ ID NO: 572, SEQ IDNO: 573, SEQ ID NO: 574, SEQ ID NO: 575, SEQ ID NO: 576, SEQ ID NO: 577,SEQ ID NO: 578, SEQ ID NO: 579, SEQ ID NO: 580, SEQ ID NO: 581, SEQ IDNO: 582, SEQ ID NO: 583, SEQ ID NO: 584, SEQ ID NO: 585, SEQ ID NO: 586,or SEQ ID NO: 587. See Table 8. In specific embodiments, the Fabfragment is of an IgG1 isotype. In specific embodiments, the twocysteines in the Cys-Tyr-Gly-Pro-Pro-Cys (CYGPPC) sequence at the C′Terminal end are each attached to a polymer (e.g., a PEG polymer). Inspecific embodiments, the first cysteine in the Cys-Tyr-Gly-Pro-Pro-Cys(CYGPPC) sequence at the C′ Terminal end is attached to a polymer (e.g.,a PEG polymer). In specific embodiments, the second cysteine in theCys-Tyr-Gly-Pro-Pro-Cys (CYGPPC) sequence at the C′ Terminal end isattached to a polymer (e.g., a PEG polymer).

In some embodiments, the anti-Factor D antibody is a Fab fragmentcomprising a heavy chain having the amino acid sequence of SEQ ID NO:588, SEQ ID NO: 589, SEQ ID NO: 590, SEQ ID NO: 591, SEQ ID NO: 592, SEQID NO: 593, SEQ ID NO: 594, SEQ ID NO: 595, SEQ ID NO: 596, SEQ ID NO:597, SEQ ID NO: 598, SEQ ID NO: 599, SEQ ID NO: 600, SEQ ID NO: 601, SEQID NO: 602, SEQ ID NO: 603, SEQ ID NO: 604, SEQ ID NO: 605, SEQ ID NO:606, SEQ ID NO: 607, SEQ ID NO: 608, SEQ ID NO: 609, SEQ ID NO: 610, SEQID NO: 611, SEQ ID NO: 612, SEQ ID NO: 613, SEQ ID NO: 614, SEQ ID NO:615, SEQ ID NO: 616, SEQ ID NO: 617, SEQ ID NO: 618, SEQ ID NO: 619, SEQID NO: 620, or SEQ ID NO: 621. In some embodiments, the anti-Factor Dantibody is a Fab fragment comprising a heavy chain having at least 90%sequence identity to the amino acid sequence of SEQ ID NO: 588, SEQ IDNO: 589, SEQ ID NO: 590, SEQ ID NO: 591, SEQ ID NO: 592, SEQ ID NO: 593,SEQ ID NO: 594, SEQ ID NO: 595, SEQ ID NO: 596, SEQ ID NO: 597, SEQ IDNO: 598, SEQ ID NO: 599, SEQ ID NO: 600, SEQ ID NO: 601, SEQ ID NO: 602,SEQ ID NO: 603, SEQ ID NO: 604, SEQ ID NO: 605, SEQ ID NO: 606, SEQ IDNO: 607, SEQ ID NO: 608, SEQ ID NO: 609, SEQ ID NO: 610, SEQ ID NO: 611,SEQ ID NO: 612, SEQ ID NO: 613, SEQ ID NO: 614, SEQ ID NO: 615, SEQ IDNO: 616, SEQ ID NO: 617, SEQ ID NO: 618, SEQ ID NO: 619, SEQ ID NO: 620,or SEQ ID NO: 621. See Table 8. In specific embodiments, the Fabfragment is of an IgG2 isotype.

In some embodiments, the anti-Factor D antibody is a Fab-C fragmentcomprising a heavy chain having the amino acid sequence of SEQ ID NO:622, SEQ ID NO: 623, SEQ ID NO: 624, SEQ ID NO: 625, SEQ ID NO: 626, SEQID NO: 627, SEQ ID NO: 628, SEQ ID NO: 629, SEQ ID NO: 630, SEQ ID NO:631, SEQ ID NO: 632, SEQ ID NO: 633, SEQ ID NO: 634, SEQ ID NO: 635, SEQID NO: 636, SEQ ID NO: 637, SEQ ID NO: 638, SEQ ID NO: 639, SEQ ID NO:640, SEQ ID NO: 641, SEQ ID NO: 642, SEQ ID NO: 643, SEQ ID NO: 644, SEQID NO: 645, SEQ ID NO: 646, SEQ ID NO: 647, SEQ ID NO: 648, SEQ ID NO:649, SEQ ID NO: 650, SEQ ID NO: 651, SEQ ID NO: 652, SEQ ID NO: 653, SEQID NO: 654, or SEQ ID NO: 655. In some embodiments, the anti-Factor Dantibody is a Fab-C fragment comprising a heavy chain having at least90% sequence identity to the amino acid sequence of SEQ ID NO: 622, SEQID NO: 623, SEQ ID NO: 624, SEQ ID NO: 625, SEQ ID NO: 626, SEQ ID NO:627, SEQ ID NO: 628, SEQ ID NO: 629, SEQ ID NO: 630, SEQ ID NO: 631, SEQID NO: 632, SEQ ID NO: 633, SEQ ID NO: 634, SEQ ID NO: 635, SEQ ID NO:636, SEQ ID NO: 637, SEQ ID NO: 638, SEQ ID NO: 639, SEQ ID NO: 640, SEQID NO: 641, SEQ ID NO: 642, SEQ ID NO: 643, SEQ ID NO: 644, SEQ ID NO:645, SEQ ID NO: 646, SEQ ID NO: 647, SEQ ID NO: 648, SEQ ID NO: 649, SEQID NO: 650, SEQ ID NO: 651, SEQ ID NO: 652, SEQ ID NO: 653, SEQ ID NO:654, or SEQ ID NO: 655. See Table 8. In specific embodiments, the Fab-Cfragment is of an IgG2 isotype. In specific embodiments, the cysteine inthe Val-Glu-Arg-Lys-Cys (VERKC) sequence at the C′ Terminal end isattached to a polymer (e.g., a PEG polymer).

In some embodiments, the anti-Factor D antibody is a Fab-C fragmentcomprising a heavy chain having the amino acid sequence of SEQ ID NO:656, SEQ ID NO: 657, SEQ ID NO: 658, SEQ ID NO: 659, SEQ ID NO: 660, SEQID NO: 661, SEQ ID NO: 662, SEQ ID NO: 663, SEQ ID NO: 664, SEQ ID NO:665, SEQ ID NO: 666, SEQ ID NO: 667, SEQ ID NO: 668, SEQ ID NO: 669, SEQID NO: 670, SEQ ID NO: 671, SEQ ID NO: 672, SEQ ID NO: 673, SEQ ID NO:674, SEQ ID NO: 675, SEQ ID NO: 676, SEQ ID NO: 677, SEQ ID NO: 678, SEQID NO: 679, SEQ ID NO: 680, SEQ ID NO: 681, SEQ ID NO: 682, SEQ ID NO:683, SEQ ID NO: 684, SEQ ID NO: 685, SEQ ID NO: 686, SEQ ID NO: 687, SEQID NO: 688, or SEQ ID NO: 689. In some embodiments, the anti-Factor Dantibody is a Fab-C fragment comprising a heavy chain having at least90% sequence identity to the amino acid sequence of SEQ ID NO: 656, SEQID NO: 657, SEQ ID NO: 658, SEQ ID NO: 659, SEQ ID NO: 660, SEQ ID NO:661, SEQ ID NO: 662, SEQ ID NO: 663, SEQ ID NO: 664, SEQ ID NO: 665, SEQID NO: 666, SEQ ID NO: 667, SEQ ID NO: 668, SEQ ID NO: 669, SEQ ID NO:670, SEQ ID NO: 671, SEQ ID NO: 672, SEQ ID NO: 673, SEQ ID NO: 674, SEQID NO: 675, SEQ ID NO: 676, SEQ ID NO: 677, SEQ ID NO: 678, SEQ ID NO:679, SEQ ID NO: 680, SEQ ID NO: 681, SEQ ID NO: 682, SEQ ID NO: 683, SEQID NO: 684, SEQ ID NO: 685, SEQ ID NO: 686, SEQ ID NO: 687, SEQ ID NO:688, or SEQ ID NO: 689. See Table 8. In specific embodiments, the Fab-Cfragment is of an IgG4 isotype. In specific embodiments, the cysteine inthe Lys-Tyr-Gly-Pro-Pro-Cys (KYGPPC) sequence at the C′ Terminal end isattached to a polymer (e.g., a PEG polymer).

In some embodiments, the anti-Factor D antibody is a Fab fragmentcomprising a heavy chain having the amino acid sequence of SEQ ID NO:690, SEQ ID NO: 691, SEQ ID NO: 692, SEQ ID NO: 693, SEQ ID NO: 694, SEQID NO: 695, SEQ ID NO: 696, SEQ ID NO: 697, SEQ ID NO: 698, SEQ ID NO:699, SEQ ID NO: 700, SEQ ID NO: 701, SEQ ID NO: 702, SEQ ID NO: 703, SEQID NO: 704, SEQ ID NO: 705, SEQ ID NO: 706, SEQ ID NO: 707, SEQ ID NO:708, SEQ ID NO: 709, SEQ ID NO: 710, SEQ ID NO: 711, SEQ ID NO: 712, SEQID NO: 713, SEQ ID NO: 714, SEQ ID NO: 715, SEQ ID NO: 716, SEQ ID NO:717, SEQ ID NO: 718, SEQ ID NO: 719, SEQ ID NO: 720, SEQ ID NO: 721, SEQID NO: 722, or SEQ ID NO: 723. In some embodiments, the anti-Factor Dantibody is a Fab fragment comprising a heavy chain having at least 90%sequence identity to the amino acid sequence of SEQ ID NO: 690, SEQ IDNO: 691, SEQ ID NO: 692, SEQ ID NO: 693, SEQ ID NO: 694, SEQ ID NO: 695,SEQ ID NO: 696, SEQ ID NO: 697, SEQ ID NO: 698, SEQ ID NO: 699, SEQ IDNO: 700, SEQ ID NO: 701, SEQ ID NO: 702, SEQ ID NO: 703, SEQ ID NO: 704,SEQ ID NO: 705, SEQ ID NO: 706, SEQ ID NO: 707, SEQ ID NO: 708, SEQ IDNO: 709, SEQ ID NO: 710, SEQ ID NO: 711, SEQ ID NO: 712, SEQ ID NO: 713,SEQ ID NO: 714, SEQ ID NO: 715, SEQ ID NO: 716, SEQ ID NO: 717, SEQ IDNO: 718, SEQ ID NO: 719, SEQ ID NO: 720, SEQ ID NO: 721, SEQ ID NO: 722,or SEQ ID NO: 723. See Table 8. In specific embodiments, the Fabfragment is of an IgG4 isotype.

In some embodiments, the anti-Factor D antibody is a Fab fragmentcomprising a heavy chain having the amino acid sequence of SEQ ID NO:724, SEQ ID NO: 725, SEQ ID NO: 726, SEQ ID NO: 727, SEQ ID NO: 728, SEQID NO: 729, SEQ ID NO: 730, SEQ ID NO: 731, SEQ ID NO: 732, SEQ ID NO:733, SEQ ID NO: 734, SEQ ID NO: 735, SEQ ID NO: 736, SEQ ID NO: 737, SEQID NO: 738, SEQ ID NO: 739, SEQ ID NO: 740, SEQ ID NO: 741, SEQ ID NO:742, SEQ ID NO: 743, SEQ ID NO: 744, SEQ ID NO: 745, SEQ ID NO: 746, SEQID NO: 747, SEQ ID NO: 748, SEQ ID NO: 749, SEQ ID NO: 750, SEQ ID NO:751, SEQ ID NO: 752, SEQ ID NO: 753, SEQ ID NO: 754, SEQ ID NO: 755, SEQID NO: 756, or SEQ ID NO: 757. In some embodiments, the anti-Factor Dantibody is a Fab fragment comprising a heavy chain having at least 90%sequence identity to the amino acid sequence of SEQ ID NO: 724, SEQ IDNO: 725, SEQ ID NO: 726, SEQ ID NO: 727, SEQ ID NO: 728, SEQ ID NO: 729,SEQ ID NO: 730, SEQ ID NO: 731, SEQ ID NO: 732, SEQ ID NO: 733, SEQ IDNO: 734, SEQ ID NO: 735, SEQ ID NO: 736, SEQ ID NO: 737, SEQ ID NO: 738,SEQ ID NO: 739, SEQ ID NO: 740, SEQ ID NO: 741, SEQ ID NO: 742, SEQ IDNO: 743, SEQ ID NO: 744, SEQ ID NO: 745, SEQ ID NO: 746, SEQ ID NO: 747,SEQ ID NO: 748, SEQ ID NO: 749, SEQ ID NO: 750, SEQ ID NO: 751, SEQ IDNO: 752, SEQ ID NO: 753, SEQ ID NO: 754, SEQ ID NO: 755, SEQ ID NO: 756,or SEQ ID NO: 757. See Table 8. In specific embodiments, the Fabfragment is of an IgG4 isotype.

In some embodiments, the anti-Factor D antibody is a Fab fragmentcomprising a heavy chain having the amino acid sequence of SEQ ID NO:758, SEQ ID NO: 759, SEQ ID NO: 760, SEQ ID NO: 761, SEQ ID NO: 762, SEQID NO: 763, SEQ ID NO: 764, SEQ ID NO: 765, SEQ ID NO: 766, SEQ ID NO:767, SEQ ID NO: 768, SEQ ID NO: 769, SEQ ID NO: 770, SEQ ID NO: 771, SEQID NO: 772, SEQ ID NO: 773, SEQ ID NO: 774, SEQ ID NO: 775, SEQ ID NO:776, SEQ ID NO: 777, SEQ ID NO: 778, SEQ ID NO: 779, SEQ ID NO: 780, SEQID NO: 781, SEQ ID NO: 782, SEQ ID NO: 783, SEQ ID NO: 784, SEQ ID NO:785, SEQ ID NO: 786, SEQ ID NO: 787, SEQ ID NO: 788, SEQ ID NO: 789, SEQID NO: 790, or SEQ ID NO: 791. In some embodiments, the anti-Factor Dantibody is a Fab fragment comprising a heavy chain having at least 90%sequence identity to the amino acid sequence of SEQ ID NO: 758, SEQ IDNO: 759, SEQ ID NO: 760, SEQ ID NO: 761, SEQ ID NO: 762, SEQ ID NO: 763,SEQ ID NO: 764, SEQ ID NO: 765, SEQ ID NO: 766, SEQ ID NO: 767, SEQ IDNO: 768, SEQ ID NO: 769, SEQ ID NO: 770, SEQ ID NO: 771, SEQ ID NO: 772,SEQ ID NO: 773, SEQ ID NO: 774, SEQ ID NO: 775, SEQ ID NO: 776, SEQ IDNO: 777, SEQ ID NO: 778, SEQ ID NO: 779, SEQ ID NO: 780, SEQ ID NO: 781,SEQ ID NO: 782, SEQ ID NO: 783, SEQ ID NO: 784, SEQ ID NO: 785, SEQ IDNO: 786, SEQ ID NO: 787, SEQ ID NO: 788, SEQ ID NO: 789, SEQ ID NO: 790,or SEQ ID NO: 791. See Table 8. In specific embodiments, the Fabfragment is of an IgG4 isotype.

In some embodiments, the anti-Factor D antibody is a Fab fragmentcomprising a heavy chain having the amino acid sequence of SEQ ID NO:792, SEQ ID NO: 793, SEQ ID NO: 794, SEQ ID NO: 795, SEQ ID NO: 796, SEQID NO: 797, SEQ ID NO: 798, SEQ ID NO: 799, SEQ ID NO: 800, SEQ ID NO:801, SEQ ID NO: 802, SEQ ID NO: 803, SEQ ID NO: 804, SEQ ID NO: 805, SEQID NO: 806, SEQ ID NO: 807, SEQ ID NO: 808, SEQ ID NO: 809, SEQ ID NO:810, SEQ ID NO: 811, SEQ ID NO: 812, SEQ ID NO: 813, SEQ ID NO: 814, SEQID NO: 815, SEQ ID NO: 816, SEQ ID NO: 817, SEQ ID NO: 818, SEQ ID NO:819, SEQ ID NO: 820, SEQ ID NO: 821, SEQ ID NO: 822, SEQ ID NO: 823, SEQID NO: 824, or SEQ ID NO: 825. In some embodiments, the anti-Factor Dantibody is a Fab fragment comprising a heavy chain having at least 90%sequence identity to the amino acid sequence of SEQ ID NO: 792, SEQ IDNO: 793, SEQ ID NO: 794, SEQ ID NO: 795, SEQ ID NO: 796, SEQ ID NO: 797,SEQ ID NO: 798, SEQ ID NO: 799, SEQ ID NO: 800, SEQ ID NO: 801, SEQ IDNO: 802, SEQ ID NO: 803, SEQ ID NO: 804, SEQ ID NO: 805, SEQ ID NO: 806,SEQ ID NO: 807, SEQ ID NO: 808, SEQ ID NO: 809, SEQ ID NO: 810, SEQ IDNO: 811, SEQ ID NO: 812, SEQ ID NO: 813, SEQ ID NO: 814, SEQ ID NO: 815,SEQ ID NO: 816, SEQ ID NO: 817, SEQ ID NO: 818, SEQ ID NO: 819, SEQ IDNO: 820, SEQ ID NO: 821, SEQ ID NO: 822, SEQ ID NO: 823, SEQ ID NO: 824,or SEQ ID NO: 825. See Table 8. In specific embodiments, the Fabfragment is of an IgG4 isotype.

In some embodiments, the anti-Factor D antibody is a Fab fragmentcomprising a heavy chain having the amino acid sequence of SEQ ID NO:826, SEQ ID NO: 827, SEQ ID NO: 828, SEQ ID NO: 829, SEQ ID NO: 830, SEQID NO: 831, SEQ ID NO: 832, SEQ ID NO: 833, SEQ ID NO: 834, SEQ ID NO:835, SEQ ID NO: 836, SEQ ID NO: 837, SEQ ID NO: 838, SEQ ID NO: 839, SEQID NO: 840, SEQ ID NO: 841, SEQ ID NO: 842, SEQ ID NO: 843, SEQ ID NO:844, SEQ ID NO: 845, SEQ ID NO: 846, SEQ ID NO: 847, SEQ ID NO: 848, SEQID NO: 849, SEQ ID NO: 850, SEQ ID NO: 851, SEQ ID NO: 852, SEQ ID NO:853, SEQ ID NO: 854, SEQ ID NO: 855, SEQ ID NO: 856, SEQ ID NO: 857, SEQID NO: 858, or SEQ ID NO: 859. In some embodiments, the anti-Factor Dantibody is a Fab fragment comprising a heavy chain having at least 90%sequence identity to the amino acid sequence of SEQ ID NO: 792, SEQ IDNO: 826, SEQ ID NO: 827, SEQ ID NO: 828, SEQ ID NO: 829, SEQ ID NO: 830,SEQ ID NO: 831, SEQ ID NO: 832, SEQ ID NO: 833, SEQ ID NO: 834, SEQ IDNO: 835, SEQ ID NO: 836, SEQ ID NO: 837, SEQ ID NO: 838, SEQ ID NO: 839,SEQ ID NO: 840, SEQ ID NO: 841, SEQ ID NO: 842, SEQ ID NO: 843, SEQ IDNO: 844, SEQ ID NO: 845, SEQ ID NO: 846, SEQ ID NO: 847, SEQ ID NO: 848,SEQ ID NO: 849, SEQ ID NO: 850, SEQ ID NO: 851, SEQ ID NO: 852, SEQ IDNO: 853, SEQ ID NO: 854, SEQ ID NO: 855, SEQ ID NO: 856, SEQ ID NO: 857,SEQ ID NO: 858, or SEQ ID NO: 859. See Table 8. In specific embodiments,the Fab fragment is of an IgG4 isotype.

In some embodiments, the anti-Factor D antibody is a Fab fragmentcomprising a heavy chain having the amino acid sequence of SEQ ID NO:882, SEQ ID NO: 883, SEQ ID NO: 884, SEQ ID NO: 885, SEQ ID NO: 886, SEQID NO: 887, SEQ ID NO: 888, SEQ ID NO: 889, SEQ ID NO: 890, SEQ ID NO:891, SEQ ID NO: 892, SEQ ID NO: 893, SEQ ID NO: 894, SEQ ID NO: 895, SEQID NO: 896, SEQ ID NO: 897, SEQ ID NO: 898, SEQ ID NO: 899, SEQ ID NO:900, SEQ ID NO: 901, SEQ ID NO: 902, SEQ ID NO: 903, SEQ ID NO: 904, SEQID NO: 905, SEQ ID NO: 906, SEQ ID NO: 907, SEQ ID NO: 908, SEQ ID NO:909, SEQ ID NO: 910, SEQ ID NO: 911, SEQ ID NO: 912, SEQ ID NO: 913, SEQID NO: 914, or SEQ ID NO: 915. In some embodiments, the anti-Factor Dantibody is a Fab fragment comprising a heavy chain having at least 90%sequence identity to the amino acid sequence of SEQ ID NO: 882, SEQ IDNO: 883, SEQ ID NO: 884, SEQ ID NO: 885, SEQ ID NO: 886, SEQ ID NO: 887,SEQ ID NO: 888, SEQ ID NO: 889, SEQ ID NO: 890, SEQ ID NO: 891, SEQ IDNO: 892, SEQ ID NO: 893, SEQ ID NO: 894, SEQ ID NO: 895, SEQ ID NO: 896,SEQ ID NO: 897, SEQ ID NO: 898, SEQ ID NO: 899, SEQ ID NO: 900, SEQ IDNO: 901, SEQ ID NO: 902, SEQ ID NO: 903, SEQ ID NO: 904, SEQ ID NO: 905,SEQ ID NO: 906, SEQ ID NO: 907, SEQ ID NO: 908, SEQ ID NO: 909, SEQ IDNO: 910, SEQ ID NO: 911, SEQ ID NO: 912, SEQ ID NO: 913, SEQ ID NO: 914,or SEQ ID NO: 915. See Table 8. Here, X in the sequence of CDKTHX is anyamino acid except T. In specific embodiments, the Fab fragment is of anIgG1 isotype. In specific embodiments, the cysteine in theCys-Asp-Lys-Thr-His-Thr-X (CDKTHTX) sequence at the C′ Terminal end isattached to a polymer (e.g., a PEG polymer). In specific embodiments,when X is C, the two cysteines in the Cys-Asp-Lys-Thr-His-Thr-X(CDKTHTX) sequence at the C′ Terminal end are each attached to a polymer(e.g., a PEG polymer). In specific embodiments, when X is C, the secondcysteine in the Cys-Asp-Lys-Thr-His-Thr-X (CDKTHTX) sequence at the C′Terminal end is attached to a polymer (e.g., a PEG polymer).

TABLE 8 Heavy chain and light chain amino acid sequences of C'terminal-modified anti-Factor D antibodies SEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 180AFD WT Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 181AFD.v1 Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 182AFD.v2 Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 183AFD.v3 Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 184AFD.v4 Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 185AFD.v5 Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 186AFD.v6 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 187AFD.v7 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 188AFD.v8 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 189AFD.v9 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 190AFD.v10 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 191AFD.v11 Heavy Chain WISTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 192AFD.v12 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVDNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 193AFD.v13 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVQNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 194AFD.v14 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVSNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 195AFD.v15 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVSNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 196huAFD.v2.0 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCD SEQ IDC' terminal-modified EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGENO: 197 huAFD.v2.1 HeavyINPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFA ChainYVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCD SEQ IDC' terminal-modified EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGENO: 198 huAFD.v2.3 HeavyINPYSGDTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFA ChainYVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCD SEQ IDC' terminal-modified EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGENO: 199 huAFD.v1 HeavyINPTNGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGF ChainAYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSN TKVDKKVEPKSCDSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 200huAFD.v1.1 Heavy INPTQGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFChain AYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSN TKVDKKVEPKSCDSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 201huAFD.v2.2 Heavy INPTSGDTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCD SEQ IDC' terminal-modified EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGENO: 202 huAFD.v2.4 HeavyINPTSGETNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFA ChainYVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCD SEQ IDC' terminal-modified EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGENO: 203 huAFD.v2.5 HeavyINPYSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFA ChainYVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCD SEQ IDC' terminal-modified EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGENO: 204 huAFD.v2.6 HeavyINPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFA ChainYVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCD SEQ IDC' terminal-modified EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGENO: 205 huAFD.v2.7 HeavyINPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFA ChainYVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCD SEQ IDC' terminal-modified EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGENO: 206 huAFD.v2.8 HeavyINPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFA ChainYVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCD SEQ IDC' terminal-modified EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGNO: 207 huAFD.v2.9 HeavyWINPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGG ChainFAYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 208huAFD.v2.10 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCD SEQ IDC' terminal-modified EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGENO: 209 huAFD.v2.11 HeavyINPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFA ChainYVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCD SEQ IDC' terminal-modified EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGENO: 210 huAFD.v2.12 HeavyINPYSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFA ChainYVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCD SEQ IDC' terminal-modified EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGENO: 211 huAFD.v2.13 HeavyINPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAYVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCD SEQ IDC' terminal-modified EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGENO: 212 huAFD.v2.14 HeavyINPTSGETNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFA ChainYVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCD SEQ IDC' terminal-modified EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGENO: 213 huAFD .v2 .15 HeavyINPYSGETNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFA ChainYVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCD SEQ IDC' terminal-modified EVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMGNO: 214 AFD WT Heavy ChainWINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDKTHLSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 215AFD.v1 Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDKTHLSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 216AFD.v2 Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDKTHLSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 217AFD.v3 Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDKTHLSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 218AFD.v4 Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDKTHLSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 219AFD.v5 Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDKTHLSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 220AFD.v6 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDKTHLSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 221AFD.v7 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDKTHLSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 222AFD.v8 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDKTHLSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 223AFD.v9 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDKTHLSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 224AFD.v10 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDKTHLSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 225AFD.v11 Heavy Chain WISTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDKTHLSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 226AFD.v12 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVDNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDKTHLSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 227AFD.v13 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVQNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDKTHLSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 228AFD.v14 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVSNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDKTHLSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 229AFD.v15 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVSNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDKTHLSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 230huAFD.v2.0 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCDKTHLSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 231huAFD.v2.1 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCDKTHLSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 232huAFD.v2.3 Heavy INPYSGDTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCDKTHLSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 233huAFD.v1 Heavy INPTNGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFChain AYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSN TKVDKKVEPKSCDKTHLSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 234huAFD.v1.1 Heavy INPTQGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFChain AYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSN TKVDKKVEPKSCDKTHLSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 235huAFD.v2.2 Heavy INPTSGDTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCDKTHLSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 236huAFD.v2.4 Heavy INPTSGETNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCDKTHLSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 237huAFD.v2.5 Heavy INPYSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCDKTHLSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 238huAFD.v2.6 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCDKTHLSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 239huAFD.v2.7 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCDKTHLSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 240huAFD.v2.8 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCDKTHLSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIG NO: 241huAFD.v2.9 Heavy WINPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGChain FAYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDKTHLSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 242huAFD.v2.10 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCDKTHLSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 243huAFD.v2.11 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCDKTHLSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 244huAFD.v2.12 Heavy INPYSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCDKTHLSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 245huAFD.v2.13 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCDKTHLSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 246huAFD.v2.14 Heavy INPTSGETNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCDKTHLSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 247huAFD.v2.15 Heavy INPYSGETNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCDKTHLSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 248AFD WT Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDKSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 249AFD.v1 Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDKSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 250AFD.v2 Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDKSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 251AFD.v3 Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDKSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 252AFD.v4 Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDKSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 253AFD.v5 Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDKSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 254AFD.v6 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDKSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 255AFD.v7 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDKSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 256AFD.v8 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDKSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 257AFD.v9 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDKSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 258AFD.v10 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDKSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 259AFD.v11 Heavy Chain WISTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDKSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 260AFD.v12 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVDNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDKSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 261AFD.v13 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVQNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDKSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 262AFD.v14 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVSNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDKSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 263AFD.v15 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVSNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDKSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 264huAFD.v2.0 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCDKSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 265huAFD.v2.1 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCDKSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 266huAFD.v2.3 Heavy INPYSGDTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCDKSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 267huAFD.v1 Heavy INPTNGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFChain AYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSN TKVDKKVEPKSCDKSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 268huAFD.v1.1 Heavy INPTQGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFChain AYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSN TKVDKKVEPKSCDKSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 269huAFD.v2.2 Heavy INPTSGDTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCDKSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 270huAFD.v2.4 Heavy INPTSGETNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCDKSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 271huAFD.v2.5 Heavy INPYSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCDKSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 272huAFD.v2.6 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCDKSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 273huAFD.v2.7 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCDKSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 274huAFD.v2.8 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCDKSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIG NO: 275huAFD.v2.9 Heavy WINPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGChain FAYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDKSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 276huAFD.v2.10 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCDKSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 277huAFD.v2.11 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCDKSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 278huAFD.v2.12 Heavy INPYSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCDKSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 279huAFD.v2.13 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCDKSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 280huAFD.v2.14 Heavy INPTSGETNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCDKSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 281huAFD.v2.15 Heavy INPYSGETNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCDKSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 282AFD WT Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDKTSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 283AFD.v1 Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDKTSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 284AFD.v2 Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDKTSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 285AFD.v3 Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDKTSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 286AFD.v4 Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDKTSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 287AFD.v5 Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDKTSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 288AFD.v6 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDKTSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 289AFD.v7 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDKTSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 290AFD.v8 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDKTSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 291AFD.v9 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDKTSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 292AFD.v10 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDKTSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 293AFD.v11 Heavy Chain WISTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDKTSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 294AFD.v12 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVDNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDKTSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 295AFD.v13 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVQNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDKTSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 296AFD.v14 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVSNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDKTSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 297AFD.v15 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVSNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDKTSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 298huAFD.v2.0 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCDKTSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 299huAFD.v2.1 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCDKTSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 300huAFD.v2.3 Heavy INPYSGDTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCDKTSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 301huAFD.v 1 Heavy INPTNGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFChain AYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSN TKVDKKVEPKSCDKTSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 302huAFD.v 1.1 Heavy INPTQGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFChain AYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSN TKVDKKVEPKSCDKTSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 303huAFD.v2.2 Heavy INPTSGDTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCDKTSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 304huAFD.v2.4 Heavy INPTSGETNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCDKTSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 305huAFD.v2.5 Heavy INPYSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCDKTSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 306huAFD.v2.6 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCDKTSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 307huAFD.v2.7 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCDKTSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 308huAFD.v2.8 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCDKTSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIG NO: 309huAFD.v2.9 Heavy WINPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGChain FAYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDKTSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 310huAFD.v2.10 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCDKTSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 311huAFD.v2.11 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCDKTSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 312huAFD.v2.12 Heavy INPYSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCDKTSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 313huAFD.v2.13 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCDKTSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 314huAFD.v2.14 Heavy INPTSGETNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCDKTSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 315huAFD.v2.15 Heavy INPYSGETNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCDKTSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 316AFD WT Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDKTHSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 317AFD.v1 Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDKTHSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 318AFD.v2 Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDKTHSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 319AFD.v3 Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDKTHSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 320AFD.v4 Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDKTHSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 321AFD.v5 Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDKTHSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 322AFD.v6 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDKTHSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 323AFD.v7 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDKTHSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 324AFD.v8 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDKTHSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 325AFD.v9 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDKTHSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 326AFD.v10 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDKTHSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 327AFD.v11 Heavy Chain WISTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDKTHSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 328AFD.v12 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVDNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDKTHSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 329AFD.v13 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVQNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDKTHSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 330AFD.v14 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVSNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDKTHSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 331AFD.v15 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVSNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDKTHSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 332huAFD.v2.0 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCDKTHSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 333huAFD.v2.1 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCDKTHSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 334huAFD.v2.3 Heavy INPYSGDTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCDKTHSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 335huAFD.v1 Heavy INPTNGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFChain AYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSN TKVDKKVEPKSCDKTHSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 336huAFD.v1.1 Heavy INPTQGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFChain AYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSN TKVDKKVEPKSCDKTHSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 337huAFD.v2.2 Heavy INPTSGDTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCDKTHSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 338huAFD.v2.4 Heavy INPTSGETNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCDKTHSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 339huAFD.v2.5 Heavy INPYSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCDKTHSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 340huAFD.v2.6 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCDKTHSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 341huAFD.v2.7 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCDKTHSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 342huAFD.v2.8 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCDKTHSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIG NO: 343huAFD.v2.9 Heavy WINPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGChain FAYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDKTHSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 344huAFD.v2.10 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCDKTHSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 345huAFD.v2.11 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCDKTHSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 346huAFD.v2.12 Heavy INPYSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCDKTHSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 347huAFD.v2.13 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCDKTHSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 348huAFD.v2.14 Heavy INPTSGETNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCDKTHSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 349huAFD.v2.15 Heavy INPYSGETNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCDKTHSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 350AFD WT Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDKTHTCSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 351AFD.v1 Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDKTHTCSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 352AFD.v2 Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDKTHTCSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 353AFD.v3 Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDKTHTCSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 354AFD.v4 Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDKTHTCSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 355AFD.v5 Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDKTHTCSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 356AFD.v6 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDKTHTCSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 357AFD.v7 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDKTHTCSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 358AFD.v8 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDKTHTCSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 359AFD.v9 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDKTHTCSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 360AFD.v10 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDKTHTCSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 361AFD.v11 Heavy Chain WISTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDKTHTCSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 362AFD.v12 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVDNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDKTHTCSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 363AFD.v13 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVQNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDKTHTCSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 364AFD.v14 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVSNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDKTHTCSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 365AFD.v15 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVSNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDKTHTCSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 366huAFD.v2.0 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCDKTHTCSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 367huAFD.v2.1 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCDKTHTCSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 368huAFD.v2.3 Heavy INPYSGDTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCDKTHTCSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 369huAFD.v1 Heavy INPTNGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFChain AYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSN TKVDKKVEPKSCDKTHTCSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 370huAFD.v1.1 Heavy INPTQGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFChain AYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSN TKVDKKVEPKSCDKTHTCSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 371huAFD.v2.2 Heavy INPTSGDTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCDKTHTCSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 372huAFD.v2.4 Heavy INPTSGETNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCDKTHTCSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 373huAFD.v2.5 Heavy INPYSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCDKTHTCSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 374huAFD.v2.6 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCDKTHTCSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 375huAFD.v2.7 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCDKTHTCSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 376huAFD.v2.8 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCDKTHTCSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIG NO: 377huAFD.v2.9 Heavy WINPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCDKTHTCSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 378huAFD.v2.10 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCDKTHTCSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 379huAFD.v2.11 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCDKTHTCSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 380huAFD.v2.12 Heavy INPYSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCDKTHTCSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 381huAFD.v2.13 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCDKTHTCSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 382huAFD.v2.14 Heavy INPTSGETNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCDKTHTCSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 383huAFD.v2.15 Heavy INPYSGETNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCDKTHTCSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 384AFD WT Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPC SEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 385AFD.v1 Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPC SEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 386AFD.v2 Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPC SEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 387AFD.v3 Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPC SEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 388AFD.v4 Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPC SEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 389AFD.v5 Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPC SEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 390AFD.v6 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPC SEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 391AFD.v7 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPC SEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 392AFD.v8 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPC SEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 393AFD.v9 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPC SEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 394AFD.v10 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPC SEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 395AFD.v11 Heavy Chain WISTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPC SEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 396AFD.v12 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVDNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPC SEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 397AFD.v13 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVQNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPC SEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 398AFD.v14 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVSNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPC SEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 399AFD.v15 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVSNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPC SEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 400huAFD.v2.0 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPC SEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 401huAFD.v2.1 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPC SEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 402huAFD.v2.3 Heavy INPYSGDTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPC SEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 403huAFD.v1 Heavy INPTNGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFChain AYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPC SEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 404huAFD.v1.1 Heavy INPTQGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFChain AYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPC SEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 405huAFD.v2.2 Heavy INPTSGDTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPC SEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 406huAFD.v2.4 Heavy INPTSGETNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPC SEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 407huAFD.v2.5 Heavy INPYSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPC SEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 408huAFD.v2.6 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPC SEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 409huAFD.v2.7 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPC SEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 410huAFD.v2.8 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPC SEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIG NO: 411huAFD.v2.9 Heavy WINPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGChain FAYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPC SEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 412huAFD.v2.10 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPC SEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 413huAFD.v2.11 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPC SEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 414huAFD.v2.12 Heavy INPYSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPC SEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 415huAFD.v2.13 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPC SEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 416huAFD.v2.14 Heavy INPTSGETNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPC SEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 417huAFD.v2.15 Heavy INPYSGETNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPC SEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 418AFD WT Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPS SEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 419AFD.v1 Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPS SEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 420AFD.v2 Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPS SEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 421AFD.v3 Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPS SEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 422AFD.v4 Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPS SEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 423AFD.v5 Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPS SEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 424AFD.v6 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPS SEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 425AFD.v7 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPS SEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 426AFD.v8 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPS SEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 427AFD.v9 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPS SEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 428AFD.v10 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPS SEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 429AFD.v11 Heavy Chain WISTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPS SEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 430AFD.v12 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVDNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPS SEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 431AFD.v13 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVQNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPS SEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 432AFD.v14 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVSNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPS SEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 433AFD.v15 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVSNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPS SEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 434huAFD.v2.0 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPS SEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 435huAFD.v2.1 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPS SEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 436huAFD.v2.3 Heavy INPYSGDTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPS SEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 437huAFD.v1 Heavy INPTNGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFChain AYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPS SEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 438huAFD.v1.1 Heavy INPTQGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFChain AYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPS SEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 439huAFD.v2.2 Heavy INPTSGDTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPS SEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 440huAFD.v2.4 Heavy INPTSGETNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPS SEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 441huAFD.v2.5 Heavy INPYSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPS SEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 442huAFD.v2.6 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPS SEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 443huAFD.v2.7 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPS SEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 444huAFD.v2.8 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPS SEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIG NO: 445huAFD.v2.9 Heavy WINPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGChain FAYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPS SEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 446huAFD.v2.10 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPS SEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 447huAFD.v2.11 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPS SEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 448huAFD.v2.12 Heavy INPYSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPS SEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 449huAFD.v2.13 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPS SEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 450huAFD.v2.14 Heavy INPTSGETNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPS SEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 451huAFD.v2.15 Heavy INPYSGETNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPS SEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 452AFD WT Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTSPPC SEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 453AFD.v1 Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTSPPC SEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 454AFD.v2 Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTSPPC SEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 455AFD.v3 Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTSPPC SEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 456AFD.v4 Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTSPPC SEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 457AFD.v5 Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTSPPC SEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 458AFD.v6 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTSPPC SEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 459AFD.v7 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTSPPC SEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 460AFD.v8 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTSPPC SEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 461AFD.v9 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTSPPC SEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 462AFD.v10 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTSPPC SEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 463AFD.v11 Heavy Chain WISTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTSPPC SEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 464AFD.v12 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVDNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTSPPC SEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 465AFD.v13 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVQNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTSPPC SEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 466AFD.v14 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVSNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTSPPC SEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 467AFD.v15 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVSNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTSPPC SEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 468huAFD.v2.0 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTSPPC SEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 469huAFD.v2.1 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTSPPC SEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 470huAFD.v2.3 Heavy INPYSGDTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTSPPC SEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 471huAFD.v1 Heavy INPTNGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFChain AYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTSPPC SEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 472huAFD.v1.1 Heavy INPTQGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFChain AYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTSPPC SEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 473huAFD.v2.2 Heavy INPTSGDTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTSPPC SEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 474huAFD.v2.4 Heavy INPTSGETNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTSPPC SEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 475huAFD.v2.5 Heavy INPYSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTSPPC SEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 476huAFD.v2.6 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTSPPC SEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 477huAFD.v2.7 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTSPPC SEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 478huAFD.v2.8 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTSPPC SEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIG NO: 479huAFD.v2.9 Heavy WINPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGChain FAYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTSPPC SEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 480huAFD.v2.10 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTSPPC SEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 481huAFD.v2.11 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTSPPC SEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 482huAFD.v2.12 Heavy INPYSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTSPPC SEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 483huAFD.v2.13 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTSPPC SEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 484huAFD.v2.14 Heavy INPTSGETNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTSPPC SEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 485huAFD.v2.15 Heavy INPYSGETNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTSPPC SEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 486AFD WT Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTAPPC SEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 487AFD.v1 Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTAPPC SEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 488AFD.v2 Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTAPPC SEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 489AFD.v3 Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTAPPC SEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 490AFD.v4 Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTAPPC SEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 491AFD.v5 Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTAPPC SEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 492AFD.v6 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTAPPC SEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 493AFD.v7 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTAPPC SEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 494AFD.v8 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTAPPC SEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 495AFD.v9 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTAPPC SEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 496AFD.v10 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTAPPC SEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 497AFD.v11 Heavy Chain WISTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTAPPC SEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 498AFD.v12 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVDNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTAPPC SEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 499AFD.v13 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVQNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTAPPC SEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 500AFD.v14 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVSNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTAPPC SEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 501AFD.v15 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVSNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTAPPC SEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 502huAFD.v2.0 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTAPPC SEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 503huAFD.v2.1 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTAPPC SEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 504huAFD.v2.3 Heavy INPYSGDTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTAPPC SEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 505huAFD.v1 Heavy INPTNGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFChain AYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTAPPC SEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 506huAFD.v1.1 Heavy INPTQGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFChain AYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTAPPC SEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 507huAFD.v2.2 Heavy INPTSGDTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTAPPC SEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 508huAFD.v2.4 Heavy INPTSGETNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTAPPC SEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 509huAFD.v2.5 Heavy INPYSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTAPPC SEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 510huAFD.v2.6 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTAPPC SEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 511huAFD.v2.7 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTAPPC SEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 512huAFD.v2.8 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTAPPC SEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIG NO: 513huAFD.v2.9 Heavy WINPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGChain FAYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTAPPC SEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 514huAFD.v2.10 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTAPPC SEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 515huAFD.v2.11 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTAPPC SEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 516huAFD.v2.12 Heavy INPYSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTAPPC SEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 517huAFD.v2.13 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTAPPC SEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 518huAFD.v2.14 Heavy INPTSGETNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTAPPC SEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 519huAFD.v2.15 Heavy INPYSGETNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTAPPC SEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 520AFD WT Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTSGGC SEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 521AFD.v1 Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTSGGC SEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 522AFD.v2 Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTSGGC SEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 523AFD.v3 Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTSGGC SEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 524AFD.v4 Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTSGGC SEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 525AFD.v5 Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTSGGC SEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 526AFD.v6 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTSGGC SEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 527AFD.v7 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTSGGC SEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 528AFD.v8 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTSGGC SEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 529AFD.v9 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTSGGC SEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 530AFD.v10 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTSGGC SEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 531AFD.v11 Heavy Chain WISTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTSGGC SEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 532AFD.v12 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVDNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTSGGC SEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 533AFD.v13 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVQNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTSGGC SEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 534AFD.v14 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVSNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTSGGC SEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 535AFD.v15 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVSNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTSGGC SEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 536huAFD.v2.0 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTSGGC SEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 537huAFD.v2.1 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTSGGC SEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 538huAFD.v2.3 Heavy INPYSGDTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSbWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTSGGC SEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 539huAFD.v1 Heavy INPTNGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFChain AYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTSGGC SEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 540huAFD.v1.1 Heavy INPTQGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFChain AYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTSGGC SEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 541huAFD.v2.2 Heavy INPTSGDTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTSGGC SEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 542huAFD.v2.4 Heavy INPTSGETNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTSGGC SEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 543huAFD.v2.5 Heavy INPYSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTSGGC SEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 544huAFD.v2.6 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTSGGC SEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 545huAFD.v2.7 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTSGGC SEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 546huAFD.v2.8 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTSGGC SEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIG NO: 547huAFD.v2.9 Heavy WINPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGChain FAYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTSGGC SEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 548huAFD.v2.10 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTSGGC SEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 549huAFD.v2.11 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTSGGC SEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 550huAFD.v2.12 Heavy INPYSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTSGGC SEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 551huAFD.v2.13 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTSGGC SEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 552huAFD.v2.14 Heavy INPTSGETNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTSGGC SEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 553huAFD.v2.15 Heavy INPYSGETNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTSGGC SEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 554AFD WT Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCYGPPCSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 555AFD.v1 Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCYGPPCSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 556AFD.v2 Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCYGPPCSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 557AFD.v3 Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCYGPPCSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 558AFD.v4 Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCYGPPCSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 559AFD.v5 Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCYGPPCSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 560AFD.v6 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCYGPPCSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 561AFD.v7 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCYGPPCSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 562AFD.v8 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCYGPPCSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 563AFD.v9 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCYGPPCSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 564AFD.v10 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCYGPPCSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 565AFD.v11 Heavy Chain WISTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCYGPPCSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 566AFD.v12 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVDNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCYGPPCSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 567AFD.v13 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVQNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCYGPPCSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 568AFD.v14 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVSNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCYGPPCSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 569AFD.v15 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVSNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCYGPPCSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 570huAFD.v2.0 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCYGPPCSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 571huAFD.v2.1 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCYGPPCSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 572huAFD.v2.3 Heavy INPYSGDTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCYGPPCSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 573huAFD.v1 Heavy INPTNGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFChain AYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSN TKVDKKVEPKSCYGPPCSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 574huAFD.v1.1 Heavy INPTQGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFChain AYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSN TKVDKKVEPKSCYGPPCSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 575huAFD.v2.2 Heavy INPTSGDTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCYGPPCSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 576huAFD.v2.4 Heavy INPTSGETNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCYGPPCSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 577huAFD.v2.5 Heavy INPYSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCYGPPCSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 578huAFD.v2.6 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCYGPPCSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 579huAFD.v2.7 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCYGPPCSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 580huAFD.v2.8 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCYGPPCSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIG NO: 581huAFD.v2.9 Heavy WINPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGChain FAYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSCYGPPCSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 582huAFD.v2.10 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCYGPPCSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 583huAFD.v2.11 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCYGPPCSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 584huAFD.v2.12 Heavy INPYSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCYGPPCSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 585huAFD.v2.13 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCYGPPCSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 586huAFD.v2.14 Heavy INPTSGETNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCYGPPCSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 587huAFD.v2.15 Heavy INPYSGETNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSCYGPPCSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 588AFD WT Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSVERKSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 589AFD.v1 Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSVERKSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 590AFD.v2 Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSVERKSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 591AFD.v3 Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSVERKSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 592AFD.v4 Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSVERKSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 593AFD.v5 Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSVERKSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 594AFD.v6 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSVERKSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 595AFD.v7 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSVERKSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 596AFD.v8 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSVERKSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 597AFD.v9 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSVERKSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 598AFD.v10 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSVERKSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 599AFD.v11 Heavy Chain WISTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSVERKSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 600AFD.v12 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVDNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSVERKSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 601AFD.v13 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVQNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSVERKSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 602AFD.v14 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVSNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSVERKSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 603AFD.v15 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVSNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSVERKSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 604huAFD.v2.0 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSVERKSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 605huAFD.v2.1 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSVERKSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 606huAFD.v2.3 Heavy INPYSGDTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSVERKSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 607huAFD.v1 Heavy INPTNGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFChain AYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSN TKVDKKVEPKSVERKSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 608huAFD.v1.1 Heavy INPTQGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFChain AYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSN TKVDKKVEPKSVERKSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 609huAFD.v2.2 Heavy INPTSGDTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSVERKSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 610huAFD.v2.4 Heavy INPTSGETNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSVERKSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 611huAFD.v2.5 Heavy INPYSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSVERKSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 612huAFD.v2.6 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSVERKSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 613huAFD.v2.7 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSVERKSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 614huAFD.v2.8 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSVERKSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIG NO: 615huAFD.v2.9 Heavy WINPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGChain FAYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSVERKSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 616huAFD.v2.10 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSVERKSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 617huAFD.v2.11 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSVERKSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 618huAFD.v2.12 Heavy INPYSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSVERKSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 619huAFD.v2.13 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSVERKSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 620huAFD.v2.14 Heavy INPTSGETNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSVERKSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 621huAFD.v2.15 Heavy INPYSGETNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSVERKSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 622AFD WT Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSVERKCSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 623AFD.v1 Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSVERKCSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 624AFD.v2 Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSVERKCSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 625AFD.v3 Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSVERKCSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 626AFD.v4 Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSVERKCSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 627AFD.v5 Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSVERKCSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 628AFD.v6 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSVERKCSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 629AFD.v7 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSVERKCSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 630AFD.v8 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSVERKCSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 631AFD.v9 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSVERKCSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 632AFD.v10 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSVERKCSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 633AFD.v11 Heavy Chain WISTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSVERKCSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 634AFD.v12 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVDNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSVERKCSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 635AFD.v13 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVQNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSVERKCSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 636AFD.v14 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVSNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSVERKCSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 637AFD.v15 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVSNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSVERKCSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 638huAFDv2.0 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSVERKCSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 639huAFD.v2.1 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSVERKCSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 640huAFD.v2.3 Heavy INPYSGDTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSVERKCSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 641huAFD.v1 Heavy INPTNGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFChain AYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSN TKVDKKVEPKSVERKCSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 642huAFD.v1.1 Heavy INPTQGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFChain AYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSN TKVDKKVEPKSVERKCSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 643huAFD.v2.2 Heavy INPTSGDTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSVERKCSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 644huAFD.v2.4 Heavy INPTSGETNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSVERKCSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 645huAFD.v2.5 Heavy INPYSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSVERKCSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 646huAFD.v2.6 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSVERKCSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 647huAFD.v2.7 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSVERKCSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 648huAFD.v2.8 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSVERKCSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIG NO: 649huAFD.v2.9 Heavy WINPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGChain FAYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSVERKCSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 650huAFD.v2.10 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSVERKCSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 651huAFD.v2.11 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSVERKCSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 652huAFD.v2.12 Heavy INPYSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSVERKCSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 653huAFD.v2.13 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSVERKCSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 654huAFD.v2.14 Heavy INPTSGETNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSVERKCSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 655huAFD.v2.15 Heavy INPYSGETNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSVERKCSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 656AFD WT Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSKYGPPCSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 657AFD.v1 Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSKYGPPCSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 658AFD.v2 Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSKYGPPCSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 659AFD.v3 Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSKYGPPCSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 660AFD.v4 Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSKYGPPCSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 661AFD.v5 Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSKYGPPCSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 662AFD.v6 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSKYGPPCSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 663AFD.v7 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSKYGPPCSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 664AFD.v8 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSKYGPPCSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 665AFD.v9 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSKYGPPCSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 666AFD.v10 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSKYGPPCSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 667AFD.v11 Heavy Chain WISTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSKYGPPCSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 668AFD.v12 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVDNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSKYGPPCSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 669AFD.v13 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVQNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSKYGPPCSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 670AFD.v14 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVSNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSKYGPPCSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 671AFD.v15 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVSNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSKYGPPCSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 672huAFD.v2.0 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSKYGPPCSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 673huAFD.v2.1 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSKYGPPCSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 674huAFD.v2.3 Heavy INPYSGDTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSKYGPPCSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 675huAFD.v1 Heavy INPTNGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFChain AYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSN TKVDKKVEPKSKYGPPCSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 676huAFD.v1.1 Heavy INPTQGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFChain AYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSN TKVDKKVEPKSKYGPPCSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 677huAFD.v2.2 Heavy INPTSGDTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSKYGPPCSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 678huAFD.v2.4 Heavy INPTSGETNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSKYGPPCSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 679huAFD.v2.5 Heavy INPYSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSKYGPPCSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 680huAFD.v2.6 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSKYGPPCSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 681huAFD.v2.7 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSKYGPPCSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 682huAFD.v2.8 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSKYGPPCSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIG NO: 683huAFD.v2.9 Heavy WINPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGChain FAYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSKYGPPCSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 684huAFD.v2.10 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSKYGPPCSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 685huAFD.v2.11 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSKYGPPCSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 686huAFD.v2.12 Heavy INPYSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSKYGPPCSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 687huAFD.v2.13 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSKYGPPCSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 688huAFD.v2.14 Heavy INPTSGETNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSKYGPPCSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 689huAFD.v2.15 Heavy INPYSGETNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSKYGPPCSEQ ID C' terminal-modifiedAEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 690FD WT Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSKYGPPSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 691AFD.v1 Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSKYGPPSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 692AFD.v2 Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSKYGPPSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 693AFD.v3 Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSKYGPPSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 694AFD.v4 Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSKYGPPSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 695AFD.v5 Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSKYGPPSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 696AFD.v6 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSKYGPPSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 697AFD.v7 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSKYGPPSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 698AFD.v8 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSKYGPPSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 699AFD.v9 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSKYGPPSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 700AFD.v10 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSKYGPPSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 701AFD.v11 Heavy Chain WISTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSKYGPPSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 702AFD.v12 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVDNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSKYGPPSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 703AFD.v13 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVQNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSKYGPPSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 704AFD.v14 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVSNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSKYGPPSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 705AFD.v15 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVSNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSKYGPPSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 706huAFD.v2.0 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSKYGPPSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 707huAFD.v2.1 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSKYGPPSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 708huAFD.v2.3 Heavy INPYSGDTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSKYGPPSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 709huAFD.v1 Heavy INPTNGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFChain AYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSN TKVDKKVEPKSKYGPPSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 710huAFD.v1.1 Heavy INPTQGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFChain AYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSN TKVDKKVEPKSKYGPPSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 711huAFD.v2.2 Heavy INPTSGDTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSKYGPPSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 712huAFD.v2.4 Heavy INPTSGETNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSKYGPPSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 713huAFD.v2.5 Heavy INPYSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSKYGPPSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 714huAFD.v2.6 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSKYGPPSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 715huAFD.v2.7 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSKYGPPSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 716huAFD.v2.8 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSKYGPPSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIG NO: 717huAFD.v2.9 Heavy WINPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGChain FAYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSKYGPPSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 718huAFD.v2.10 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSKYGPPSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 719huAFD.v2.11 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSKYGPPSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 720huAFD.v2.12 Heavy INPYSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSKYGPPSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 721huAFD.v2.13 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSKYGPPSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 722huAFD.v2.14 Heavy INPTSGETNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSKYGPPSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 723huAFD.v2.15 Heavy INPYSGETNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSKYGPPSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 724AFD WT Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSKYGPSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 725AFD.v1 Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSKYGPSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 726AFD.v2 Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSKYGPSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 727AFD.v3 Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSKYGPSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 728AFD.v4 Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSKYGPSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 729AFD.v5 Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSKYGPSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 730AFD.v6 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSKYGPSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 731AFD.v7 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSKYGPSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 732AFD.v8 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSKYGPSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 733AFD.v9 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSKYGPSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 734AFD.v10 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSKYGPSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 735AFD.v11 Heavy Chain WISTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSKYGPSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 736AFD.v12 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVDNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSKYGPSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 737AFD.v13 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVQNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSKYGPSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 738AFD.v14 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVSNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSKYGPSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 739AFD.v15 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVSNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSKYGPSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 740huAFD.v2.0 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSKYGPSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 741huAFD.v2.1 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSKYGPSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 742huAFD.v2.3 Heavy INPYSGDTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSKYGPSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 743huAFD.v1 Heavy INPTNGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFChain AYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSN TKVDKKVEPKSKYGPSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 744huAFD.v1.1 Heavy INPTQGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFChain AYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSN TKVDKKVEPKSKYGPSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 745huAFD.v2.2 Heavy INPTSGDTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSKYGPSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 746huAFD.v2.4 Heavy INPTSGETNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSKYGPSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 747huAFD.v2.5 Heavy INPYSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSKYGPSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 748huAFD.v2.6 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSKYGPSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 749huAFD.v2.7 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSKYGPSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 750huAFD.v2.8 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSKYGPSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIG NO: 751huAFD.v2.9 Heavy WINPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGChain FAYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSKYGPSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 752huAFD.v2.10 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSKYGPSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 753huAFD.v2.11 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSKYGPSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 754huAFD.v2.12 Heavy INPYSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSKYGPSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 755huAFD.v2.13 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSKYGPSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 756huAFD.v2.14 Heavy INPTSGETNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSKYGPSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 757huAFD.v2.15 Heavy INPYSGETNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSKYGPSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 758AFD WT Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSKYGSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 759AFD.v1 Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSKYGSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 760AFD.v2 Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSKYGSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 761AFD.v3 Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSKYGSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 762AFD.v4 Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSKYGSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 763AFD.v5 Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSKYGSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 764AFD.v6 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSKYGSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 765AFD.v7 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSKYGSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 766AFD.v8 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSKYGSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 767AFD.v9 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSKYGSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 768AFD.v10 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSKYGSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 769AFD.v11 Heavy Chain WISTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSKYGSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 770AFD.v12 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSKYGSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 771AFD.v13 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVQNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSKYGSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 772AFD.v14 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVSNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSKYGSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 773AFD.v15 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVSNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSKYGSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 774huAFD.v2.0 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSKYGSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 775huAFD.v2.1 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSKYGSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 776huAFD.v2.3 Heavy INPYSGDTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSKYGSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 777huAFD.v1 Heavy INPTNGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFChain AYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSN TKVDKKVEPKSKYGSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 778huAFD.v1.1 Heavy INPTQGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFChain AYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSN TKVDKKVEPKSKYGSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 779huAFD.v2.2 Heavy INPTSGDTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSKYGSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 780huAFD.v2.4 Heavy INPTSGETNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSKYGSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 781huAFD.v2.5 Heavy INPYSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSKYGSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 782huAFD.v2.6 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSKYGSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 783huAFD.v2.7 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSKYGSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 784huAFD.v2.8 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSKYGSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIG NO: 785huAFD.v2.9 Heavy WINPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGChain FAYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSKYGSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 786huAFD.v2.10 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSKYGSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 787huAFD.v2.11 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSKYGSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 788huAFD.v2.12 Heavy INPYSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSKYGSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 789huAFD.v2.13 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSKYGSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 790huAFD.v2.14 Heavy INPTSGETNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSKYGSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 791huAFD.v2.15 Heavy INPYSGETNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSKYGSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 792AFD WT Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSKYSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 793AFD.v1 Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSKYSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 794AFD.v2 Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSKYSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 795AFD.v3 Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSKYSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 796AFD.v4 Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSKYSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 797AFD.v5 Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSKYSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 798AFD.v6 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSKYSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 799AFD.v7 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSKYSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 800AFD.v8 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSKYSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 801AFD.v9 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSKYSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 802AFD.v10 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSKYSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 803AFD.v11 Heavy Chain WISTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSKYSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 804AFD.v12 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVDNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSKYSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 805AFD.v13 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVQNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSKYSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 806AFD.v14 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVSNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSKYSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 807AFD.v15 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVSNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSKYSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 808huAFD.v2.0 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSKY SEQ IDC' terminal-modified EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGENO: 809 huAFD.v2.1 HeavyINPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFA ChainYVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSKY SEQ IDC' terminal-modified EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGENO: 810 huAFD.v2.3 HeavyINPYSGDTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFA ChainYVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSKY SEQ IDC' terminal-modified EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGENO: 811 huAFD.v1 HeavyINPTNGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGF ChainAYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSN TKVDKKVEPKSKYSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 812huAFD.v1.1 Heavy INPTQGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFChain AYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSN TKVDKKVEPKSKYSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 813huAFD.v2.2 Heavy INPTSGDTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSKY SEQ IDC' terminal-modified EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGENO: 814 huAFD.v2.4 HeavyINPTSGETNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFA ChainYVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSKY SEQ IDC' terminal-modified EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGENO: 815 huAFD.v2.5 HeavyINPYSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFA ChainYVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSKY SEQ IDC' terminal-modified EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGENO: 816 huAFD.v2.6 HeavyINPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFA ChainYVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSKY SEQ IDC' terminal-modified EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGENO: 817 huAFD.v2.7 HeavyINPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFA ChainYVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSKY SEQ IDC' terminal-modified EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGENO: 818 huAFD.v2.8 HeavyINPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFA ChainYVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSKY SEQ IDC' terminal-modified EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGNO: 819 huAFD.v2.9 HeavyWINPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGG ChainFAYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSKYSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 820huAFD.v2.10 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSKY SEQ IDC' terminal-modified EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGENO: 821 huAFD.v2.11 HeavyINPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFA ChainYVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSKY SEQ IDC' terminal-modified EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGENO: 822 huAFD.v2.12 HeavyINPYSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFA ChainYVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSKY SEQ IDC' terminal-modified EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGENO: 823 huAFD.v2.13 HeavyINPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFA ChainYVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSKY SEQ IDC' terminal-modified EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGENO: 824 huAFD.v2.14 HeavyINPTSGETNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFA ChainYVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSKY SEQ IDC' terminal-modified EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGENO: 825 huAFD.v2.15 HeavyINPYSGETNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFA ChainYVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSKY SEQ IDC' terminal-modified EVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMGNO: 826 AFD WT Heavy ChainWINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSKSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 827AFD.v1 Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSKSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 828AFD.v2 Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSKSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 829AFD.v3 Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSKSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 830AFD.v4 Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSKSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 831AFD.v5 Heavy Chain WINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSKSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 832AFD.v6 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSKSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 833AFD.v7 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSKSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 834AFD.v8 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSKSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 835AFD.v9 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSKSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 836AFD.v10 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSKSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 837AFD.v11 Heavy Chain WISTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSKSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 838AFD.v12 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVDNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSKSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 839AFD.v13 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVQNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSKSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 840AFD.v14 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVSNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSKSEQ ID C' terminal-modifiedEVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMG NO: 841AFD.v15 Heavy Chain WINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVSNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSKSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 842huAFD.v2.0 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSK SEQ IDC' terminal-modified EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGENO: 843 huAFD.v2.1 HeavyINPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFA ChainYVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSK SEQ IDC' terminal-modified EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGENO: 844 huAFD.v2.3 HeavyINPYSGDTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFA ChainYVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSK SEQ IDC' terminal-modified EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGENO: 845 huAFD.v1 HeavyINPTNGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGF ChainAYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSN TKVDKKVEPKSK SEQ IDC' terminal-modified EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGENO: 846 huAFD.v1.1 HeavyINPTQGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGF ChainAYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSN TKVDKKVEPKSK SEQ IDC' terminal-modified EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGENO: 847 huAFD.v2.2 HeavyINPTSGDTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFA ChainYVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSK SEQ IDC' terminal-modified EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGENO: 848 huAFD.v2.4 HeavyINPTSGETNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFA ChainYVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSK SEQ IDC' terminal-modified EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGENO: 849 huAFD.v2.5 HeavyINPYSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFA ChainYVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSK SEQ IDC' terminal-modified EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGENO: 850 huAFD.v2.6 HeavyINPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFA ChainYVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSK SEQ IDC' terminal-modified EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGENO: 851 huAFD.v2.7 HeavyINPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFA ChainYVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSK SEQ IDC' terminal-modified EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGENO: 852 huAFD.v2.8 HeavyINPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFA ChainYVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSK SEQ IDC' terminal-modified EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGNO: 853 huAFD.v2.9 HeavyWINPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGG ChainFAYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS NTKVDKKVEPKSKSEQ ID C' terminal-modifiedEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGE NO: 854huAFD.v2.10 Heavy INPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFAChain YVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSK SEQ IDC' terminal-modified EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGENO: 855 huAFD.v2.11 HeavyINPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFA ChainYVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSK SEQ IDC' terminal-modified EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGENO: 856 huAFD.v2.12 HeavyINPYSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFA ChainYVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSK SEQ IDC' terminal-modified EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGENO: 857 huAFD.v2.13 HeavyINPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFA ChainYVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSK SEQ IDC' terminal-modified EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGENO: 858 huAFD.v2.14 HeavyINPTSGETNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFA ChainYVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSK SEQ IDC' terminal-modified EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGENO: 859 huAFD.v2.15 HeavyINPYSGETNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFA ChainYVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT KVDKKVEPKSK SEQ IDC' terminal-modified EVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMGNO: 882 AFD WT Heavy ChainWINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHX (X is any amino acid except T) SEQ ID C'terminal-modified EVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMGNO: 883 AFD.v1 Heavy ChainWINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHX (X is any amino acid except T) SEQ ID C'terminal-modified EVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMGNO: 884 AFD.v2 Heavy ChainWINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHX (X is any amino acid except T) SEQ ID C'terminal-modified EVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMGNO: 885 AFD.v3 Heavy ChainWINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHX (X is any amino acid except T) SEQ ID C'terminal-modified EVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMGNO: 886 AFD.v4 Heavy ChainWINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHX (X is any amino acid except T) SEQ ID C'terminal-modified EVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMGNO: 887 AFD.v5 Heavy ChainWINTYTGETTYADDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHX (X is any amino acid except T) SEQ ID C'terminal-modified EVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMGNO: 888 AFD.v6 Heavy ChainWINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHX (X is any amino acid except T) SEQ ID C'terminal-modified EVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMGNO: 889 AFD.v7 Heavy ChainWINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHX (X is any amino acid except T) SEQ ID C'terminal-modified EVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMGNO: 890 AFD.v8 Heavy ChainWINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHX (X is any amino acid except T) SEQ ID C'terminal-modified EVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMGNO: 891 AFD.v9 Heavy ChainWINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHX (X is any amino acid except T) SEQ ID C'terminal-modified EVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMGNO: 892 AFD.v10 Heavy ChainWINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHX (X is any amino acid except T) SEQ ID C'terminal-modified EVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMGNO: 893 AFD.v11 Heavy ChainWISTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVNNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHX (X is any amino acid except T) SEQ ID C'terminal-modified EVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMGNO: 894 AFD.v12 Heavy ChainWINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVDNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHX (X is any amino acid except T) SEQ ID C'terminal-modified EVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMGNO: 895 AFD.v13 Heavy ChainWINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVQNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHX (X is any amino acid except T) SEQ ID C'terminal-modified EVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMGNO: 896 AFD.v14 Heavy ChainWINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVSNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHX (X is any amino acid except T) SEQ ID C'terminal-modified EVQLVQSGPELKKPGASVKVSCKASGYTFTNYGMNWVRQAPGQGLEWMGNO: 897 AFD.v15 Heavy ChainWINTYTGETTYAEDFKGRFVFSLDTSVSTAYLQISSLKAEDTAVYYCEREGGVSNWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHX (X is any amino acid except T) SEQ ID C'terminal-modified EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGENO: 898 huAFD.v2.0 HeavyINPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFA ChainYVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHX (X is any amino acid except T) SEQ ID C'terminal-modified EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGENO: 899 huAFD.v2.1 HeavyINPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFA ChainYVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHX (X is any amino acid except T) SEQ ID C'terminal-modified EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGENO: 900 huAFD.v2.3 HeavyINPYSGDTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFA ChainYVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHX (X is any amino acid except T) SEQ ID C'terminal-modified EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGENO: 901 huAFD.v1 HeavyINPTNGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGF ChainAYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHX (X is any amino acid except T) SEQ ID C'terminal-modified EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGENO: 902 huAFD.v1.1 HeavyINPTQGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGF ChainAYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHX (X is any amino acid except T) SEQ ID C'terminal-modified EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGENO: 903 huAFD.v2.2 HeavyINPTSGDTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFA ChainYVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHX (X is any amino acid except T) SEQ ID C'terminal-modified EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGENO: 904 huAFD.v2.4 HeavyINPTSGETNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFA ChainYVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHX (X is any amino acid except T) SEQ ID C'terminal-modified EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGENO: 905 huAFD.v2.5 HeavyINPYSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFA ChainYVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHX (X is any amino acid except T) SEQ ID C'terminal-modified EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGENO: 906 huAFD.v2.6 HeavyINPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFA ChainYVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHX (X is any amino acid except T) SEQ ID C'terminal-modified EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGENO: 907 huAFD.v2.7 HeavyINPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFA ChainYVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHX (X is any amino acid except T) SEQ ID C'terminal-modified EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGENO: 908 huAFD.v2.8 HeavyINPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFA ChainYVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHX (X is any amino acid except T) SEQ ID C'terminal-modified EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGNO: 909 huAFD.v2.9 HeavyWINPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGG ChainFAYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHX (X is any amino acid except T) SEQ ID C'terminal-modified EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGENO: 910 huAFD.v2.10 HeavyINPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFA ChainYVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHX (X is any amino acid except T) SEQ ID C'terminal-modified EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGENO: 911 huAFD.v2.11 HeavyINPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFA ChainYVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHX (X is any amino acid except T) SEQ ID C'terminal-modified EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGENO: 912 huAFD.v2.12 HeavyINPYSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFA ChainYVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHX (X is any amino acid except T) SEQ ID C'terminal-modified EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGENO: 913 huAFD.v2.13 HeavyINPTSGGTNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFA ChainYVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHX (X is any amino acid except T) SEQ ID C'terminal-modified EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGENO: 914 huAFD.v2.14 HeavyINPTSGETNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFA ChainYVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHX (X is any amino acid except T) SEQ ID C'terminal-modified EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMYWVRQAPGQGLEWIGENO: 915 huAFD.v2.15 HeavyINPYSGETNFNEKFKSRATLTVDTSTSTAYLELSSLRSEDTAVYYCAREGGFA ChainYVVGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHX (X is any amino acid except T)

In some embodiments, the anti-Factor D antibody is a Fab fragment, aFab′ fragment or a F(ab′)2 fragment comprising a light chain constantregion having the amino acid sequence of SEQ ID NO: 860. In someembodiments, the anti-Factor D antibody is a Fab fragment, a Fab′fragment or a F(ab′)2 fragment comprising a light chain constant regionhaving at least 90% sequence identity to the amino acid sequence of SEQID NO: 860. See Table 9.

In some embodiments, the anti-Factor D antibody is a Fab fragmentcomprising a heavy chain constant region having the amino acid sequenceof SEQ ID NO: 861, SEQ ID NO: 862, SEQ ID NO: 869, SEQ ID NO: 870, SEQID NO: 871, SEQ ID NO: 872, SEQ ID NO: 873, SEQ ID NO: 874, SEQ ID NO:877, SEQ ID NO: 878, SEQ ID NO: 879, SEQ ID NO: 880, SEQ ID NO: 881, orSEQ ID NO: 916. In some embodiments, the anti-Factor D antibody is a Fabfragment, a Fab′ fragment or a F(ab′)2 fragment comprising a heavy chainconstant region having the amino acid sequence of SEQ ID NO: 864, SEQ IDNO: 865, SEQ ID NO: 866, SEQ ID NO: 867, or SEQ ID NO: 868. In someembodiments, the anti-Factor D antibody is a Fab-C fragment comprising aheavy chain constant region having the amino acid sequence of SEQ ID NO:863, SEQ ID NO: 875, or SEQ ID NO: 876. In some embodiments, theanti-Factor D antibody is a Fab fragment comprising a heavy chainconstant region having at least 90% sequence identity to the amino acidsequence of SEQ ID NO: 861, SEQ ID NO: 862, SEQ ID NO: 869, SEQ ID NO:870, SEQ ID NO: 871, SEQ ID NO: 872, SEQ ID NO: 873, SEQ ID NO: 874, SEQID NO: 877, SEQ ID NO: 878, SEQ ID NO: 879, SEQ ID NO: 880, SEQ ID NO:881, or SEQ ID NO: 916. In some embodiments, the anti-Factor D antibodyis a Fab fragment, a Fab′ fragment or a F(ab′)2 fragment comprising aheavy chain constant region having at least 90% sequence identity to theamino acid sequence of SEQ ID NO: 864, SEQ ID NO: 865, SEQ ID NO: 866,SEQ ID NO: 867, or SEQ ID NO: 868. In some embodiments, the anti-FactorD antibody is a Fab-C fragment comprising a heavy chain constant regionhaving at least 90% sequence identity to the amino acid sequence of SEQID NO: 863, SEQ ID NO: 875, or SEQ ID NO: 876. See Table 9.

TABLE 9Amino acid sequences of anti-Factor D antibody light chain constant regionsand heavy chain constant regions SEQ IDRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSNO: 860 STLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC SEQ IDASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTNO: 861 VPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHT SEQ IDASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTNO: 862 VPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHL SEQ IDASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTNO: 863 VPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTC SEQ IDASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTNO: 864 VPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPC SEQ IDASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTNO: 865 VPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPS SEQ IDASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTNO: 866 VPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTSPPC SEQ IDASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTNO: 867 VPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTAPPC SEQ IDASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTNO: 868 VPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTSGGC SEQ IDASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTNO: 869 VPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCYGPPC SEQ IDASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTNO: 870 VPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTH SEQ IDASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTNO: 871 VPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKT SEQ IDASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTNO: 872 VPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDK SEQ IDASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTNO: 873 VPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCD SEQ IDASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTNO: 874 VPSSNFGTQTYTCNVDHKPSNTKVDKTVERK SEQ IDASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTNO: 875 VPSSNFGTQTYTCNVDHKPSNTKVDKTVERKC SEQ IDASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTNO: 876 VPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPC SEQ IDASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTNO: 877 VPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPP SEQ IDASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTNO: 878 VPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGP SEQ IDASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTNO: 879 VPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYG SEQ IDASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTNO: 880 VPSSSLGTKTYTCNVDHKPSNTKVDKRVESKY SEQ IDASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTNO: 881 VPSSSLGTKTYTCNVDHKPSNTKVDKRVESK SEQ IDASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTNO: 916VPSSS LGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHX (X is any amino acid except T)

In specific embodiments, the Factor D inhibitor is a small moleculeinhibitor. In specific embodiments, the Factor D inhibitor is anucleotide (e.g., a DNA, an RNA, an shRNA, an miRNA, an siRNA, anantisense DNA). In specific embodiments, the Factor D inhibitor is apeptide, a protein, a peptide mimetic, an aptamer, or any other moleculethat binds to Factor D.

In the methods of determining the potency of a Factor D inhibitordescribed above, the anti-Factor Ba, anti-Factor Bb, and/or anti-FactorC3b may be replaced by a peptide, a non-antibody protein, a peptidememetic, an aptamer, a nucleotide (e.g., DNA, RNA, shRNA, miRNA, siRNA,antisense DNA), or any other molecule that binds to Factor Ba, FactorBb, or anti-Factor C3b, respectively. Alternatively, the Factor Ba,Factor Bb, and/or Factor C3b may be directed attached to the donor oracceptor (as the case may be) by direct chemical labeling.

In specific embodiments of the methods of determining the potency of aFactor D inhibitor described herein, the Factor D is a recombinantlyexpressed Factor D. In specific embodiments of the methods ofdetermining the potency of a Factor D inhibitor described herein, theFactor D is endogenously expressed Factor D purified from a samplederived from a subject.

In specific embodiments of the methods of determining the potency of aFactor D inhibitor described herein, the Factor B is a recombinantlyexpressed Factor B. In specific embodiments of the methods ofdetermining the potency of a Factor D inhibitor described herein, theFactor B is endogenously expressed Factor B purified from a samplederived from a subject.

The term “sample” referred to in the methods described herein, can be,but is not limited to, a blood sample or a serum sample.

The subject referred to in the methods described herein, can be, but isnot limited to, a human or non-human vertebrate such as a wild, domesticor farm animal. In certain embodiments, the subject is a mammal, e.g., ahuman, a cow, a dog, a cat, a goat, a horse, a sheep, a pig, a rat, or amouse. In a preferred embodiment, the subject is a human.

5.5. Methods of Screening for Factor D Inhibitors

In another aspect, provided herein are methods of screening for a FactorD inhibitor from a plurality of Factor D inhibitor candidates,comprising performing a proximity-based measurement assay, wherein theproximity-based measurement assay measures the cleavage of Factor B. Theproximity-based measurement assay can utilize any proximity-basedtechnology known in the art for measuring the binding of a protein pair,as described in Section 5.1. The methods described in this section areuseful, for example, in high-throughput screening for new Factor Dinhibitors.

In various embodiments, the methods of screening for a Factor Dinhibitor comprise: (a) mixing a Factor D inhibitor candidate withFactor D, Factor B and Factor C3b in a test reaction mix; (b) incubatingthe test reaction mix; (c) adding to the test reaction mix ananti-Factor Ba antibody labeled with a first moiety and an anti-FactorBb antibody labeled with a second moiety after the step of (b), whereinone of the moieties is a donor, and the other is an acceptor, andwherein a proximity signal generated by the acceptor and/or the donorindicates that Factor Ba and Factor Bb are in proximity; and (d)measuring the value of the proximity signal from the test reaction mix;wherein the degree of Factor D activity inhibition by a Factor Dcandidate is positively correlated with the value of the proximitysignal. In certain embodiments, the steps of (a)-(d) are carried out foreach Factor D inhibitor candidate from the plurality.

In certain aspects of such various embodiments, the methods of screeningfor a Factor D inhibitor further comprise: (e) mixing a control reactionmix; (f) incubating the control reaction mix; (g) adding to the controlreaction mix the anti-Factor Ba antibody labeled with the first moietyand the anti-Factor Bb antibody labeled with the second moiety after thestep of (f); and (h) measuring the value of the proximity signal fromthe control test reaction mix; wherein a greater value of the proximitysignal from the test reaction mix relative to the control reaction mix(e.g., about 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 80%, 90%greater or more, or about 1-fold, 1.5-fold, 2-fold, 3-fold, 4-fold,5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 15-fold, 20-fold,30-fold, 40-fold, 50-fold greater or more) indicates a greaterinhibition of Factor D activity by the Factor D inhibitor candidate inthe test reaction mix relative to the control reaction mix.

When the proximity signal generated by the donor and/or the acceptor isbased on energy transfer between the donor and the acceptor upon lightactivation, in various embodiments, the methods of screening for aFactor D inhibitor comprise: (A) mixing a Factor D inhibitor candidatewith Factor D, Factor B and Factor C3b in a test reaction mix; (B)incubating the test reaction mix; (C) adding to the test reaction mix ananti-Factor Ba antibody labeled with a first moiety and an anti-FactorBb antibody labeled with a second moiety after the step of (B), whereinone of the moieties is a donor, and the other is an acceptor; (D)providing a light source to excite the donor in the test reaction mix;and (E) measuring the donor fluorescence emission intensity from thetest reaction mix, and/or the acceptor fluorescence emission intensityfrom the test reaction mix; wherein the degree of Factor D activityinhibition by a Factor D candidate is negatively correlated with thedonor fluorescence emission intensity from the test reaction mix, and/oris positively correlated with the acceptor fluorescence emissionintensity from the test reaction mix. In specific embodiments, the stepof (B) is conducted for about 15 min, 30 min, 45 min, 60 min, 75 min, or90 min. In some embodiments, the step of (B) is conducted for about 45min. In certain embodiments, the step of (E) is performed after a periodof time of the step of (D) that results in a decrease in interferingshort-lived background signals. In specific embodiments, the methods ofscreening for a Factor D inhibitor further comprise: (F) mixing acontrol reaction mix; (G) incubating the control reaction mix; (H)adding to the control reaction mix the anti-Factor Ba antibody labeledwith the first moiety and the anti-Factor Bb antibody labeled with thesecond moiety after the step of (G); (I) providing the same light sourceto excite the donor in the control reaction mix; and (J) measuring thedonor fluorescence emission intensity from the control reaction mix,and/or the acceptor fluorescence emission intensity from the controlreaction mix; wherein a lower donor fluorescence emission intensity fromthe test reaction mix relative to the control reaction mix, and/or ahigher acceptor fluorescence emission intensity from the test reactionmix relative to the control reaction mix, indicates a greater inhibitionof Factor D activity by the Factor D inhibitor candidate in the testreaction mix relative to the control reaction mix. In specificembodiments, the steps of (B) and (G) are conducted for about 15 min, 30min, 45 min, 60 min, 75 min, or 90 min. In some embodiments, the stepsof (B) and (G) are conducted for about 45 min. In certain embodiments,the step of (E) is performed after a period of time of the step of (D)that results in a decrease in interfering short-lived backgroundsignals, and the step of (J) is performed after the same period of timeof the step of (J). In certain embodiments, the steps of (A)-(E) arecarried out for each Factor D inhibitor candidate from the plurality.

In certain embodiments, the anti-Factor Ba antibody and the anti-FactorBb antibody used in the methods of screening for a Factor D inhibitorquench the activity of Factor D. In such embodiments, the need to addanother quencher specifically is obviated. In certain embodiments, themethods of screening for a Factor D inhibitor further comprise a step ofquenching the activity of Factor D in the sample by providing anexcessive amount of a quencher to the sample before the step of (c).When a control sample is used, in certain embodiments, the methods ofscreening for a Factor D inhibitor further comprise a step of quenchingthe activity of Factor D in the sample by providing an excessive amountof a quencher to the sample before the step of (c), and a step ofquenching the activity of Factor D in the control sample by providing anexcessive amount of the quencher to the control sample before the stepof (g). In specific embodiments, the quencher is a Factor D inhibitor(for example, an anti-Factor D antibody or an excess amount of EDTA).

In certain embodiments, the anti-Factor Ba antibody is biotinylated, andthe first moiety comprises streptavidin, avidin, or neutravidin. In someembodiments, the anti-Factor Ba antibody is biotinylated, and the firstmoiety comprises streptavidin. In certain embodiments, the anti-FactorBb antibody is biotinylated, and the second moiety comprisesstreptavidin, avidin, or neutravidin. In some embodiments, theanti-Factor Bb antibody is biotinylated, and the second moiety comprisesstreptavidin.

In other various embodiments, the methods of screening for a Factor Dinhibitor comprise: (a) mixing a Factor D inhibitor candidate withFactor D, Factor B and Factor C3b in a test reaction mix; (b) incubatingthe test reaction mix; (c) adding to the test reaction mix ananti-Factor C3b antibody labeled with a first moiety and an anti-FactorBa antibody labeled with a second moiety after the step of (b), whereinone of the moieties is a donor, and the other is an acceptor, andwherein a proximity signal generated by the acceptor and/or the donorindicates that Factor C3b and Factor Ba are in proximity; and (d)measuring the value of the proximity signal from the test reaction mix;wherein the degree of Factor D activity inhibition by a Factor Dcandidate is positively correlated with the value of the proximitysignal. In certain embodiments, the steps of (a)-(d) are carried out foreach Factor D inhibitor candidate from the plurality.

In certain aspects of such other various embodiments, the methods ofscreening for a Factor D inhibitor further comprise: (e) mixing acontrol reaction mix; (f) incubating the control reaction mix; (g)adding to the control reaction mix the anti-Factor C3b antibody labeledwith the first moiety and the anti-Factor Ba antibody labeled with thesecond moiety after the step of (f); and (h) measuring the value of theproximity signal from the control test reaction mix; wherein a greatervalue of the proximity signal from the test reaction mix relative to thecontrol reaction mix (e.g., about 10%, 15%, 20%, 25%, 30%, 40%, 50%,60%, 70%, 80%, 90% greater or more, or about 1-fold, 1.5-fold, 2-fold,3-fold, 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold,15-fold, 20-fold, 30-fold, 40-fold, 50-fold greater or more) indicates agreater inhibition of Factor D activity by the Factor D inhibitorcandidate in the test reaction mix relative to the control reaction mix.

When the proximity signal generated by the donor and/or the acceptor isbased on energy transfer between the donor and the acceptor upon lightactivation, in various embodiments, the methods of screening for aFactor D inhibitor comprise: (A) mixing a Factor D inhibitor candidatewith Factor D, Factor B and Factor C3b in a test reaction mix; (B)incubating the test reaction mix; (C) adding to the test reaction mix ananti-Factor C3b antibody labeled with a first moiety and an anti-FactorBa antibody labeled with a second moiety after the step of (B), whereinone of the moieties is a donor, and the other is an acceptor; (D)providing a light source to excite the donor in the test reaction mix;and (E) measuring the donor fluorescence emission intensity from thetest reaction mix, and/or the acceptor fluorescence emission intensityfrom the test reaction mix; wherein the degree of Factor D activityinhibition by a Factor D candidate is negatively correlated with thedonor fluorescence emission intensity from the test reaction mix, and/oris positively correlated with the acceptor fluorescence emissionintensity from the test reaction mix. In specific embodiments, the stepof (B) is conducted for about 15 min, 30 min, 45 min, 60 min, 75 min, or90 min. In some embodiments, the step of (B) is conducted for about 45min. In certain embodiments, the step of (E) is performed after a periodof time of the step of (D) that results in a decrease in interferingshort-lived background signals. In specific embodiments, the methods ofscreening for a Factor D inhibitor further comprise: (F) mixing acontrol reaction mix; (G) incubating the control reaction mix; (H)adding to the control reaction mix the anti-Factor C3b antibody labeledwith the first moiety and the anti-Factor Ba antibody labeled with thesecond moiety after the step of (G); (I) providing said light source toexcite the donor in the control reaction mix; and (J) measuring thedonor fluorescence emission intensity from the control reaction mix,and/or the acceptor fluorescence emission intensity from the controlreaction mix; wherein a lower donor fluorescence emission intensity fromthe test reaction mix relative to the control reaction mix, and/or ahigher acceptor fluorescence emission intensity from the test reactionmix relative to the control reaction mix, indicates a greater inhibitionof Factor D activity by the Factor D inhibitor candidate in the testreaction mix relative to the control reaction mix. In specificembodiments, the steps of (B) and (G) are conducted for about 15 min, 30min, 45 min, 60 min, 75 min, or 90 min. In some embodiments, the stepsof (B) and (G) are conducted for about 45 min. In certain embodiments,the step of (E) is performed after a period of time of the step of (d)that results in a decrease in interfering short-lived backgroundsignals, and the step of (J) is performed after the same period of timeof the step of (I). In certain embodiments, the steps of (A)-(E) arecarried out for each Factor D inhibitor candidate from the plurality.

In certain embodiments when anti-Factor C3b antibody and anti-Factor Baantibody are used, the anti-Factor C3b antibody is biotinylated, and thefirst moiety comprises streptavidin, avidin, or neutravidin. In someembodiments, the anti-Factor C3b antibody is biotinylated, and the firstmoiety comprises streptavidin. In certain embodiments, the anti-FactorBa antibody is biotinylated, and the second moiety comprisesstreptavidin, avidin, or neutravidin. In some embodiments, theanti-Factor Ba antibody is biotinylated, and the second moiety comprisesstreptavidin.

In certain embodiments when anti-Factor C3b antibody and anti-Factor Baantibody are used, the anti-Factor C3b antibody and the anti-Factor Baantibody used in the methods of screening for a Factor D inhibitorquench the activity of Factor D. In such embodiments, the need to addanother quencher specifically is obviated. In certain embodiments whenanti-Factor C3b antibody and anti-Factor Ba antibody are used, themethods of screening for a Factor D inhibitor further comprise a step ofquenching the activity of Factor D in the sample by providing anexcessive amount of a quencher to the sample before the step of (c).When a control sample is used, in certain embodiments, the methods ofscreening for a Factor D inhibitor further comprise a step of quenchingthe activity of Factor D in the sample by providing an excessive amountof a quencher to the sample before the step of (c), and a step ofquenching the activity of Factor D in the control sample by providing anexcessive amount of the quencher to the control sample before the stepof (g). In specific embodiments, the quencher is a Factor D inhibitor(for example, an anti-Factor D antibody or an excess amount of EDTA).

The control reaction mix can comprise, for example, a different Factor Dinhibitor with known potency (e.g., 100% potency) or no Factor Dinhibitor, but contains everything else essentially the same as the testreaction mix. In specific embodiments, more than one control reactionmix is used in the methods described herein. In certain embodiments, astandard curve has been generated for screening for Factor D inhibitorswithout the need to measure a control reaction mix.

The donor/acceptor pair can be any known in the art, or as described inSection 5.1.

The Factor D inhibitor candidate can be any pharmaceutical agent thatmay reduce or block the activity of Factor D. In specific embodiments,the Factor D inhibitor candidate is an antibody or an antigen-bindingfragment thereof, for example, an antibody or an antigen-bindingfragment thereof that binds to Factor D. In specific embodiments, theantibody is a bispecific antibody. In specific embodiments, the Factor Dinhibitor candidate is a small molecule inhibitor. In specificembodiments, the Factor D inhibitor candidate is a nucleotide (e.g., aDNA, an RNA, an shRNA, an miRNA, an siRNA, an antisense DNA). Inspecific embodiments, the Factor D inhibitor candidate is a peptide, aprotein, a peptide mimetic, an aptamer, or any other molecule that bindsto Factor D.

In the methods of screening for a Factor D inhibitor described above,the anti-Factor Ba, anti-Factor Bb, and/or anti-Factor C3b may bereplaced by a peptide, a non-antibody protein, a peptide memetic, anaptamer, a nucleotide (e.g., DNA, RNA, shRNA, miRNA, siRNA, antisenseDNA), or any other molecule that binds to Factor Ba, Factor Bb, oranti-Factor C3b, respectively. Alternatively, the Factor Ba, Factor Bb,and/or Factor C3b may be directed attached to the donor or acceptor (asthe case may be) by direct chemical labeling.

In specific embodiments of the methods of screening for a Factor Dinhibitor described herein, the Factor D is a recombinantly expressedFactor D. In specific embodiments of the methods of screening for aFactor D inhibitor described herein, the Factor D is endogenouslyexpressed Factor D purified from a sample derived from a subject.

In specific embodiments of the methods of screening for a Factor Dinhibitor described herein, the Factor B is a recombinantly expressedFactor B. In specific embodiments of the methods of screening for aFactor D inhibitor described herein, the Factor B is endogenouslyexpressed Factor B purified from a sample derived from a subject.

The term “sample” referred to in the methods described herein, can be,but is not limited to, a blood sample or a serum sample.

The subject referred to in the methods described herein, can be, but isnot limited to, a human or non-human vertebrate such as a wild, domesticor farm animal. In certain embodiments, the subject is a mammal, e.g., ahuman, a cow, a dog, a cat, a goat, a horse, a sheep, a pig, a rat, or amouse. In a preferred embodiment, the subject is a human.

5.6. Kits

In another aspect, provided herein are kits for measuring Factor Dactivity, determining Factor D inhibitor potency, and/or screening forFactor D inhibitors. The kits described herein can be used in accordancewith any methods described above as appropriate.

In various embodiments, the kits comprise an anti-Factor Ba antibody, ananti-Factor Bb antibody, a first moiety and a second moiety, wherein:(a) the anti-Factor Ba antibody is labeled or can be labeled with thefirst moiety, the anti-Factor Bb antibody is labeled or can be labeledwith the second moiety; and (b) one of the moieties is a donor, and theother moiety is an acceptor. When using the kits, in specificembodiments a proximity signal can be generated by the donor and/or theacceptor, which indicates that the acceptor and the donor are inproximity.

When the proximity signal generated by the donor and/or the acceptor isbased on energy transfer between the donor and the acceptor upon lightactivation, in various embodiments, the kits comprise an anti-Factor Baantibody, an anti-Factor Bb antibody, a first moiety and a secondmoiety, wherein: (a) the anti-Factor Ba antibody is labeled or can belabeled with the first moiety, the anti-Factor Bb antibody is labeled orcan be labeled with the second moiety; and (b) one of the moieties is adonor, and the other moiety is an acceptor. When using the kits, inspecific embodiments upon excitation by a light source the ratio betweenthe acceptor fluorescence emission intensity and the donor fluorescenceemission intensity that is higher than a baseline level indicates thatthe donor and the acceptor are in proximity (a baseline level here isthe ratio between the acceptor's fluorescence emission intensity and thedonor's fluorescence emission intensity when the acceptor and the donorare apart (e.g., more than 10 nm, 20 nm, 50 nm, 100 nm, or 200 nmapart)).

In specific embodiments, the anti-Factor Ba antibody is biotinylated,and the first moiety comprises streptavidin, avidin, or neutravidin. Insome embodiments, the anti-Factor Ba antibody is biotinylated, and thefirst moiety comprises streptavidin. In certain embodiments, theanti-Factor Bb antibody is biotinylated, and the second moiety comprisesstreptavidin, avidin, or neutravidin. In some embodiments, theanti-Factor Bb antibody is biotinylated, and the second moiety comprisesstreptavidin.

In specific embodiments, the anti-Factor Ba antibody and/or theanti-Factor Bb antibody is immobilized on a solid surface. In specificembodiments, the solid surface is a plate, a microplate, a chip, amembrane, or a bead.

In other various embodiments, the kits comprise an anti-Factor C3bantibody, an anti-Factor Ba antibody, a first moiety and a secondmoiety, wherein: (a) the anti-Factor C3b antibody is labeled or can belabeled with the first moiety, the anti-Factor Ba antibody is labeled orcan be labeled with the second moiety; and (b) one of the moieties is adonor, and the other moiety is an acceptor. When using the kits, inspecific embodiments a proximity signal can be generated by the donorand/or the acceptor, which indicates that the acceptor and the donor arein proximity.

When the proximity signal generated by the donor and/or the acceptor isbased on energy transfer between the donor and the acceptor upon lightactivation, in various embodiments, the kits comprise an anti-Factor C3bantibody, an anti-Factor Ba antibody, a first moiety and a secondmoiety, wherein: (a) the anti-Factor C3b antibody is labeled or can belabeled with the first moiety, the anti-Factor Ba antibody is labeled orcan be labeled with the second moiety; and (b) one of the moieties is adonor, and the other moiety is an acceptor. When using the kits, inspecific embodiments upon excitation by a light source the ratio betweenthe acceptor fluorescence emission intensity and the donor fluorescenceemission intensity that is higher than a baseline level indicates thatthe donor and the acceptor are in proximity (a baseline level here isthe ratio between the acceptor's fluorescence emission intensity and thedonor's fluorescence emission intensity when the acceptor and the donorare apart (e.g., more than 10 nm, 20 nm, 50 nm, 100 nm, or 200 nmapart)).

In specific embodiments, the anti-Factor C3b antibody is biotinylated,and the first moiety comprises streptavidin, avidin, or neutravidin. Insome embodiments, the anti-Factor C3b antibody is biotinylated, and thefirst moiety comprises streptavidin. In certain embodiments, theanti-Factor Ba antibody is biotinylated, and the second moiety comprisesstreptavidin, avidin, or neutravidin. In some embodiments, theanti-Factor Ba antibody is biotinylated, and the second moiety comprisesstreptavidin.

In specific embodiments, the anti-Factor C3b antibody and/or theanti-Factor Ba antibody is immobilized on a solid surface. In specificembodiments, the solid surface is a plate, a microplate, a chip, amembrane, or a bead.

In certain embodiments, the kits described herein further comprise acontrol sample with known Factor D activity.

In certain embodiments, the kits described herein further comprise acontrol Factor D inhibitor with known potency of inhibiting Factor Dactivity (e.g., 100% potency). In certain embodiments, the kits furthercomprise a control sample containing no Factor D inhibitor.

In certain embodiments, the kits described herein further comprise aquencher. In specific embodiments, the quencher is a Factor D inhibitor(for example, an anti-Factor D antibody or an excess amount of EDTA).

In specific embodiments, the kits further comprise a recombinantlyexpressed Factor B. In specific embodiments, the kits further comprisean endogenously expressed Factor B purified from a sample derived from asubject.

In specific embodiments, the kits further comprise a recombinantlyexpressed Factor D. In specific embodiments, the kits further comprisean endogenously expressed Factor D purified from a sample derived from asubject.

The term “sample” referred to in the kits described herein, can be, butis not limited to, a blood sample or a serum sample.

The subject referred to in the kits described herein, can be, but is notlimited to, a human or non-human vertebrate such as a wild, domestic orfarm animal. In certain embodiments, the subject is a mammal, e.g., ahuman, a cow, a dog, a cat, a goat, a horse, a sheep, a pig, a rat, or amouse. In a preferred embodiment, the subject is a human.

The donor/acceptor pair can be any known in the art, or as described inSection 5.1

The individual components of the kits (e.g., anti-Factor Ba antibody,anti-Factor Bb antibody, first moiety, second moiety, quencher, control)can be packed in one or more containers. In some embodiments, eachcomponent is packed in its own container. In some embodiments when thekit comprises anti-Factor Ba antibody and anti-Factor Bb antibody,anti-Factor Ba antibody and the first moiety are packed in onecontainer. In some embodiments when the kit comprises anti-Factor Baantibody and anti-Factor Bb antibody, anti-Factor Bb antibody and thesecond moiety are packed in one container. In some embodiments when thekit comprises anti-Factor C3b antibody and anti-Factor Ba antibody,anti-Factor C3b antibody and the first moiety are packed in onecontainer. In some embodiments when the kit comprises anti-Factor C3bantibody and anti-Factor Ba antibody, anti-Factor Ba antibody and thesecond moiety are packed in one container. The one or more containerscan comprise bottle(s), vial(s), tube(s), plate(s), and/ormicroplate(s). In specific embodiments, the kits further compriseinstructions for use of the kits.

6. EXAMPLE

This following non-limiting example demonstrates that proximity-basedmeasurement assays are desirable methods to measure Factor D activityand Factor D inhibitor potency.

6.1. Introduction

Factor D activity has been identified as the key driver in theactivation of the alternative complement pathway.

Lampalizumab is a Fab directed against the complement component Factor D(Katsche et al., 2012, J Biol Chem 287:12886-12892). Factor D is ahighly specific chymotrypsin-like serine protease that is arate-limiting enzyme in the activation of the complement alternativepathway (Katsche et al., 2012, J Biol Chem 287:12886-12892). Thesubstrate for Factor D is another alternative complement pathway serineprotease, Factor B. Factor C3b binds to Factor B; then, Factor D cleavesFactor B into Factor Ba and Factor Bb (Volanakis and Narayana, 1996,Protein Sci 5:553-564). Factor Bb remains bound to Factor C3b, formingthe active C3 convertase, which initiates the alternative complementpathway. Increased activation of the alternative complement pathway hasbeen found in drusen, cytotoxic deposits present on the Bruch'smembrane, which are associated with the development of age-relatedmacular degeneration (AMD) (Damico et al., 2012, Arq Bras Oftalmol75:71-75).

Lampalizumab inhibits Factor D-mediated cleavage of Factor B, preventingalternative pathway activation, and thereby inhibiting inflammation andcytotoxic activity of the activated complement components (Tanhehco,1999, Transplant Proc 31:2168-2171).

Activation of the alternative complement pathway is typically measuredby adding human serum to rabbit erythrocytes. Next, intact erythrocytesand cellular debris are pelleted by centrifugation and lysis isdetermined by measuring the absorbance at 412 nm arising from therelease of hemoglobin into the supernatant.

An alternative method was developed to measure Factor D enzymaticactivity by measuring the cleavage of Factor B using TimeResolved-Förster Energy Resonance Transfer (i.e., fluorescence resonanceenergy transfer, FRET). The method was used to characterize the activityof a neutralizing Fab fragment directed against Factor D. This assay issimple, homogeneous and shows reproducible dose-response curves in theconcentration range of 2 to 125 ng/mL. With interassay variability ofless than 5% and recovery of 97-104%, this assay demonstrates acceptableprecision and accuracy, and it is able to detect degradative changes inthe anti-Factor D Fab fragment samples subjected to oxidative stress,suggesting that it is suitable for use as a potency method in qualitycontrol.

Strategies for assay development and optimization, as well as resultsfrom the characterization of the assay are presented below.

6.2. Materials and Methods

6.2.1. Materials

The following reagents were used for the FRET study: Lampalizumab,recombinant human Factor D and the anti-Factor Ba and anti-Factor Bbantibodies were generated at Genentech (South San Francisco, Calif.).Complement Factor B and Complement Factor C3b were purchased fromComplement Technologies (Tyler, Tex.). Biotinylation of anti-Factor Bbwas performed at Genentech using a kit purchased from Pierce (Rockland,Ill.). The Streptavidin-Alexa Fluor® 647 and custom conjugation ofComplement Factor Ba to Europium were provided by Life Technologies(Grand Island, N.Y.).

The following reagents were used for the AlphaScreen® assay: theanti-Factor B antibodies, Complement Factors B, Factor C3b and Factor D,and the anti-Factor D antibody are as described above. TheStreptavidin-coated donor beads and acceptor beads were purchased fromPerkin Elmer (Waltham, Mass.).

The following reagents were used for the hemolysis assay: rabbiterythrocytes were purchased from Colorado Serum (Denver, Colo.). Veronalbuffer and Gelatin were purchased from Lonza (Allendale, N.J.).C1q-depleted human serum was purchased from Quidel (San Diego, Calif.).

6.2.2. Factor B Cleavage Assay Procedure

FIG. 1 shows the assay schematic for the Lampalizumab TR-FRET (TimeResolved-FRET) assay. All reagents were prepared in Enzymatic ReactionBuffer (75 mM Sodium Chloride 1 mM Magnesium Chloride, 25 mM Tris,0.005% Tween® 20 pH 7.3). Reference and sample Lampalizumab weretitrated. Factor D was diluted to 12.5 ng/mL and Lampalizumab titrationswere added 1:1 with the diluted Factor D. Complement Factor B andComplement Factor C3b were diluted to 1 μg/mL and 7 μg/mL, respectively,and combined 1:1. 50 μL per well of the Lampalizumab/Factor D mixturewas added to a non-binding 96 well plate from Greiner (Monroe, N.C.)followed by 50 μL of the Factor B/Factor C3b mixture and the plate wasincubated for 45 minutes with gentle agitation at 25C. Workingconcentrations of these reagents were determined by AlphaScreen® assay(data not shown). 50 μL of the detection mixture (1.2 μg/mL biotinylatedanti-Factor Bb, 4.0 nM anti-Factor Ba-Europium and 25 nMStreptavidin-Alexa Fluor® 647) was added and the plate was incubated for1 hour with gentle agitation at 25C. The Europium and Alexa Fluor® 647fluorescence signals were measured on a Paradigm plate reader with anHTRF cartridge (Molecular Devices Sunnyvale, CA) with filtersappropriate for the excitation of Europium (340 nm) and emission of theEuropium and Alexa Fluor® 647 fluorophores (615 nm and 665 nm,respectively). The TR-FRET ratio was determined by dividing thefluorescence from the Alexa Fluor® 647 by the fluorescence of theEuropium and multiplying by 10,000. The TR-FRET ratio of theLampalizumab was plotted against the antibody concentrations using a 4parameter curve-fitting program (Softmax® Pro, Molecular Devices,Sunnyvale, CA).

6.2.3. Hemolysis Assay Procedure

For determining alternative pathway activity, rabbit erythrocytes (Er)were washed 3 times in Gelatin Veronal Buffer (GVB) (0.1% gelatin inveronal buffer and resuspended to 2×109/ml). Lampalizumab (50 μl) and 20μl of Er suspension were mixed 1:1 with GVB/0.1M EGTA/0.1M MgCl₂.Complement activation was initiated by the addition of C1q-depletedhuman serum (Quidel; 30 μl diluted 1:3 in GVB). After a 30 minuteincubation at room temperature, 200 μl GVB/10 mM EDTA were added to stopthe reaction and samples were centrifuged for 5 min at 500 g. Hemolysiswas quantified in 200 μl supernatant by measuring absorbance at 412 nm.Data were expressed as % of hemolysis induced in the absence of theinhibitor.

6.3. Results

6.3.1. Optimization of Conditions for Detection of Factor B Cleavage

In order to optimize the signal of the TR-FRET assay, varyingconcentrations of the Streptavidin-Alexa Fluor® 647 and anti-FactorBa-Europium were analyzed with fixed concentrations of the otherreagents and then the assay was performed as described in Section 6.1.FIG. 2 shows this co-titration of Streptavidin-Alexa Fluor® 647 andanti-Factor Ba-Europium. Working concentrations of theStreptavidin-Alexa Fluor® 647 and anti-Factor Ba-Europium that providedoptimal signal were 4.0 nM anti-Factor Ba-Europium and 25 nMStreptavidin-Alexa Fluor® 647, respectively.

The anti-Factor Ba and anti-Factor Bb detection reagents were tested fortheir ability to inhibit the cleavage of Factor B by Factor D. FIG. 3shows that the activity of Factor D was greatly diminished when thedetection reagents were added from prior to initiation of the enzymaticreaction (t=0) and increased with increasing time. The small amount ofactivity seen in the t=0 is likely due to incomplete inactivation ofFactor D by anti-Factor Ba and anti-Factor Bb and the extended amount oftime required to conduct this experiment. The forty-five minuteenzymatic incubation time was determined to provide suitable signal androbust method performance.

Next, the incubation with detection reagents was optimized. The assaywas run as described in Section 6.2, but the incubation with detectionreagent was varied from 10-120 minutes. As seen in FIG. 4, a 60 minutedetection reagent incubation provided suitable signal and robust methodperformance.

To demonstrate that it is possible to use alternate detection reagentsto measure cleavage of Factor B, the assay was performed usingAlphaScreen® reagents. Streptavidin-conjugated alpha donor beads andanti-Factor Ba-conjugated alpha acceptor beads were substituted forTR-FRET reagent. FIGS. 5A and 5B show that both detection technologiesgenerated good signal and dynamic range.

6.3.2. Characterization of the anti-Factor D TR-FRET assay

Using the final assay format, we further characterized the assay byconducting a study for initial evaluation of accuracy and precision.Briefly, anti-Factor D was diluted to nominal concentrations of 0.3,0.4, 0.5, 0.6 and 0.7 mg/mL, corresponding to 60, 80, 100 and 120 and140% of the target concentration of 0.5 mg/mL, respectively. The proteinconcentrations of these dilutions were determined accurately by a UVspectrophotometric scan and determined to be 0.307, 0.381, 0.512, 0.597,0.722 mg/mL. Each sample was subsequently diluted further into EnzymaticReaction buffer and tested as described in Section 6.1. Each sample wasassayed twelve times (6 times each by 2 different analysts) using newsample and reference dilutions for each assay.

To assess the accuracy of the assay, the measured activities weredivided by the expected activities and expressed as percentagerecoveries. Table 10 shows that mean activities of 60, 79, 100, 120 and139% were obtained. This represents percentage recoveries ranging from97-104%. Interassay variability, indicated by coefficient of variation(CV) was less than 5%.

These data strongly suggest that the assay is sensitive to differencesin affinity

TABLE 10 Assessment of the accuracy of the Lampalizumab TR-FRET assayMeasure Activity Expected activity (mg/mL) Interassay (mg/mL) Mean +/−SD (n = 12) Accuracy % CV % 0.307 0.300 +/− 0.0102 98 3 0.381 0.395 +/−0.0096 104 3 0.512 0.500 +/− 0.0154 98 3 0.597 0.600 +/− 0.0259 101 50.722 0.695 +/− 0.0260 97 4

The ability of the Factor B cleavage assay to detect changes in activityof Lampalizumab samples subjected to stress was evaluated. Each samplewas tested in 3 assays according to the method described above. Theresults are summarized in Table 11. Lampalizumab samples subjected tooxidation conditions (30 mM AAPH) exhibited a reduced activity of 63%compared to the control value of 93%.

TABLE 11 Assessment of the ability of the Lampalizumab TR-FRET assay todetect changes in activity of samples subjected to oxidiation stressTR-FRET Hemolytic Stressed Sample Activity Mean Unstressed control 93+/− 9 81 +/− 27 Oxidized, 30 mM AAPH 63 +/− 6 82 +/− 16 Thermal Stress 86 (1% diff) 102 +/− 23  Thermal control 103 (0% diff) 96 +/− 18

The activity of the stress samples was also measured using the rabbiterythrocyte lysis assay to compare the capability of the two methods.The data from this comparison are shown in Table 11 and demonstrate thatthe Factor B cleavage method is more precise and more sensitive tothermal and oxidative degradation.

6.4. Conclusion

The activity of Lampalizumab is dependent on its ability to bind toFactor D and inhibit its enzymatic activity. This type of activity canbe measured in vitro by monitoring rabbit erythrocyte cell lysis afterincubation with the Fab fragment. The TR-FRET assay described heremeasures the ability of Lampalizumab to bind to and inhibit theenzymatic activity of Factor D, the rate-limiting step in activation ofthe Alternate Complement pathway. To determine whether this method couldserve as a suitable measure of Factor D activity, it was assessed forits ability to detect changes in the activity of Lampalizumab that wassubjected to oxidative stress, and the data generated by this methodwere compared to data generated with a more established hemolyticmethod. The TR-FRET assay is capable of detecting losses in the activityof anti-Factor D subjected to oxidative stress. The results obtainedusing the TR-FRET assay reveal more sensitivity to stress than thehemolytic method, demonstrating that the TR-FRET assay is a suitablemethod to measure Factor D activity.

7. INCORPORATION BY REFERENCE

Various references such as patents, patent applications, andpublications are cited herein, the disclosures of which are herebyincorporated by reference herein in their entireties.

What is claimed is:
 1. A method of measuring the activity of Factor D in a sample derived from a subject, comprising performing a proximity-based measurement assay, wherein the proximity-based measurement assay measures the cleavage of Factor B and comprises: (a) adding to the sample an anti-Factor Ba antibody labeled with a first moiety and an anti-Factor Bb antibody labeled with a second moiety, wherein one of the moieties is a donor, and the other moiety is an acceptor, and wherein a proximity signal generated by the acceptor and/or the donor indicates that Factor Ba and Factor Bb are in proximity; and (b) measuring the value of the proximity signal from the sample; wherein the activity of Factor D in the sample is negatively correlated with the value of the proximity signal.
 2. The method of claim 1, further comprising: (c) adding to a control sample the anti-Factor Ba antibody labeled with the first moiety and the anti-Factor Bb antibody labeled with the second moiety; and (d) measuring the value of the proximity signal from the control sample; wherein a greater value of the proximity signal from the sample relative to the control sample indicates a lower activity of Factor D in the sample relative to the control sample.
 3. A method of measuring the activity of Factor D in a sample derived from a subject, comprising performing a proximity-based measurement assay that comprises: (a) adding to the sample an anti-Factor C3b antibody labeled with a first moiety and an anti-Factor Ba antibody labeled with a second moiety, wherein one of the moieties is a donor, and the other moiety is an acceptor, and wherein a proximity signal generated by the acceptor and/or the donor indicates that Factor C3b and Factor Ba are in proximity; and (b) measuring the value of the proximity signal from the sample; wherein the activity of Factor D in the sample is negatively correlated with the value of the proximity signal.
 4. A method of determining the potency of a Factor D inhibitor in inhibiting Factor D activity, comprising performing a proximity-based measurement assay, wherein the proximity-based measurement assay measures the cleavage of Factor B and comprises: (a) mixing the Factor D inhibitor with Factor D, Factor B, and Factor C3b in a test reaction mix; (b) incubating the test reaction mix; (c) adding to the test reaction mix an anti-Factor Ba antibody labeled with a first moiety and an anti-Factor Bb antibody labeled with a second moiety after the step of (b), wherein one of the moieties is a donor, and the other moiety is an acceptor, and wherein a proximity signal generated by the acceptor and/or the donor indicates that Factor Ba and Factor Bb are in proximity; and (d) measuring the value of the proximity signal from the text reaction mix; wherein the potency of the Factor D inhibitor is positively correlated with the value of the proximity signal.
 5. A method of determining the potency of a Factor D inhibitor in inhibiting Factor D activity, comprising performing a proximity-based measurement assay, wherein the proximity-based measurement assay measures the cleavage of Factor B and comprises: (a) mixing the Factor D inhibitor with Factor D, Factor B and Factor C3b in a test reaction mix; (b) incubating the test reaction mix; (c) adding to the test reaction mix an anti-Factor C3b antibody labeled with a first moiety and an anti-Factor Ba antibody labeled with a second moiety after the step of (b), wherein one of the moieties is a donor, and the other moiety is an acceptor, and wherein a proximity signal generated by the acceptor and/or the donor indicates that Factor C3b and Factor Ba are in proximity; and (d) measuring the value of the proximity signal from the test reaction mix; wherein the potency of the Factor D inhibitor is positively correlated with the value of the proximity signal.
 6. The method of claim 4, wherein the Factor D inhibitor is an antibody or an antigen-binding fragment thereof.
 7. A method of screening for a Factor D inhibitor from a plurality of Factor D inhibitor candidates, comprising performing a proximity-based measurement assay, wherein the proximity-based measurement assay measures the cleavage of Factor B and comprises: (a) mixing a Factor D inhibitor candidate with Factor D, Factor B and Factor C3b in a test reaction mix; (b) incubating the test reaction mix; (c) adding to the test reaction mix an anti-Factor Ba antibody labeled with a first moiety and an anti-Factor Bb antibody labeled with a second moiety after the step of (b), wherein one of the moieties is a donor, and the other is an acceptor, and wherein a proximity signal generated by the acceptor and/or the donor indicates that Factor Ba and Factor Bb are in proximity; and (d) measuring the value of the proximity signal from the test reaction mix; wherein the degree of Factor D activity inhibition by a Factor D candidate is positively correlated with the value of the proximity signal.
 8. A method of screening for a Factor D inhibitor from a plurality of Factor D inhibitor candidates, comprising performing a proximity-based measurement assay, wherein the proximity-based measurement assay measures the cleavage of Factor B and comprises: (a) mixing a Factor D inhibitor candidate with Factor D, Factor B and Factor C3b in a test reaction mix; (b) incubating the test reaction mix; (c) adding to the test reaction mix an anti-Factor C3b antibody labeled with a first moiety and an anti-Factor Ba antibody labeled with a second moiety after the step of (b), wherein one of the moieties is a donor, and the other is an acceptor, and wherein a proximity signal generated by the acceptor and/or the donor indicates that Factor C3b and Factor Ba are in proximity; and (d) measuring the value of the proximity signal from the test reaction mix; wherein the degree of Factor D activity inhibition by a Factor D candidate is positively correlated with the value of the proximity signal.
 9. The method of claim 1, wherein the anti-Factor Ba antibody and the anti-Factor Bb antibody quench the activity of Factor D.
 10. The method of claim 2, wherein the anti-Factor Ba antibody and the anti-Factor Bb antibody quench the activity of Factor D.
 11. The method of claim 3, further comprising: (c) adding to a control sample the anti-Factor C3b antibody labeled with the first moiety and the anti-Factor Ba antibody labeled with the second moiety; and (d) measuring the value of the proximity signal from the control sample; wherein a greater value of the proximity signal from the sample relative to the control sample indicates a lower activity of Factor D in the sample relative to the control sample.
 12. The method of claim 1, further comprising a step of quenching the activity of Factor D in the sample by providing an excessive amount of a quencher to the sample before the step of (a).
 13. The method of claim 3, further comprising a step of quenching the activity of Factor D in the sample by providing an excessive amount of a quencher to the sample before the step of (a).
 14. The method of claim 2, further comprising a step of quenching the activity of Factor D in the sample by providing an excessive amount of a quencher to the sample before the step of (a), and a step of quenching the activity of Factor D in the control sample by providing an excessive amount of the quencher to the control sample before the step of (c).
 15. The method of claim 11, further comprising a step of quenching the activity of Factor D in the sample by providing an excessive amount of a quencher to the sample before the step of (a), and a step of quenching the activity of Factor D in the control sample by providing an excessive amount of the quencher to the control sample before the step of (c).
 16. The method of claim 12, wherein the quencher is a Factor D inhibitor.
 17. The method of claim 13, wherein the quencher is a Factor D inhibitor.
 18. The method of claim 14, wherein the quencher is a Factor D inhibitor.
 19. The method of claim 15, wherein the quencher is a Factor D inhibitor.
 20. The method of claim 1, wherein the subject is a human.
 21. The method of claim 3, wherein the subject is a human.
 22. The method of claim 4, comprising: (e) mixing a control reaction mix; (f) incubating the control reaction mix; (g) adding to the control reaction mix the anti-Factor Ba antibody labeled with the first moiety and the anti-Factor Bb antibody labeled with the second moiety after the step of (f); and (h) measuring the value of the proximity signal from the control test reaction mix; wherein a greater value of the proximity signal from the test reaction mix relative to the control reaction mix indicates a greater inhibition of Factor D activity by the Factor D inhibitor in the test reaction mix relative to the control reaction mix.
 23. The method of claim 4, further comprising a step of quenching the activity of Factor D in the sample by providing an excessive amount of a quencher to the sample before the step of (c).
 24. The method of claim 22, further comprising a step of quenching the activity of Factor D in the sample by providing an excessive amount of a quencher to the sample before the step of (c), and a step of quenching the activity of Factor D in the control sample by providing an excessive amount of the quencher to the control sample before the step of (h).
 25. The method of claim 23, wherein the quencher is a Factor D inhibitor.
 26. The method of claim 24, wherein the quencher is a Factor D inhibitor.
 27. The method of claim 5, wherein the Factor D inhibitor is an antibody or an antigen-binding fragment thereof.
 28. The method of claim 5, further comprising: (e) mixing a control reaction mix; (f) incubating the control reaction mix; (g) adding to the control reaction mix the anti-Factor C3b antibody labeled with the first moiety and the anti-Factor Ba antibody labeled with the second moiety after the step of (f); and (h) measuring the value of the proximity signal from the control reaction mix; wherein the potency of the Factor D inhibitor is positively correlated with the value of the proximity signal.
 29. The method of claim 5, further comprising a step of quenching the activity of Factor D in the sample by providing an excessive amount of a quencher to the sample before the step of (c).
 30. The method of claim 28, further comprising a step of quenching the activity of Factor D in the sample by providing an excessive amount of a quencher to the sample before the step of (c), and a step of quenching the activity of Factor D in the control sample by providing an excessive amount of the quencher to the control sample before the step of (h).
 31. The method of claim 29, wherein the quencher is a Factor D inhibitor.
 32. The method of claim 30, wherein the quencher is a Factor D inhibitor.
 33. The method of claim 7, wherein the Factor D inhibitor candidate is an antibody or an antigen-binding fragment thereof.
 34. The method of claim 7, further comprising: (e) mixing a control reaction mix; (f) incubating the control reaction mix; (g) adding to the control reaction mix the anti-Factor Ba antibody labeled with the first moiety and the anti-Factor Bb antibody labeled with the second moiety after the step of (g); and (h) measuring the value of the proximity signal from the control test reaction mix; wherein a greater value of the proximity signal from the test reaction mix relative to the control reaction mix indicates a greater inhibition of Factor D activity by the Factor D inhibitor candidate in the test reaction mix relative to the control reaction mix.
 35. The method of claim 7, wherein the anti-Factor Ba antibody and the anti-Factor Bb antibody quench the activity of Factor D.
 36. The method of claim 34, wherein the anti-Factor Ba antibody and the anti-Factor Bb antibody quench the activity of Factor D.
 37. The method of claim 7, further comprising a step of quenching the activity of Factor D in the sample by providing an excessive amount of a quencher to the sample before the step of (c).
 38. The method of claim 37, wherein the quencher is a Factor D inhibitor.
 39. The method of claim 34, further comprising a step of quenching the activity of Factor D in the sample by providing an excessive amount of a quencher to the sample before the step of (c), and a step of quenching the activity of Factor D in the control sample by providing an excessive amount of the quencher to the control sample before the step of (g).
 40. The method of claim 39, wherein the quencher is a Factor D inhibitor.
 41. The method of claim 7, wherein the steps of (a)-(d) are carried out for each Factor D inhibitor candidate from the plurality.
 42. The method of claim 8, wherein the Factor D inhibitor candidate is an antibody or an antigen-binding fragment thereof.
 43. The method of claim 8, further comprising: (e) mixing a control reaction mix; (f) incubating the control reaction mix; (g) adding to the control reaction mix the anti-Factor C3b antibody labeled with the first moiety and the anti-Factor Ba antibody labeled with the second moiety after the step of (g); and (h) measuring the value of the proximity signal from the control test reaction mix; wherein a greater value of the proximity signal from the test reaction mix relative to the control reaction mix indicates a greater inhibition of Factor D activity by the Factor D inhibitor candidate in the test reaction mix relative to the control reaction mix.
 44. The method of claim 8, further comprising a step of quenching the activity of Factor D in the sample by providing an excessive amount of a quencher to the sample before the step of (c).
 45. The method of claim 44, wherein the quencher is a Factor D inhibitor.
 46. The method of claim 43, further comprising a step of quenching the activity of Factor D in the sample by providing an excessive amount of a quencher to the sample before the step of (c), and a step of quenching the activity of Factor D in the control sample by providing an excessive amount of the quencher to the control sample before the step of (g).
 47. The method of claim 46, wherein the quencher is a Factor D inhibitor.
 48. The method of claim 8, wherein the steps of (a)-(d) are carried out for each Factor D inhibitor candidate from the plurality. 